Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

BRENDA Home
show all | hide all No of entries

Information on EC 3.4.23.39 - plasmepsin II and Organism(s) Plasmodium falciparum and UniProt Accession Q8I6V3

for references in articles please use BRENDA:EC3.4.23.39
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
     3 Hydrolases
         3.4 Acting on peptide bonds (peptidases)
             3.4.23 Aspartic endopeptidases
                3.4.23.39 plasmepsin II
Specify your search results
Select one or more organisms in this record: ?
This record set is specific for:
Plasmodium falciparum
UNIPROT: Q8I6V3 not found.
Show additional data
Do not include text mining results
Include (text mining) results
Include results (AMENDA + additional results, but less precise)
Word Map
The taxonomic range for the selected organisms is: Plasmodium falciparum
The enzyme appears in selected viruses and cellular organisms
Reaction Schemes
Hydrolysis of the bonds linking certain hydrophobic residues in hemoglobin or globin. Also cleaves the small molecule substrates such as Ala-Leu-Glu-Arg-Thr-Phe!Phe(NO2)-Ser-Phe-Pro-Thr
Synonyms
plasmepsin ii, pm ii, pfpm2, plm ii, plasmepsin 2, plmii, ah ii, malarial aspartic protease, pfapd, more
SYNONYM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
AH II
-
-
-
-
aspartic hemoglobinase II
-
-
-
-
malarial aspartic protease
-
-
PFAPD
-
-
-
-
plasmepsin 2
PLm II
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
hydrolysis of peptide bond
-
-
-
-
PATHWAY SOURCE
PATHWAYS
-
-
CAS REGISTRY NUMBER
COMMENTARY hide
159447-18-4
-
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
Hemoglobin + H2O
?
show the reaction diagram
-
-
-
?
4-(4-dimethylaminophenylazo)benzoyl-CH2-CH2-CO-ALERMFLSFP-diaminopimelate-5-[(2-aminoethyl)amino]naphthalene-1-sulfonic acid + H2O
?
show the reaction diagram
-
-
-
-
?
4-(4-dimethylaminophenylazo)benzoyl-CH2-CH2-CO-CO-ALERMFLSFP-diaminopimelate-5-[(2-aminoethyl)amino]naphthalene-1-sulfonic acid + H2O
?
show the reaction diagram
-
-
-
-
?
4-(4-dimethylaminophenylazo)benzoyl-CH2-CH2-CO-ERMFLSFP-diaminopimelate-5-[(2-aminoethyl)amino]naphthalene-1-sulfonic acid + H2O
?
show the reaction diagram
-
-
-
-
?
4-[[4'-(dimethylamino)phenyl]azo]-benzoyl-Glu-Arg-Met-Phe-Leu-Ser-Phe-Pro-(gamma-aminobutyryl)-5-[(2'-aminoethyl)-amino]naphthalenesulfonic acid + H2O
?
show the reaction diagram
-
-
-
-
?
4-[[4'-(dimethylamino)phenyl]azo]-benzoyl-Glu-Arg-Nle-Phe-Leu-Ser-Phe-Pro-5-[(2'-aminoethyl)-amino]naphthalenesulfonic acid + H2O
?
show the reaction diagram
-
-
-
-
?
Abz-Thr-Ile-Nle-(4-nitro)Phe-Gln-Arg-NH2 + H2O
Abz-Thr-Ile-Nle + (4-nitro)Phe-Gln-Arg-NH2
show the reaction diagram
-
-
-
?
actin + H2O
?
show the reaction diagram
-
-
-
-
?
Ala-Leu-Glu-Arg-Nle-Phe-Phe(NO2)-Ser-Phe-Pro + H2O
Ala-Leu-Glu-Arg-Nle-Phe + Phe(NO2)-Ser-Phe-Pro
show the reaction diagram
-
-
-
-
?
Ala-Leu-Glu-Arg-Thr-Phe-Leu-Ser-Phe-Pro-Thr + H2O
Ala-Leu-Glu-Arg-Thr-Phe + Leu-Ser-Phe-Pro-Thr
show the reaction diagram
-
-
-
-
?
Ala-Leu-Glu-Arg-Thr-Phe-Phe(NO2)-Ser-Phe-Pro-Thr + H2O
Ala-Leu-Glu-Arg-Thr-Phe + Phe(NO2)-Ser-Phe-Pro-Thr
show the reaction diagram
-
-
-
-
?
Ala-Leu-Glu-Arg-Thr-Phe-Phe(p-NO2)-Ser-Phe-Pro-Thr + H2O
Ala-Leu-Glu-Arg-Thr-Phe + Phe(p-NO2)-Ser-Phe-Pro-Thr
show the reaction diagram
-
-
-
-
?
Arg-Gln-Phe-Phe(p-NO2)-Ile-Thr + H2O
Arg-Gln-Phe + Phe(p-NO2)-Ile-Thr
show the reaction diagram
-
-
-
?
DABCYL-Glu-Arg-Nle-Phe-Leu-Ser-Phe-Pro-EDANS + H2O
?
show the reaction diagram
-
FRET substrate, substrate is designed to mimic the hemoglobin cleavage site. The substrate is conjugated with the fluorescent donor EDANS and the quencher DABCYL
-
-
?
DABCYL-L-Glu-L-Arg-L-Nle-L-Phe-L-Leu-L-Ser-L-Phe-L-Pro-EDANS + H2O
?
show the reaction diagram
-
FRET-based substrate
-
-
?
EDANS-CO-CH2-CH2-CO-Ala-Leu-Glu-Arg-Met-Phe-Leu-Ser-Phe-Pro-Dap-(DABCYL)-OH + H2O
?
show the reaction diagram
EDANS-CO-CH2-CH2-CO-L-Ala-L-Leu-L-Glu-L-Arg-L-Met-L-Phe-L-Leu-L-Ser-L-Phe-L-Pro-Dap(DABCYL)-OH + H2O
?
show the reaction diagram
-
-
-
-
?
EDANS-CO-CH2-CH2-COALERMFLSFP-diaminopimelate-(DABCYL)OH + H2O
?
show the reaction diagram
-
-
-
-
?
GST-SH3 peptide + H2O
?
show the reaction diagram
-
Y-/-V and L-/-L are major cleavage sites
-
-
?
Hemoglobin + H2O
?
show the reaction diagram
hemoglobin alpha-chain + H2O
?
show the reaction diagram
-
cleavage sites: Phe33-/-Leu34, Thr108-/-Leu109, Leu136-/-Thr137
-
-
?
hemoglobin beta-chain + H2O
?
show the reaction diagram
-
cleavage site: Leu32-/-Val33
-
-
?
Leu-Glu-Arg-Ile-Phe-Phe(NO2)-Ser-Phe + H2O
Leu-Glu-Arg-Ile-Phe + Phe(NO2)-Ser-Phe
show the reaction diagram
-
-
-
-
?
Leu-Glu-Arg-Val-Phe-Phe(NO2)-Ser-Phe + H2O
Leu-Glu-Arg-Val-Phe + Phe(NO2)-Ser-Phe
show the reaction diagram
-
-
-
-
?
Leu-Ser-Phe(NO2)-Nle-Ala-Leu-OMe + H2O
?
show the reaction diagram
-
-
-
-
?
Lys-Ala-Ile-Glu-Phe-Phe(NO2)-Arg-Leu + H2O
Lys-Ala-Ile-Glu-Phe + Phe(NO2)-Arg-Leu
show the reaction diagram
-
-
-
-
?
Lys-Asp-Ile-Glu-Phe-Phe(NO2)-Arg-Leu + H2O
Lys-Asp-Ile-Glu-Phe + Phe(NO2)-Arg-Leu
show the reaction diagram
-
-
-
-
?
Lys-Glu-Leu-Val-Phe-Phe(NO2)-Ala-Leu-Lys + H2O
Lys-Glu-Leu-Val-Phe + Phe(NO2)-Ala-Leu-Lys
show the reaction diagram
-
-
-
-
?
Lys-Glu-Phe-Asn-Phe-Phe(NO2)-Ala-Leu-Lys + H2O
Lys-Glu-Phe-Asn-Phe + Phe(NO2)-Ala-Leu-Lys
show the reaction diagram
-
-
-
-
?
Lys-Glu-Phe-Ile-Phe-Phe(NO2)-Ala-Leu-Lys + H2O
Lys-Glu-Phe-Ile-Phe + Phe(NO2)-Ala-Leu-Lys
show the reaction diagram
-
-
-
-
?
Lys-Glu-Phe-Val-Lys-Phe(NO2)-Ala-Leu-Lys + H2O
?
show the reaction diagram
-
-
-
-
?
Lys-Glu-Phe-Val-Lys-Phe(NO2)-Ala-Leu-Lys + H2O
Lys-Glu-Phe-Val-Lys + Phe(NO2)-Ala-Leu-Lys +
show the reaction diagram
-
-
-
-
?
Lys-Glu-Phe-Val-Phe-4-nitrophenylalanine-Ala-Leu-Lys + H2O
?
show the reaction diagram
-
-
-
-
?
Lys-Glu-Phe-Val-Phe-Phe(NO2)-Ala-Leu-Lys + H2O
Lys-Glu-Phe-Val-Phe + Phe(NO2)-Ala-Leu-Lys
show the reaction diagram
-
-
-
-
?
Lys-Glu-Phe-Val-Phe-Phe(NO2)-Arg-Leu-Lys + H2O
Lys-Glu-Phe-Val-Phe + Phe(NO2)-Arg-Leu-Lys
show the reaction diagram
-
-
-
-
?
Lys-Lys-Ile-Glu-Phe-Phe(NO2)-Arg-Leu + H2O
Lys-Lys-Ile-Glu-Phe + Phe(NO2)-Arg-Leu
show the reaction diagram
-
-
-
-
?
Lys-Phe-Ile-Glu-Phe-Phe(NO2)-Arg-Leu + H2O
Lys-Phe-Ile-Glu-Phe + Phe(NO2)-Arg-Leu
show the reaction diagram
-
-
-
-
?
Lys-Pro-Ala-Glu-Phe-Phe(NO2)-Arg-Leu + H2O
Lys-Pro-Ala-Glu-Phe + Phe(NO2)-Arg-Leu
show the reaction diagram
-
-
-
-
?
Lys-Pro-Asp-Glu-Phe-Phe(NO2)-Arg-Leu + H2O
Lys-Pro-Asp-Glu-Phe + Phe(NO2)-Arg-Leu
show the reaction diagram
-
-
-
-
?
Lys-Pro-Ile-Ala-Phe-Phe(NO2)-Arg-Leu + H2O
Lys-Pro-Ile-Ala-Phe + Phe(NO2)-Arg-Leu
show the reaction diagram
-
-
-
-
?
Lys-Pro-Ile-Asp-Phe-Phe(NO2)-Arg-Leu + H2O
Lys-Pro-Ile-Asp-Phe + Phe(NO2)-Arg-Leu
show the reaction diagram
-
-
-
-
?
Lys-Pro-Ile-Glu-Phe-NO2Phe-Arg-Leu + H2O
Lys-Pro-Ile-Glu-Phe + NO2Phe-Arg-Leu
show the reaction diagram
-
-
-
-
?
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Ala-Leu + H2O
Lys-Pro-Ile-Glu-Phe + Phe(NO2)-Ala-Leu
show the reaction diagram
-
-
-
-
?
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Arg-Arg + H2O
Lys-Pro-Ile-Glu-Phe + Phe(NO2)-Arg-Arg
show the reaction diagram
-
-
-
-
?
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Arg-Asp + H2O
Lys-Pro-Ile-Glu-Phe + Phe(NO2)-Arg-Asp
show the reaction diagram
-
-
-
-
?
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Arg-Ile + H2O
Lys-Pro-Ile-Glu-Phe + Phe(NO2)-Arg-Ile
show the reaction diagram
-
-
-
-
?
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Arg-Leu + H2O
Lys-Pro-Ile-Glu-Phe + Phe(NO2)-Arg-Leu
show the reaction diagram
-
-
-
-
?
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Arg-Ser + H2O
Lys-Pro-Ile-Glu-Phe + Phe(NO2)-Arg-Ser
show the reaction diagram
-
-
-
-
?
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Arg-Val + H2O
Lys-Pro-Ile-Glu-Phe + Phe(NO2)-Arg-Val
show the reaction diagram
-
-
-
-
?
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Glu-Leu + H2O
Lys-Pro-Ile-Glu-Phe + Phe(NO2)-Glu-Leu
show the reaction diagram
-
-
-
-
?
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Lys-Leu + H2O
Lys-Pro-Ile-Glu-Phe + Phe(NO2)-Lys-Leu
show the reaction diagram
-
-
-
-
?
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Ser-Leu + H2O
Lys-Pro-Ile-Glu-Phe + Phe(NO2)-Ser-Leu
show the reaction diagram
-
-
-
-
?
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Val-Leu + H2O
Lys-Pro-Ile-Glu-Phe + Phe(NO2)-Val-Leu
show the reaction diagram
-
-
-
-
?
Lys-Pro-Ile-Leu-Phe-Nph-Arg-Leu + H2O
?
show the reaction diagram
-
chromogenic peptide substrate
-
-
?
Lys-Pro-Ile-Leu-Phe-Phe(NO2)-Arg-Leu + H2O
Lys-Pro-Ile-Leu-Phe + Phe(NO2)-Arg-Leu
show the reaction diagram
-
-
-
-
?
Lys-Pro-Ile-Lys-Phe-Phe(NO2)-Arg-Leu + H2O
Lys-Pro-Ile-Lys-Phe + Phe(NO2)-Arg-Leu
show the reaction diagram
-
-
-
-
?
Lys-Pro-Ile-Nle-Phe-Phe(NO2)-Arg-Leu + H2O
Lys-Pro-Ile-Nle-Phe + Phe(NO2)-Arg-Leu
show the reaction diagram
-
-
-
-
?
Lys-Pro-Ile-Ser-Phe-Phe(NO2)-Arg-Leu + H2O
Lys-Pro-Ile-Ser-Phe + Phe(NO2)-Arg-Leu
show the reaction diagram
-
-
-
-
?
Lys-Pro-Ile-Val-Phe-Phe(NO2)-Arg-Leu + H2O
Lys-Pro-Ile-Val-Phe + Phe(NO2)-Arg-Leu
show the reaction diagram
-
-
-
-
?
Lys-Pro-Lys-Glu-Phe-Phe(NO2)-Arg-Leu + H2O
Lys-Pro-Lys-Glu-Phe + Phe(NO2)-Arg-Leu
show the reaction diagram
-
-
-
-
?
Lys-Pro-Phe-Glu-Phe-Phe(NO2)-Arg-Leu + H2O
Lys-Pro-Phe-Glu-Phe + Phe(NO2)-Arg-Leu
show the reaction diagram
-
-
-
-
?
Lys-Pro-Ser-Glu-Phe-Phe(NO2)-Arg-Leu + H2O
Lys-Pro-Ser-Glu-Phe + Phe(NO2)-Arg-Leu
show the reaction diagram
-
-
-
-
?
Lys-Ser-Ile-Glu-Phe-Phe(NO2)-Arg-Leu + H2O
Lys-Ser-Ile-Glu-Phe + Phe(NO2)-Arg-Leu
show the reaction diagram
-
-
-
-
?
Myoglobin + H2O
?
show the reaction diagram
-
horse myoglobin is used
-
-
?
p47phox-PX + H2O
?
show the reaction diagram
-
PX domain of p47phox, a cytosolic factor of the neutrophil NADPH oxydase is digested
-
-
?
plasmepsin 2 + H2O
?
show the reaction diagram
-
PSM2 auto-cleavage after F112 is complete after 20 min in 10 mM citrate pH 4.5
-
-
?
protein 4.1 + H2O
?
show the reaction diagram
-
-
-
-
?
spectrin + H2O
?
show the reaction diagram
additional information
?
-
-
the enzyme has a preference for a small hydrophobic residue in the P3 position of the substrate. The S2 and S3 subsites of plasmepsin II are hydrophobic in nature and on this basis the hemoglobin-related substrate, with Arg and Thr in the P3 and P2 positions respectively may not represent the optimal substrate
-
-
?
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
Hemoglobin + H2O
?
show the reaction diagram
-
-
-
?
Hemoglobin + H2O
?
show the reaction diagram
plasmepsin 2 + H2O
?
show the reaction diagram
-
PSM2 auto-cleavage after F112 is complete after 20 min in 10 mM citrate pH 4.5
-
-
?
spectrin + H2O
?
show the reaction diagram
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1R,2R,3R,4R)-1,4-bis[[(2E)-3-bromoprop-2-en-1-yl]oxy]-1,4-bis[5-(4-tert-butylphenyl)-1,3,4-oxadiazol-2-yl]butane-2,3-diol
-
-
(1R,2R,3R,4S)-3-[(4-butylphenyl)sulfonyl]-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine
-
(1R,2R,3R,4S)-3-[(4-heptylphenyl)sulfonyl]-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine
-
(1R,2R,3R,4S)-3-[(4-hexylphenyl)sulfonyl]-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine
-
(1R,2R,3R,4S)-3-[[4-(2-cyclobutylethyl)phenyl]sulfonyl]-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine
-
(1R,2R,3R,4S)-3-[[4-(2-cyclopentylethyl)phenyl]sulfonyl]-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine
-
(1R,2R,3R,4S)-3-[[4-(3-cyclohexylpropyl)phenyl]sulfonyl]-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine
-
(1R,2R,3R,4S)-3-[[4-(3-cyclopentylpropyl)phenyl]sulfonyl]-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine
-
(1R,2R,3R,4S)-3-[[4-(3-ethoxypropyl)phenyl]sulfonyl]-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine
-
(1R,2R,3R,4S)-3-[[4-(4,4-dimethylpentyl)phenyl]sulfonyl]-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine
-
(1R,2R,3R,4S)-3-[[4-(4-fluorobutyl)phenyl]sulfonyl]-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine
-
(1R,2R,3R,4S)-3-[[4-(4-methoxybutyl)phenyl]sulfonyl]-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine
-
(1R,2R,3R,4S)-3-[[4-(6-fluorohexyl)phenyl]sulfonyl]-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine
-
(1R,2R,3R,4S)-N-(naphthalen-2-ylmethyl)-3-[(4-pentylphenyl)sulfonyl]-7-azabicyclo[2.2.1]heptan-2-amine
-
(1R,2R,3R,4S)-N-(naphthalen-2-ylmethyl)-3-[[4-(2-propoxyethyl)phenyl]sulfonyl]-7-azabicyclo[2.2.1]heptan-2-amine
-
(1R,2R,3R,4S)-N-(naphthalen-2-ylmethyl)-3-[[4-(pentyloxy)phenyl]sulfonyl]-7-azabicyclo[2.2.1]heptan-2-amine
-
(1R,2R,3R,4S,5R)-5-[(cyclobutylamino)methyl]-N-(naphthalen-2-ylmethyl)-3-[(4-pentylphenyl)sulfonyl]-7-azabicyclo[2.2.1]heptan-2-amine
-
(1R,2R,3R,4S,5R)-5-[(cyclopentylamino)methyl]-N-(naphthalen-2-ylmethyl)-3-[(4-pentylphenyl)sulfonyl]-7-azabicyclo[2.2.1]heptan-2-amine
-
(1R,2R,3R,4S,6R)-6-[(cyclobutylamino)methyl]-N-(naphthalen-2-ylmethyl)-3-[(4-pentylphenyl)sulfonyl]-7-azabicyclo[2.2.1]heptan-2-amine
-
(1R,2R,3R,4S,6R)-6-[(cyclopentylamino)methyl]-N-(naphthalen-2-ylmethyl)-3-[(4-pentylphenyl)sulfonyl]-7-azabicyclo[2.2.1]heptan-2-amine
-
(1R,2R,3S,4S)-2,3-bis(naphthalen-2-ylmethoxy)-7-azabicyclo[2.2.1]heptane
-
(1R,4S)-6-[2-(1,3-benzothiazol-2-ylsulfanyl)ethoxy]-7-(naphthalen-1-ylmethoxy)-1,2,3,4-tetrahydro-1,4-epiminonaphthalene
-
(1R,4S)-6-[2-(1,3-benzothiazol-2-ylsulfanyl)ethoxy]-7-(naphthalen-2-ylmethoxy)-1,2,3,4-tetrahydro-1,4-epiminonaphthalene
-
(1R,4S)-6-[2-(1,3-benzothiazol-2-ylsulfanyl)ethoxy]-7-[2-(naphthalen-1-yl)ethoxy]-1,2,3,4-tetrahydro-1,4-epiminonaphthalene
-
(1R,4S)-6-[2-[(6-chloro-1,3-benzothiazol-2-yl)sulfanyl]ethoxy]-7-(naphthalen-1-ylmethoxy)-1,2,3,4-tetrahydro-1,4-epiminonaphthalene
-
(1R,4S)-6-[2-[(6-chloro-1,3-benzothiazol-2-yl)sulfanyl]ethoxy]-7-(naphthalen-2-ylmethoxy)-1,2,3,4-tetrahydro-1,4-epiminonaphthalene
-
(1R,4S)-6-[2-[(6-chloro-1,3-benzothiazol-2-yl)sulfanyl]ethoxy]-7-[2-(naphthalen-1-yl)ethoxy]-1,2,3,4-tetrahydro-1,4-epiminonaphthalene
-
(1R,4S)-6-[3-(1,3-benzothiazol-2-ylsulfanyl)propyl]-7-(naphthalen-1-ylmethoxy)-1,2,3,4-tetrahydro-1,4-epiminonaphthalene
-
(1R,4S)-6-[3-[(6-chloro-1,3-benzothiazol-2-yl)sulfanyl]propyl]-7-(naphthalen-1-ylmethoxy)-1,2,3,4-tetrahydro-1,4-epiminonaphthalene
-
(1RS) 3,3-difluoro-N-[2-(2-naphthyl)ethyl]-4-oxo-N-(4-pentylphenyl)cyclohexanecarboxamide
-
-
(1RS,4RS)-3,3-difluoro-4-hydroxy-N-[2-(2-naphthyl)ethyl]-N(4-pentylphenyl)cyclohexanecarboxamide
-
-
(1S)-3,3-difluoro-4,4-dihydroxy-N-(naphthalen-2-ylmethyl)-N-(4-pentylphenyl)cyclohexanecarboxamide
-
(1S,2S,3R,4R)-2-([4-[3-(1,3-benzodioxol-5-yl)propyl]benzyl]oxy)-3-(naphthalen-2-ylmethoxy)-7-azabicyclo[2.2.1]heptane
-
(1S,2S,3R,4R)-2-[(4-bromobenzyl)oxy]-3-(naphthalen-2-ylmethoxy)-7-azabicyclo[2.2.1]heptane
-
(1S,2S,3S,4R)-3-(4-bromophenylsulfonyl)-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine
-
-
(1S,2S,3S,4R)-3-(4-hexylphenylsulfonyl)-N-((2'-methoxybiphenyl-3-yl)methyl)-7-azabicyclo[2.2.1]heptan-2-amine
-
-
(1S,2S,3S,4R)-3-(4-hexylphenylsulfonyl)-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine
-
-
(1S,2S,3S,4R)-N-(3-bromobenzyl)-3-(4-hexylphenylsulfonyl)-7-azabicyclo[2.2.1]heptan-2-amine
-
-
(1SR,4RS)-3,3-difluoro-4-hydroxy-N-[2-(2-naphthyl)ethyl]-N(4-pentylphenyl)cyclohexanecarboxamide
-
-
(1Z)-(3,4-dimethoxyphenyl)-N'-[[(3,4,5-trichlorophenoxy)acetyl]oxy]ethanimidamide
-
(1Z)-N'-{[(4-chloro-3,5-dimethylphenoxy)acetyl]oxy}-2-(3,4-dimethoxyphenyl)ethanimidamide
-
-
(2E)-2-[(2H-1,3-benzodioxol-5-yl)methylidene]hydrazine-1-carboximidamide
-
(2R,3R)-4-(N-benzyl-N'-benzyloxycarbonyl-hydrazino)-2-(4-bromobenzyloxy)-3-hydroxy-N-((1S,2R)-2-hydroxyindan-1-yl)-butyramide
-
0.005 mM, 25% inhibition
(2R,3R)-4-(N-benzyl-N'-benzyloxycarbonyl-hydrazino)-2-(4-bromobenzyloxy)-3-hydroxy-N-(2-piperidin-1-yl-ethyl)-butyramide
-
0.005 mM, 68% inhibition
(2R,3R)-4-(N-benzyl-N'-benzyloxycarbonyl-hydrazino)-2-(4-bromobenzyloxy)-3-hydroxy-N-(2-piperidin-1-ylethyl)-butyramide
-
0.005 mM, 74% inhibition
(2R,3R)-4-(N-benzyl-N'-benzyloxycarbonyl-hydrazino)-2-(4-bromobenzyloxy)-3-hydroxy-N-(pyridin-3-yl-methyl)-butyramide
-
0.005 mM, 39% of maximal activity
(2R,3R)-4-(N-benzyloxycarbonylbenzylamino)-2-(4-bromobenzyloxy)-3-hydroxy-N-(2-piperidin-1-yl-ethyl)-butyramide
-
0.005 mM, 40% inhibition
(2R,3R)-4-(N-benzyloxycarbonylbenzylamino)-2-(4-bromobenzyloxy)-3-hydroxy-N-(pyridin-3-yl-methyl)-butyramide
-
0.005 mM, 54% inhibition
(2R,3R)-4-[((S)-2-N-benzyloxycarbonylamino-3-methylbutyryl)-benzylamino]-2-(4-bromobenzyloxy)-3-hydroxy-N-(2-piperidin-1-yl-ethyl)-butyramide
-
0.005 mM, 43% inhibition
(2R,3R)-4-[((S)-2-N-benzyloxycarbonylamino-3-methylbutyryl)-benzylamino]-2-(4-bromobenzyloxy)-3-hydroxy-N-(pyridin-3-yl-methyl)-butyramide
-
0.005 mM, 64% inhibition
(2R,3R)-4-[N-benzyl-N'-((S)-2-benzyloxycarbonylamino-3-methyl-butyryl)-hydrazino]-2-(4-bromobenzyloxy)-3-hydroxy-N-(pyridin-3-yl-methyl)-butyramide
-
0.005 mM, 50% inhibition
(2R,3R)-4-[N-benzyl-N'-((S)-2-tert-butyloxycarbonyl-amino-3-methyl-butyryl)-hydrazino]-2-(4-bromobenzyloxy)-3-hydroxy-N-((1S,2R)-2-hydroxy-indan-1-yl)-butyramide
-
0.005 mM, 49% inhibition
(2R,3R,4R)-2-(benzyloxy)-3,4-dihydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-4-[(2R)-3-oxo-1-oxa-4-azacyclotridecan-2-yl]butanamide
-
-
(2R,3R,4R)-2-(benzyloxy)-3,4-dihydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-4-[(2R,11E)-3-oxo-1-oxa-4-azacyclotridec-11-en-2-yl]butanamide
-
-
(2R,3R,4R,5R)-2,5-bis(benzyloxy)-3,4-dihydroxy-N,N'-bis[(1S)-2-methyl-1-(methylcarbamoyl)propyl]hexanediamide
-
-
(2R,3R,4R,5R)-2,5-bis(benzyloxy)-3,4-dihydroxy-N,N'-bis[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]hexanediamide
-
-
(2R,3R,4R,5R)-2,5-bis[[(2E)-3-(1,3-benzodioxol-5-yl)prop-2-en-1-yl]oxy]-3,4-dihydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-6-oxo-6-[2-(3-phenylpropanoyl)hydrazino]hexanamide
-
-
(2R,3R,4R,5R)-2,5-bis[[(2E)-3-(3,5-dimethylisoxazol-4-yl)prop-2-en-1-yl]oxy]-3,4-dihydroxy-N,N'-bis[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]hexanediamide
-
-
(2R,3R,4R,5R)-2,5-bis[[(2E)-3-(4-acetylphenyl)prop-2-en-1-yl]oxy]-3,4-dihydroxy-N,N'-bis[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]hexanediamide
-
-
(2R,3R,4R,5R)-2,5-bis[[(2E)-3-(4-acetylphenyl)prop-2-en-1-yl]oxy]-3,4-dihydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-6-oxo-6-[2-(3-phenylpropanoyl)hydrazino]hexanamide
-
-
(2R,3R,4R,5R)-2,5-bis[[(2E)-3-bromoprop-2-en-1-yl]oxy]-3,4-dihydroxy-N,N'-bis[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]hexanediamide
-
-
(2R,3R,4R,5R)-2,5-bis[[(2E)-3-bromoprop-2-en-1-yl]oxy]-3,4-dihydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5-(5-methyl-1,3,4-oxadiazol-2-yl)pentanamide
-
-
(2R,3R,4R,5R)-2,5-bis[[(2E)-3-bromoprop-2-en-1-yl]oxy]-3,4-dihydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5-[5-(2-phenylethyl)-1,3,4-oxadiazol-2-yl]pentanamide
-
-
(2R,3R,4R,5R)-2,5-bis[[(2E)-3-bromoprop-2-en-1-yl]oxy]-3,4-dihydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-6-oxo-6-[2-(3-phenylpropanoyl)hydrazino]hexanamide
-
-
(2R,3R,4R,5R)-2,5-bis[[(2E)-3-bromoprop-2-en-1-yl]oxy]-5-[5-(4-tert-butylphenyl)-1,3,4-oxadiazol-2-yl]-3,4-dihydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]pentanamide
-
-
(2R,3R,4R,5R)-2,5-bis[[(2E)-3-bromoprop-2-en-1-yl]oxy]-6-[2-[(4-tert-butylphenyl)carbonyl]hydrazino]-3,4-dihydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-6-oxohexanamide
-
-
(2R,3R,4R,5R)-2,5-bis[[(2E)-3-bromoprop-2-en-1-yl]oxy]-N'1,N'6-bis[(4-tert-butylphenyl)carbonyl]-3,4-dihydroxyhexanedihydrazide
-
-
(2R,3R,4R,5R)-3,4-dihydroxy-N,N'-bis[(1S)-2-methyl-1-(methylcarbamoyl)propyl]-2,5-bis(prop-2-en-1-yloxy)hexanediamide
-
-
(2R,3R,4R,5R)-3,4-dihydroxy-N,N'-bis[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-2,5-bis(prop-2-en-1-yloxy)hexanediamide
-
-
(2R,3R,4R,5R)-3,4-dihydroxy-N,N'-bis[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-2,5-bis[[(2E)-3-phenylprop-2-en-1-yl]oxy]hexanediamide
-
-
(2R,3R,4R,5R)-3,4-dihydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-6-oxo-6-[2-(3-phenylpropanoyl)hydrazino]-2,5-bis(prop-2-en-1-yloxy)hexanamide
-
-
(2R,3R,4R,5R)-5-(5-benzyl-1,3,4-oxadiazol-2-yl)-2,5-bis[[(2E)-3-bromoprop-2-en-1-yl]oxy]-3,4-dihydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]pentanamide
-
-
(2R,3R,4R,5R)-5-(benzyloxy)-3,4-dihydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-6-oxo-1-oxa-7-azacyclohexadecane-2-carboxamide
-
-
(2R,3R,4R,5R)-6-(2-acetylhydrazino)-2,5-bis[[(2E)-3-bromoprop-2-en-1-yl]oxy]-3,4-dihydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-6-oxohexanamide
-
-
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E)-3-(2,4-dimethoxy-3,5-pyrimidin)-2-propenyl-oxy]-3,4-dihydroxyhexane-1,6-diamide
-
-
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E)-3-(2,5-dimethyl-3,4-oxazol)-2-propenyloxy]-3,4-dihydroxyhexane-1,6-diamide
-
-
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E)-3-(3,4-methylenedioxyphenyl)-2-propenyloxy]-3,4-dihydroxyhexane-1,6-diamide
-
-
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E)-3-(3-thienyl)-2-propenyloxy]-3,4-dihydroxyhexane-1,6-diamide
-
-
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E)-3-(4-acetylphenyl)-2-propenyloxy]-3,4-dihydroxyhexane-1,6-diamide
-
-
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E)-3-(4-fluorophenyl)-2-propenyloxy]-3,4-dihydroxyhexane-1,6-diamide
-
-
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E)-3-(4-tolyl)-2-propenyloxy]-3,4-dihydroxyhexane-1,6-diamide
-
-
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E)-3-bromo-2-propenyloxy]-3,4-dihydroxyhexane-1,6-diamide
-
-
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E)-3-phenyl-2-propenyloxy]-3,4-dihydroxyhexane-1,6-diamide
-
-
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E)-5-phenyl-pent-2-en-4-ynyl]-3,4-dihydroxyhexane-1,6-diamide
-
-
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E)-5-trimethylsilyl-pent-2-en-4-ynyl]-3,4-dihydroxyhexane-1,6-diamide
-
-
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E)-pent-2-en-4-ynyl]-3,4-dihydroxyhexane-1,6-diamide
-
-
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E,4E)-5-(methoxycarbonyl)-pent-2,4-dienyloxy]-3,4-dihydroxyhexane-1,6-diamide
-
-
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E,4E)-5-phenyl-pentadienyloxy]-3,4-dihydroxyhexane-1,6-diamide
-
-
(2R,3R,4R,5R,14E)-5-(benzyloxy)-3,4-dihydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-6-oxo-1-oxa-7-azacyclohexadec-14-ene-2-carboxamide
-
-
(2R,3R,4S,6R)-6-[[(E)-2-(4-acetylphenyl)ethenyl]oxy]-2-[[(2E)-3-(4-acetylphenyl)prop-2-en-1-yl]oxy]-3,4-dihydroxy-N,N'-bis[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]heptanediamide
-
inhibitor candidate, designed according to inhibitor modeling. Selectivity index Ki value Cathepsin D to Ki value PlmII is 333
(2S,3R)-4-(N-benzyl-N'-benzyloxycarbonyl-hydrazino)-2-(4-bromobenzyloxy)-3-hydroxy-N-(2-piperidin-1-yl-ethyl)-butyramide
-
0.005 mM, 35% inhibition
(2S,3S)-4-(N-benzyl-N'-benzyloxycarbonyl-hydrazino)-2-(4-bromobenzyloxy)-3-hydroxy-N-(2-piperidin-1-yl-ethyl)-butyramide
-
0.005 mM, 20% inhibition
(2S,5S,14S,17S,18S)-N-(2-amino-2-oxoethyl)-17-benzyl-18-hydroxy-14-[[N-(3-methylbutanoyl)-L-valyl]amino]-2-(1-methylethyl)-3,8,15,20-tetraoxo-1,4,9,16-tetraazacycloicosane-5-carboxamide
-
-
(2S,5S,6R)-3-aza-2-(p-bromobenzyl)-5-hydroxy-7-phenyl-6-[(picolyl-L-valinyl)amino]heptanoyl amide
-
-
(2S,5S,6R)-3-aza-2-[m-(m-aminophenyl)benzyl]-5-hydroxy-7-phenyl-6-[(picolyl-L-valinyl)amino]heptanoyl amide
-
-
(2S,5S,6R)-3-aza-2-[m-(p-methylphenyl)benzyl]-5-hydroxy-7-phenyl-6-[(picolyl-L-valinyl)amino]heptanoyl amide
-
-
(2S,5S,6R)-3-aza-2-[p-(m-aminophenyl)benzyl]-5-hydroxy-7-phenyl-6-[(picolyl-L-valinyl)amino]heptanoyl amide
-
-
(2S,5S,6R)-3-aza-2-[p-(p-methylphenyl)benzyl]-5-hydroxy-7-phenyl-6-[(picolyl-L-valinyl)amino]heptanoyl amide
-
-
(2S,5S,6R)-3-aza-5-hydroxy-2-[m-(o-methoxyphenyl)-benzyl]-7-phenyl-6-[(picolyl-L-valinyl)amino]heptanoyl amide
-
-
(2S,5S,6R)-3-aza-5-hydroxy-2-[p-(o-methoxyphenyl)-benzyl]-7-phenyl-6-[(picolyl-L-valinyl)amino]heptanoyl amide
-
-
(2S,5S,6R)-3-aza-5-hydroxy-7-phenyl-2-(m-phenylbenzyl)-6-[(picolyl-L-valinyl)amino]heptanoyl amide
-
-
(2S,5S,6R)-3-aza-5-hydroxy-7-phenyl-2-(p-phenylbenzyl)-6-[(picolyl-L-valinyl)amino]heptanoyl amide
-
-
(2S,5S,6R)-3-aza-5-hydroxy-7-phenyl-6-[(picolyl-L-valinyl)amino]-2-(m-(trifluoromethanesulfonyloxy)benzyl)-heptanoyl amide
-
-
(3S,4S)-4-[([4-[4-amino-3-(4-chlorophenyl)butanoyl]-1-(biphenyl-4-ylmethyl)piperazin-2-yl]acetyl)amino]-N-butyl-3-hydroxy-5-phenylpentanamide
-
-
(3S,4S)-4-[[(2S)-2-(benzylamino)-3-methylbutanoyl]amino]-N-[(1S)-1-(cyclohexylmethyl)-2-[[3-(1H-imidazol-1-yl)propyl]amino]-2-oxoethyl]-3-hydroxy-5-phenylpentanamide
-
-
(3S,4S)-5-(4-bromobenzyloxy)-3-hydroxy-4-(2-thiophen-2-ylacetylamino)pentanoic acid [(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethyl]amide
-
-
(3S,4S)-5-(4-bromobenzyloxy)-4-(3,3-diphenylpropionylamino)-3-hydroxypentanoic acid [(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethyl]amide
-
-
(3S,4S)-5-(4-bromobenzyloxy)-4-diphenylacetylamino-3-hydroxypentanoic acid [(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethyl]amide
-
-
(3S,4S)-N-butyl-3-hydroxy-6-methyl-4-((2S,3R)-3-methyl-2-(2-(naphthalen-2-yl)acetamido)pentanamido)heptanamide
-
-
(3S,4S)-N-butyl-3-hydroxy-6-methyl-4-((2S,3S)-3-methyl-2-(2-(naphthalen-2-yloxy)acetamido)pentanamido)heptanamide
-
-
(3S,4S)-pyrrolidine-3,4-diyl bis(3,3-dimethylbutanoate)
-
(3S,4S)-pyrrolidine-3,4-diyl bis(3-methylbutanoate)
-
(3S,4S)-pyrrolidine-3,4-diyl bis(naphthalen-1-ylacetate)
(3S,4S)-pyrrolidine-3,4-diyl bis(naphthalen-2-ylacetate)
-
(3S,4S)-pyrrolidine-3,4-diyl bis(phenylacetate)
-
(3S,4S)-pyrrolidine-3,4-diyl dibenzoate
(3S,4S)-pyrrolidine-3,4-diyl dicyclohexanecarboxylate
-
(3S,6S,9S,12S,15S,18S)-15-(3-amino-3-oxopropyl)-18-sec-butyl-3,9-dibutyl-1-((S)-1-((S)-2,6-diaminohexanoyl)pyrrolidin-2-yl)-6-(hydroxymethyl)-12-isobutyl-1,4,7,13,16-pentaoxo-2,5,8,11,14,17-hexaazanonadecan-19-oic acid
-
-
(4R)-3-[(2S,3S)-3-[[(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
-
(4R)-N-tert-butyl-3-[(2S,3S)-2-hydroxy-3-([N-[(isoquinolin-5-yloxy)acetyl]-S-methyl-L-cysteinyl]amino)-4-phenylbutanoyl]-1,3-thiazolidine-4-carboxamide
-
-
(5-[[(4-bromobenzoyl)oxy]methyl]-2,3,4,7-tetrahydro-1H-azepin-3-yl)methyl 4-aminobenzoate
-
(5S)-1-[(2S,3R)-2-hydroxy-4-phenyl-3-[(picolyl-L-valinyl)amino]butyl]-5-(p-phenylbenzyl)imidazolidine-2,4-dione
-
-
(5S)-5-(p-bromobenzyl)-1-[(2S,3R)-2-hydroxy-4-phenyl-3-[(picolyl-L-valinyl)amino]butyl]imidazoline-2,4-dione
-
-
(5S,8S,12S,13S,16S,19S)-13-benzyl-12-hydroxy-8,23,23-trimethyl-16,19-bis(1-methylethyl)-5-(2-methylpropyl)-4,7,10,15,18,21-hexaoxo-3,6,9,14,17,20-hexaazatetracosan-1-amide
-
-
(6S,9S,12R,13S,17S,20R,21S)-13,21-dihydroxy-2,17-dimethyl-6,9-bis(1-methylethyl)-4,7,10,15,18-pentaoxo-12,20-bis(trifluoromethyl)-5,8,11,16,19-pentaazatricosan-23-oic acid
-
-
(R)-N-[(1S,2R)-2-hydroxyindan-1-yl]-3-[(2S,3S)-3-(2,6-dimethyl-4-(pyridine-2-ylmethyl)amino-phenoxyacetyl)amino-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
anti-malarial activity, EC50 value 0.00030 mM
(R)-N-[(1S,2R)-2-hydroxyindan-1-yl]-3-[(2S,3S)-3-(2,6-dimethyl-4-(pyridine-4-ylmethyl)amino-phenoxyacetyl)amino-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
anti-malarial activity, EC50 value 0.00049 mM
(R)-N-[(1S,2R)-2-hydroxyindan-1-yl]-3-[(2S,3S)-3-(2,6-dimethyl-4-ethylamino-phenoxyacetyl)amino-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
anti-malarial activity, EC50 value 0.00072 mM
(R)-N-[(1S,2R)-2-hydroxyindan-1-yl]-3-[(2S,3S)-3-(2,6-dimethyl-4-methylamino-phenoxyacetyl)amino-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
anti-malarial activity, EC50 value 0.00045 mM
(R)-N-[(1S,2R)-2-hydroxyindan-1-yl]-3-[(2S,3S)-3-(4-hydroxymethylphenoxyacetyl)amino-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
anti-malarial activity, EC50 value 0.0011 mM
(S)-2,3-dihydro-1H-indole-2-carboxylic acid ((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl)amide
-
-
(S)-propyl 6-(tert-butoxycarbonylamino)-2-((S)-2-(4-(4-((2S,3S)-1-((3S,4S)-1-(butylamino)-3-hydroxy-6-methyl-1-oxoheptan-4-ylamino)-3-methyl-1-oxopentan-2-ylcarbamoyl)phenoxy)benzamido)-4-methylpentanamido)hexanoate
-
not cytotoxic against human fibroblasts at 0.100 mM and are highly selective for plasmepsins vs human cathepsin D
(S)-propyl 6-amino-2-((S)-2-(4-(4-((2S,3S)-1-((3S,4S)-1-(butylamino)-3-hydroxy-6-methyl-1-oxoheptan-4-ylamino)-3-methyl-1-oxopentan-2-ylcarbamoyl)phenoxy)benzamido)-4-methylpentanamido)hexanoate
-
-
1,2-diphenylhydrazine
-
1-(3-methylbutyl)-N-(4-pentylbenzyl)-N-(4-pyridin-3-ylbenzyl)piperidin-4-amine
-
-
1-(4-chlorophenyl)-2-[2-(pyridin-2-yl)-1H-benzimidazol-1-yl]ethanone
-
IC50 700 nM for antiplasmodial activity
1-(4-nitrophenyl)-2-[2-(pyridin-2-yl)-1H-benzimidazol-1-yl]ethanone
-
IC50 2100 nM for antiplasmodial activity
1-(benzylamino)-3-(3,6-dichloro-9H-carbazol-9-yl)propan-2-ol
-
1-(biphenyl-4-yl)-2-[2-(pyridin-2-yl)-1H-benzimidazol-1-yl]ethanone
-
highest antiplasmodial activity among compounds tested with IC50 of 160 nM
1-(diphenylmethyl)azetidin-3-ol
-
1-acetyl-piperidine-4-carboxylic acid (2-benzo[1,3]dioxol-5-yl-ethyl)-[3-(4-benzyloxy-3,5-dimethoxy-benzoylamino)-2-hydroxy-4-phenyl-butyl]-amide
-
-
1-acetyl-piperidine-4-carboxylic acid (2-benzo[1,3]dioxol-5-yl-ethyl)-[3-[2-(3-chloro-phenoxy)-acetylamino]-2-hydroxy-4-phenyl-butyl]-amide
-
-
1-acetyl-piperidine-4-carboxylic acid (2-benzo[1,3]dioxol-5-yl-ethyl)-[3-[2-(3-chloro-phenylamino)-acetylamino]-2-hydroxy-4-phenyl-butyl]-amide
-
-
1-Acetyl-piperidine-4-carboxylic acid (2-benzo[1,3]dioxol-5-yl-ethyl)-{3-[2-(3-chloro-phenoxy)-acetylamino]-2-hydroxy-4-phenyl-butyl}-amide
-
-
1-Acetyl-piperidine-4-carboxylic acid (2-benzo[1,3]dioxol-5-yl-ethyl)-{3-[2-(3-chloro-phenylamino)-acetylamino]-2-hydroxy-4-phenyl-butyl}-amide
-
-
1-amino-3-(4-nitroanilino)propan-2-ol
-
1-methyl-piperidine-4-carboxylic acid (2-benzo[1,3]dioxol-5-yl-ethyl)-(3-[2-(3-chloro-phenoxy)-acetylamino]-2-hydroxy-4-phenyl-butyl)-amide
-
-
1-Methyl-piperidine-4-carboxylic acid (2-benzo[1,3]dioxol-5-yl-ethyl)-{3-[2-(3-chloro-phenoxy)-acetylamino]-2-hydroxy-4-phenyl-butyl}-amide
-
-
1-Methyl-piperidine-4-carboxylic acid [3-(4-benzyloxy-3,5-dimethoxy-benzoylamino)-2-hydroxy-4-phenyl-butyl]-[2-(4-methoxy-phenyl)-ethyl]-amide
-
-
1-methyl-piperidine-4-carboxylic acid [3-[2-(3-chloro-phenoxy)-acetylamino]-2-hydroxy-4-phenyl-butyl]-[2-(4-methoxy-phenyl)-ethyl]-amide
-
-
1-Methyl-piperidine-4-carboxylic acid {3-[2-(3-chloro-phenoxy)-acetylamino]-2-hydroxy-4-phenyl-butyl}-[2-(4-methoxy-phenyl)-ethyl]-amide
-
-
1-phenyl-N-(propan-2-yl)methanesulfonamide
-
1-[2-hydroxy-3-(1,2,3,4,5,6,7,8-octahydrophenanthren-9-yloxy)propyl]-4-(3-methoxyphenyl)piperazin-1-ium
-
-
1-[3-chloro-6-(trifluoromethyl)phenanthren-9-yl]-3-(dibutylamino)propan-1-ol
-
1-[6-chloro-3-(3,4-dichlorophenyl)naphthalen-1-yl]-2-(dibutylamino)ethanol
-
17-benzyl-14-[2-(3,3-dimethyl-butyrylamino)-3-methyl-butyrylamino]-18-hydroxy-2-isopropyl-3,8,15,20-tetraoxo-1,4,9,16-tetraaza-cycloicosane-5-carboxylic acid carbamoylmethyl-amide
-
-
17-Benzyl-14-[2-(3,3-dimethyl-butyrylamino)-3-methyl-butyrylamino]-18-hydroxy-2-isopropyl-3,8,15,20-tetraoxo-1,4,9,16tetraaza-cycloicosane-5-carboxylic acid carbamoylmethyl-amide
-
-
2,2-diphenylacetohydrazide
-
2,3,4,7-tetrahydro-1H-azepine-3,5-diyldimethanediyl bis(4-aminobenzoate)
Ki value for human cathepsin D 0.142 mM
2,3,4-trifluoro-N-([[1-(3-methylbutyl)piperidin-4-yl](4-pentylbenzoyl)amino]methyl)benzamide
-
2,3-difluoro-4-methyl-N-[4-([[1-(3-methylbutyl)piperidin-4-yl][(4-pentylphenyl)carbonyl]amino]methyl)phenyl]benzamide
-
-
2,5-Bis-allyloxy-3,4-dihydroxy-hexanedioic acid bis-[(2-hydroxy-indan-1-yl)-amide]
-
-
2,5-Bis-benzyloxy-3,4-dihydroxy-hexanedioic acid bis-[(2-hydroxy-indan-1-yl)-amide]
-
-
2-(1,3-benzothiazol-2-ylamino)-N-(2-chlorophenyl)-6-oxo-1,4,5,6­tetrahydro-4-pyrimidinecarboxamide
-
-
2-(1-naphthyl)-N'-[(4-nitrobenzoyl)oxy]ethanimidamide
-
-
2-(2-naphthyl)-N-(4-pentylphenyl)-N-piperidin-4-ylacetamide hydrochloride
-
-
2-(dihexylamino)-1-(1,2,3,4-tetrahydrophenanthren-9-yl)ethanol
-
2-([2-[4-([[(1S,2S,3R,4R)-3-(naphthalen-2-ylmethoxy)-7-azabicyclo[2.2.1]hept-2-yl]oxy]methyl)phenoxy]ethyl]sulfanyl)-1,3-benzothiazole
-
2-([2-[4-([[3-(naphthalen-2-ylmethoxy)-7-azabicyclo[2.2.1]hept-2-yl]oxy]methyl)phenoxy]ethyl]sulfanyl)-1,3-benzothiazole
-
-
2-([4'-(([2-(dibutylamino)ethyl](4-pentylbenzyl)amino)methyl)biphenyl-4-yl]oxy)ethanol
-
IC50: 441 nM
2-([N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-(methylsulfonyl)glycyl]amino)-N-isobutylbenzamide
-
-
2-amino-3-[(oxolan-2-yl)methyl]quinazolin-4(3H)-one
-
2-amino-7-(4-butylphenyl)-3-[(5-phenyltetrahydrofuran-2-yl)methyl]quinazolin-4(3H)-one
-
2-amino-7-(4-pentylphenyl)-3-[(5-phenyltetrahydrofuran-2-yl)methyl]quinazolin-4(3H)-one
-
2-amino-7-phenyl-3-(tetrahydrofuran-2-ylmethyl)quinazolin-4(3H)-one
-
2-amino-7-phenyl-3-[(5-phenyltetrahydrofuran-2-yl)methyl]quinazolin-4(3H)-one
-
2-amino-7-[4-(4-phenylbutyl)phenyl]-3-[(5-phenyltetrahydrofuran-2-yl)methyl]quinazolin-4(3H)-one
-
2-anilino-3-chloro-N-phenyl-4-(phenylimino)-2-butenamide
-
-
2-anilino-4-(3-furyl)-6-oxo-N-phenyl-1-cyclohexene-1-carboxamide
-
-
2-methoxybenzohydrazide
-
2-nitrobenzohydrazide
-
2-[(Z)-1-(4-chlorophenyl)-2-[3-(pyridin-2-yl)isoquinolin-1-yl]ethenyl]hydrazine-1-carboximidothioic acid
-
2-[4'-(([2-(dibutylamino)ethyl](4-pentylbenzyl)amino)methyl)biphenyl-4-yl]ethanol
-
IC50: 0.00147 mM
2-[bis(4-methylpentyl)amino]-1-(1,2,3,4-tetrahydrophenanthren-9-yl)ethanol
-
3'-(((1S,2S,3S,4R)-3-(4-hexylphenylsulfonyl)-7-azabicyclo[2.2.1]heptan-2-ylamino)methyl)biphenyl-2-ol
-
-
3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,5a,6,11,11a-octahydrotetracen-1-yl 3,4-di-O-acetyl-2,6-dideoxyhexopyranoside
-
-
3-amino-N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-1-(2-methylpropyl)-5-phenylpentyl]benzamide
-
-
3-amino-N-[(4S,6S,7S)-7-[[(2,6-dimethylphenoxy)acetyl]amino]-6-hydroxy-2-methyl-8-phenyloctan-4-yl]benzamide
-
3-chloro-N-([2-(2-methoxybenzoyl)hydrazino]carbonothioyl)-1-benzothiophene-2-carboxamide
-
-
3-[3-(4-chlorophenyl)-3-hydroxy-3-phenylpropyl]-3-azoniabicyclo[4.2.1]nonane
-
-
4'-(([2-(dibutylamino)ethyl](4-pentylbenzyl)amino)methyl)biphenyl-4-carbonitrile
4'-(([2-(dibutylamino)ethyl](phenylcarbonyl)amino)methyl)biphenyl-3-carboxylic acid
-
IC50: 208 nM
4'-(([2-(dibutylamino)ethyl](phenylcarbonyl)amino)methyl)biphenyl-4-carboxylic acid
-
IC50: 495 nM
4'-(([2-(dibutylamino)ethyl][(4-pentylphenyl)carbonyl]amino)methyl)-N,N-dimethylbiphenyl-4-carboxamide
-
IC50: 77 nM
4,4'-(hydrazine-1,2-diyl)dipyridine
-
4-(1,2-benzothiazol-3-yl)-N-methylpiperazine-1-carboxamide
-
4-(1,3-benzodioxol-5-yl)-Nalpha-[(2S,3S)-2-hydroxy-3-([N-[3-(1H-indol-3-yl)propanoyl]-L-valyl]amino)-4-phenylbutyl]-L-phenylalaninamide
-
-
4-(1-benzofuran-2-yl)-Nalpha-[(2S,3S)-2-hydroxy-4-phenyl-3-[[N-(pyridin-2-ylcarbonyl)-L-valyl]amino]butyl]-L-phenylalaninamide
-
-
4-(benzyloxy)-N-[(1S,2S)-3-[(1-benzylpiperidin-4-yl)amino]-1-(cyclohexylmethyl)-2-hydroxypropyl]-3,5-dimethoxybenzamide
-
-
4-(imidazo[2,1-b][1,3]thiazol-6-yl)aniline
-
4-([[(4-phenoxyphenyl)amino]carbonyl]amino)benzenecarboximidamide
-
-
4-amino-N'-(benzyloxy)-N-(2-methylphenyl)-1,2,5-oxadiazole-3-carboximidamide
-
4-amino-N'-(benzyloxy)-N-(2-methylphenyl)-1,2,5-oxadiazole-3­carboximidamide
-
-
4-amino-N'-(benzyloxy)-N-(4-methylphenyl)-1,2,5-oxadiazole-3­carboximidamide
-
-
4-amino-N'-[(2,4-dichlorobenzyl)oxy]-N-(2-methylphenyl)-1,2,5­oxadiazole-3-carboximidamide
-
-
4-amino-N'-[(2,4-dichlorophenyl)methoxy]-N-(2-methylphenyl)-1,2,5-oxadiazole-3-carboximidamide
-
4-amino-N'-[(2-methyl-1-naphthyl)methoxy]-1,2,5-oxadiazole-3­carboximidamide
-
-
4-amino-N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-1-(2-methylpropyl)-5-phenylpentyl]benzamide
-
-
4-amino-N-[(4S,6S,7S)-7-[[(2,6-dimethylphenoxy)acetyl]amino]-6-hydroxy-2-methyl-8-phenyloctan-4-yl]benzamide
-
4-butoxy-N-[2-(dibutylamino)ethyl]-N-(3-phenoxybenzyl)benzamide
-
IC50: 0.0059 mM
4-butoxy-N-[2-(dibutylamino)ethyl]-N-[4-(trifluoromethyl)benzyl]benzamide
-
IC50: 0.0103 mM
4-butyl-N-[2-(dibutylamino)ethyl]-N-(3-phenoxybenzyl)benzamide
-
IC50: 0.0023 mM
4-butyl-N-[2-(dibutylamino)ethyl]-N-[4-(trifluoromethyl)benzyl]benzamide
-
IC50: 0.0039 mM
4-chloro-5-(4-chlorophenoxy)-2-[([[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl)amino]benzenesulfonate
-
-
4-methoxy-N-(2-[5-(2-nitrophenyl)-2-furyl]-1-([(4-pyridinylmethyl)amino]carbonyl)vinyl)benzamide
-
-
4-methyl-N-[2-[2-(naphthalen-2-yl)hydrazinyl]phenyl]benzene-1-sulfonamide
-
5-methyl-N3-phenyl-1H-pyrazole-3,4-diamine
-
5-[4-([(1S,2R,3R,4R)-3-[(naphthalen-2-ylmethyl)amino]-7-azabicyclo[2.2.1]hept-2-yl]sulfonyl)phenyl]pentan-1-ol
-
5-[bis[(benzyloxy)carbonyl]amino]-6-[[1-hydrazinyl-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-6-oxohexan-1-aminium
-
-
6-((2-[(5-chloro-2-methoxyphenyl)amino]-2-oxoethyl)thio)-5-cyano-N-(2-methoxyphenyl)-2-methyl-4-phenyl-1,4-dihydro-3-pyridinecarboxamide
-
-
6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-one N­phenylthiosemicarbazone
-
-
6-[3-(1,3-benzothiazol-2-ylsulfanyl)propyl]-7-(2-naphthalen-1-ylethoxy)-1,2,3,4-tetrahydro-1,4-epiminonaphthalene
-
-
6-[4-([(1S,2R,3R,4R)-3-[(naphthalen-2-ylmethyl)amino]-7-azabicyclo[2.2.1]hept-2-yl]sulfonyl)phenyl]hex-5-yn-1-ol
-
6-[4-([(1S,2R,3R,4R)-3-[(naphthalen-2-ylmethyl)amino]-7-azabicyclo[2.2.1]hept-2-yl]sulfonyl)phenyl]hexan-1-ol
-
Ac-Val-Val-Sta-Ala-Sta
-
IC50: 0.6 nM
benzo[1,3]dioxole-5-carboxylic acid ((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl)-amide
-
-
benzyl 2-benzyl-2-[(2S,3R)-3-[(4-bromobenzyl)oxy]-2-hydroxy-4-oxo-4-[(2-piperidin-1-ylethyl)amino]butyl]hydrazinecarboxylate
-
-
benzyl 3-benzyl-4-([2-[(1-formyl-3-methylbutyl)amino]-2-oxo-1-phenylethyl]amino)-4-oxobutanoate
-
-
benzyl [(1S,4S,5R,6R,7S,10S)-4,7-bis[(4-cyanophenoxy)methyl]-5,6-dihydroxy-1,10-bis(1-methylethyl)-2,9,12-trioxo-14-phenyl-13-oxa-3,8,11-triazatetradec-1-yl]carbamate
-
-
butanehydrazide
-
butyloxycarbonyl-His-Pro-Phe-His-Leu-PSI[CH(OH)-CH2]-Val-Ile-His
-
IC50: 150 nM
butyloxycarbonyl-His-Pro-Phe-His-Sta-Leu-Phe-NH2
-
IC50: 1000 nM
Chloroquine-hemin complex
-
-
extract from Plexaura homomalla
-
black sea rod, extract contains a reversible tight-binding inhibitor
-
extract from Xestospongia muta
-
giant barrel sponge, extract contains a reversible tight-binding inhibitor
-
Iva-Val-Val-Sta-Ala-Sta
KNI-10333
-
nanomolar inhibition activity
KNI-10343
-
nanomolar inhibition activity
KNI-10395
-
nanomolar inhibition activity
KNI-10742
-
nanomolar inhibition activity
KNI-10743
-
nanomolar inhibition activity
L-lysyl-L-prolyl-L-phenylalanyl-N-[(1S)-1-benzyl-2-[[(1S)-1-benzyl-2-[[(1S)-2-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-1-(hydroxymethyl)-2-oxoethyl]amino]-2-oxoethyl]amino]ethyl]-L-norleucinamide
-
-
Lac-Val-Sta-Ala-Sta
-
IC50: 100 mM
LCu(CH3COO)2
-
copper(II) nanohybrid solids are synthesized and are shown to be capped by a bis(benzimidazole) diamide ligand (L)
LCuCl2
-
copper(II) nanohybrid solids are synthesized and are shown to be capped by a bis(benzimidazole) diamide ligand (L)
methyl 4'-([[1-(1H-imidazol-2-ylmethyl)piperidin-4-yl][(4-pentylphenyl)carbonyl]amino]methyl)biphenyl-4-carboxylate
-
-
methyl [4'-(([1-(1H-imidazol-2-ylmethyl)piperidin-4-yl][(4-pentylphenyl)carbonyl]amino)methyl)biphenyl-4-yl]acetate
-
-
methyl [4'-(([2-(dibutylamino)ethyl](phenylcarbonyl)amino)methyl)biphenyl-4-yl]acetate
-
IC50: 124 nM
methyl [4'-(([2-(dibutylamino)ethyl][(4-pentylphenyl)carbonyl]amino)methyl)biphenyl-4-yl]acetate
-
IC50: 183 nM
methyl [4'-([[1-(1H-imidazol-2-ylmethyl)piperidin-4-yl](4-pentylbenzoyl)amino]methyl)biphenyl-4-yl]acetate
-
methyl [4'-([[1-(1H-imidazol-2-ylmethyl)piperidin-4-yl][(4-pentylphenyl)carbonyl]amino]methyl)biphenyl-4-yl]acetate
-
-
methyl [4'-([[1-(3-methylbutyl)piperidin-4-yl][(4-pentylcyclohexyl)carbonyl]amino]methyl)biphenyl-4-yl]acetate
-
-
methyl [4'-([[1-(3-methylbutyl)piperidin-4-yl][(4-pentylphenyl)carbonyl]amino]methyl)biphenyl-4-yl]acetate
-
-
N',N'''-1,2-phenylenebis[N-(3-chlorophenyl)urea]
-
-
N',N''-[1,10-phenanthroline-2,9-diyldi(E)methylylidene]bis[N-(2-methylphenyl)pyridine-2-carbohydrazonamide]
-
N'-(3,4-dimethylacridin-9-yl)-2-hydroxybenzohydrazide
-
N'-(3,4-dimethylacridin-9-yl)-3-methylbenzohydrazide
-
N'-(4-chlorophenyl)-N'-(2-[[(3-chlorophenyl)carbamoyl]amino]phenyl)urea
-
N'-[(4-methoxy-3-nitrobenzoyl)oxy]-2-(1-naphthyl)ethanimidamide
-
-
N'1-[(E)-(2,3-dihydroxyphenyl)methylidene]-N'3-[(Z)-(2,3-dihydroxyphenyl)methylidene]benzene-1,3-dicarbohydrazide
-
-
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis(N-benzyl-2-phenylacetamide)
N,N'-([(4,6-dimethyl-2-quinazolinyl)amino]methylylidene)dipropanamide
-
-
N,N-dibutyl-3-(1,4-dihydronaphthalen-1-yl)-3-hydroxybutan-1-aminium
-
-
N,N-dibutyl-N'-(4-pentylbenzyl)-N'-(4-pyridin-2-ylbenzyl)ethane-1,2-diamine
-
IC50: 0.0013 mM
N,N-dibutyl-N'-(4-pentylbenzyl)-N'-(4-pyridin-4-ylbenzyl)ethane-1,2-diamine
-
IC50: 0.001603 mM
N,N-dibutyl-N'-(4-pentylbenzyl)-N'-(4-pyrimidin-5-ylbenzyl)ethane-1,2-diamine
-
IC50: 0.001631 nM
N,N-dibutyl-N'-(4-pentylbenzyl)-N'-([4'-(2-pyrrolidin-1-ylethoxy)biphenyl-4-yl]methyl)ethane-1,2-diamine
-
IC50: 0.002 mM
N,N-dibutyl-N'-[(2'-fluorobiphenyl-4-yl)methyl]-N'-(4-pentylbenzyl)ethane-1,2-diamine
-
IC50: 0.001022 mM
N-((1S,2S)-1-(4-benzo[1,3]dioxol-5-yl-benzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-hydroxy-propyl)-2,4,6-trifluorobenzamide
-
-
N-((1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-[2-(3-methoxyphenyl)ethylcarbamoyl]propyl)-2,4,6-trifluorobenzamide
-
-
N-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl)-2,4,6-trifluorobenzamide
-
-
N-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl)-3,4-dichlorobenzamide
-
-
N-((1S,2S)-1-(biphenyl-4-ylmethoxymethyl)-2-hydroxy-3-[2-(3-methoxy-phenyl)-ethylcarbamoyl]-propyl)-2,4,6-trifluorobenzamide
-
-
N-((1S,2S)-1-(biphenyl-4-ylmethoxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-hydroxy-propyl)-2,4,6-trifluorobenzamide
-
-
N-((1S,2S)-2-hydroxy-3-[2-(3-methoxy-phenyl)-ethyl-carbamoyl]-1-(4-thiophen-3-yl-benzyloxymethyl)-propyl)-2,4,6-trifluorobenzamide
-
-
N-((2,3-dihydro-1,4-benzodioxin-6-ylamino)[(6-methyl-4-oxo-1,4-dihydro-2-pyrimidinyl)amino]methylene)benzamide
-
-
N-((2,3-dihydro-1,4-benzodioxin-6-ylamino)[(6-oxo-4-propyl-1,6-dihydro-2-pyrimidinyl)amino]methylene)-4-methoxybenzamide
-
-
N-((2S)-1-((2S)-6-amino-1-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-1-oxohexan-2-ylamino)-1-oxopropan-2-yl)-4-(4-((2S,3S)-1-((3S,4S)-1-(butylamino)-3-hydroxy-6-methyl-1-oxoheptan-4-ylamino)-3-methyl-1-oxopentan-2-ylcarbamoyl)phenoxy)benzamide
-
-
N-((2S)-1-((2S)-6-amino-1-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-1-oxohexan-2-ylamino)-4-methyl-1-oxopentan-2-yl)-4-(4-((2S,3R)-1-((3S,4S)-1-(butylamino)-3-hydroxy-6-methyl-1-oxoheptan-4-ylamino)-3-methyl-1-oxopentan-2-ylcarbamoyl)phenoxy)benzamide
-
-
N-((2S,3S)-1-((3S,4S)-1-(butylamino)-3-hydroxy-6-methyl-1-oxoheptan-4-ylamino)-3-methyl-1-oxopentan-2-yl)-4-(4-((2S)-1-((2S)-1-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-1-oxopropan-2-ylamino)-1-oxopropan-2-ylcarbamoyl)phenoxy)benzamide
-
-
N-((2S,3S)-1-((3S,4S)-1-(butylamino)-3-hydroxy-6-methyl-1-oxoheptan-4-ylamino)-3-methyl-1-oxopentan-2-yl)-4-(4-((2S)-1-((2S)-1-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-1-oxopropan-2-ylamino)-4-methyl-1-oxopentan-2-ylcarbamoyl)phenoxy)benzamide
-
not cytotoxic against human fibroblasts at 0.100 mM and are highly selective for plasmepsins vs human cathepsin D
N-((2S,3S)-1-((3S,4S)-1-(butylamino)-3-hydroxy-6-methyl-1-oxoheptan-4-ylamino)-3-methyl-1-oxopentan-2-yl)-4-(4-((2S)-1-((2S)-1-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-4-methyl-1-oxopentan-2-ylamino)-4-methyl-1-oxopentan-2-ylcarbamoyl)phenoxy)benzamid
-
-
N-((2S,3S)-1-((3S,4S)-1-(butylamino)-3-hydroxy-6-methyl-1-oxoheptan-4-ylamino)-3-methyl-1-oxopentan-2-yl)-4-(4-((2S)-1-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-4-methyl-1-oxopentan-2-ylcarbamoyl)phenoxy)benzamide
-
not cytotoxic against human fibroblasts at 0.100 mM and are highly selective for plasmepsins vs human cathepsin D
N-((2S,3S)-1-((3S,4S)-1-(butylamino)-3-hydroxy-6-methyl-1-oxoheptan-4-ylamino)-3-methyl-1-oxopentan-2-yl)-4-(4-(4-(6-methoxyquinolin-8-ylamino)pentylcarbamoyl)phenoxy)benzamide
-
-
N-((4'-[2-(benzylamino)-2-oxoethyl]biphenyl-4-yl)methyl)-N-[2-(dibutylamino)ethyl]-4-pentylbenzamide
-
IC50: 46 nM
N-((S)-1-(((2S,3S)-3-hydroxy-5-oxo-5-(((S)-1-oxo-3-phenyl-1-(prop-2-yn-1-ylamino)propan-2-yl)amino)-1-phenylpentan-2-yl)-amino)-3-methyl-1-oxobutan-2-yl)picolinamide
-
-
N-((S)-1-(((2S,3S)-5-(((R)-1-(((S)-1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-chloro-1-oxopropan-2-yl)amino)-3-hydroxy-5-oxo-1-phenylpentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)-picolinamide
-
-
N-((S)-1-(((2S,3S)-5-(((S)-1-(((S)-1-amino-4-methyl-1-oxopentan-2-yl)amino)-1-oxopent-4-yn-2-yl)amino)-3-hydroxy-5-oxo-1-phenylpentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)-picolinamide
-
-
N-((S)-1-(((2S,3S)-5-(((S)-1-(((S)-1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-cyano-1-oxopropan-2-yl)amino)-3-hydroxy-5-oxo-1-phenylpentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)picolinamide
-
-
N-(([2-(4-ethylphenyl)-6-methyl-2H-1,2,3-benzotriazol-5-yl]amino)carbonothioyl)-2-nitrobenzamide
-
-
N-(([6-methyl-2-(4-methylphenyl)-2H-1,2,3-benzotriazol-5-yl]amino)carbonothioyl)-2-nitrobenzamide
-
-
N-(1,3-benzodioxol-5-ylmethyl)-N'-[4-(2-oxo-2H-chromen-3-yl)-1,3­thiazol-2-yl]succinamide
-
-
N-(2,5-dimethyl-1H-pyrrol-1-yl)-4-hydroxybenzamide
-
N-(2-([3-(1,3-benzodioxol-5-yl)-3-oxo-1-propen-1-yl]amino)phenyl)-4-nitrobenzenesulfonamide
-
-
N-(2-aminoethyl)-N-(biphenyl-4-ylmethyl)-4-pentylbenzamide
-
IC50: 0.003329 nM
N-(2-benzo[1,3]dioxol-5-yl-ethyl)-N-[3-[2-(2,5-dimethyl-phenoxy)-acetylamino]-2-hydroxy-4-phenyl-butyl]-3-(dioxo-1,3-dihydro-isoindol-2-yl)-propionamide
-
-
N-(2-benzo[1,3]dioxol-5-yl-ethyl)-N-[3-[2-(3-chloro-phenoxy)-acetylamino]-2-hydroxy-4-phenyl-butyl]-3-(dioxo-1,3-dihydro-isoindol-2-yl)-propionamide
-
-
N-(2-Benzo[1,3]dioxol-5-yl-ethyl)-N-{3-[2-(2,5-dimethyl-phenoxy)-acetylamino]-2-hydroxy-4-phenyl-butyl}-3-(dioxo-1,3-dihydro-isoindol-2-yl)-propionamide
-
-
N-(2-Benzo[1,3]dioxol-5-yl-ethyl)-N-{3-[2-(3-chloro-phenoxy)-acetylamino]-2-hydroxy-4-phenyl-butyl}-3-(dioxo-1,3-dihydro-isoindol-2-yl)-propionamide
-
-
N-(2-methoxyphenyl)-2-(5H-[1,2,4]triazino[5,6-b]indol-3­ylthio)butanamide
-
-
N-(3,4-dichlorophenyl)-2-[(4,6-dimethyl-2-pyrimidinyl)amino]­3a,4,5,6,7,7a-hexahydro-1H-benzimidazole-1-carboxamide
-
-
N-(3,4-dichlorophenyl)-2-[(4,6-dimethylpyrimidin-2-yl)amino]-3a,4,5,6,7,7a-hexahydro-1H-benzimidazole-1-carboxamide
-
N-(3,4-dimethylphenyl)-N'-(imino[(4,6,7-trimethyl-2-quinazolinyl)amino]methyl)thiourea
-
-
N-(3-carbamoylthiophen-2-yl)thiophene-2-carboxamide
-
N-(3-{(2-Benzo[1,3]dioxol-5-yl-ethyl)-[3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propionyl]-amino}-1-benzyl-2-hydroxy-propyl)-4-benzyloxy-3,5-dimethoxy-benzamide
-
-
N-(4-hexylphenyl)-2-(2-naphthyl)-N-piperidin-4-ylacetamide hydrochloride
-
-
N-(4-[5-(1,3-benzodioxol-5-yl)pyridin-2-yl]benzyl)-N-[2-(dibutylamino)ethyl]-4-pentylbenzamide
-
IC50: 1912 nM
N-(4-[6-(1,3-benzodioxol-5-yl)pyridin-3-yl]benzyl)-N-[2-(dibutylamino)ethyl]-4-pentylbenzamide
-
IC50: 437 nM
N-(4-[benzyl(methyl)amino]benzyl)-N-[2-(dibutylamino)ethyl]-4-pentylbenzamide
-
IC50: 289 nM
N-(amino[(4,6-dimethyl-2-quinazolinyl)amino]methylene)-2-(4-chlorophenyl)acetamide
-
-
N-(biphenyl-4-ylmethyl)-4-butoxy-N-[2-(dibutylamino)ethyl]benzamide
-
IC50: 0.0047 mM
N-(biphenyl-4-ylmethyl)-4-butyl-N-[2-(dibutylamino)ethyl]benzamide
-
IC50: 0.0015 mM
N-(biphenyl-4-ylmethyl)-N',N'-dibutyl-N-(4-pentylbenzyl)ethane-1,2-diamine
-
IC50: 0.002067 mM
N-(biphenyl-4-ylmethyl)-N-(2-[bis(1-methylethyl)amino]ethyl)-4-pentylbenzamide
-
IC50: 0.003943 mM
N-(biphenyl-4-ylmethyl)-N-[2-(butylamino)ethyl]-4-pentylbenzamide
-
IC50: 0.001161 mM
N-(biphenyl-4-ylmethyl)-N-[2-(dibutylamino)ethyl]-4-pentylbenzamide
N-(biphenyl-4-ylmethyl)-N-[2-(dibutylamino)ethyl]-4-propylbenzamide
-
IC50: 0.0129 mM
N-(biphenyl-4-ylmethyl)-N-[2-(diethylamino)ethyl]-4-pentylbenzamide
-
IC50: 0.002317 mM
N-(cyclopentylcarbamothioyl)-4-ethoxy-3-nitrobenzamide
-
N-([(1RS)-3,3-difluoro-4-oxocyclohexyl]methyl)-2-(2-naphthyl)-N-(4-pentylphenyl)acetamide
-
-
N-([(1RS)-3,3-difluoro-4-oxocyclopentyl]methyl)-2-(2-naphthyl)-N-(4-pentylphenyl)acetamide
-
-
N-([(1RS,4RS)-3,3-difluoro-4-hydroxycyclohexyl]methyl)-2-(2-naphthyl)-N-(4-pentylphenyl)acetamide
-
-
N-([(1RS,4SR)-3,3-difluoro-4-hydroxycyclohexyl]methyl)-2-(2-naphthyl)-N-(4-pentylphenyl)acetamide
-
-
N-([(1SR,4RS)-3,3-difluoro-4-hydroxycyclopentyl]methyl)-2-(2-naphthyl)-N-(4-pentylphenyl)acetamide
-
-
N-([(1SR,4SR)-3,3-difluoro-4-hydroxycyclopentyl]methyl)-2-(2-naphthyl)-N-(4-pentylphenyl)acetamide
-
-
N-([(2,4-dimethylphenyl)amino][(4-oxo-1,4,5,6,7,8-hexahydro-2-quinazolinyl)amino]methylene)benzamide
-
-
N-([3',5'-bis(trifluoromethyl)biphenyl-4-yl]methyl)-N-[2-(dibutylamino)ethyl]benzamide
-
IC50: 0.0017 mM
N-([3',5'-bis(trifluoromethyl)biphenyl-4-yl]methyl)-N-[3-(dibutylamino)propyl]-4-pentylbenzamide
-
IC50: 0.00119 mM
N-([5-[3,5-bis(trifluoromethyl)phenyl]furan-2-yl]methyl)-N-[1-(3-methylbutyl)piperidin-4-yl]-4-pentylbenzamide
-
N-([5-[3,5-bis(trifluoromethyl)phenyl]furan-2-yl]methyl)-N-[1-(3-methylbutyl)piperidin-4-yl]-5-pentylpyridine-2-carboxamide
-
-
N-([[1-(3-methylbutyl)piperidin-4-yl](4-pentylbenzoyl)amino]methyl)-1-benzothiophene-2-carboxamide
-
N-([[1-(3-methylbutyl)piperidin-4-yl](4-pentylbenzoyl)amino]methyl)pyridine-3-carboxamide
-
N-acetyl-L-leucyl-L-leucyl-norleucinal
-
-
N-benzyl-2-([3-(3-nitrophenyl)acryloyl]amino)benzamide
-
-
N-benzyl-2-bromo-N-[(4-[[2-(2,4-dichlorophenyl)ethyl](4-phenylbutanoyl)amino]pyrrolidin-3-yl)methyl]-4,5-dimethoxybenzamide
-
N-benzyl-2-bromo-N-[(4-[[2-(2,4-dichlorophenyl)ethyl][3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propanoyl]amino]pyrrolidin-3-yl)methyl]-4,5-dimethoxybenzamide
-
N-benzyl-2-bromo-N-[[4-([[3-(2,4-dichlorophenyl)propyl](3-phenylpropyl)amino]methyl)pyrrolidin-3-yl]methyl]-4,5-dimethoxybenzamide
-
N-benzyl-2-bromo-N-[[4-([[3-(2,4-dichlorophenyl)propyl][2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]amino]methyl)pyrrolidin-3-yl]methyl]-4,5-dimethoxybenzamide
-
N-benzyl-4'-(([2-(dibutylamino)ethyl][(4-pentylphenyl)carbonyl]amino)methyl)biphenyl-4-carboxamide
-
IC50: 72 nM
N-butyl-N-[2-[6-chloro-3-(3,4-dichlorophenyl)naphthalen-1-yl]-2-hydroxyethyl]butan-1-aminium
-
-
N-hexyl-N-[2-hydroxy-2-(1,2,3,4-tetrahydrophenanthren-9-yl)ethyl]hexan-1-aminium
-
-
N-hexyl-N-[2-hydroxy-2-(phenanthren-9-yl)ethyl]hexan-1-aminium
-
-
N-[(1S)-1-([(1S,2S)-1-([(4-bromobenzyl)oxy]methyl)-4-([(1S)-2-([(1S)-1-carbamoylbutyl]amino)-2-hydroxy-1-methylethyl]amino)-2-hydroxy-4-oxobutyl]carbamoyl)-2-methylpropyl]-4,5-dihydropyridine-2-carboxamide
-
-
N-[(1S)-1-([(1S,2S)-3-[(2-amino-2-oxoethyl)(benzyl)amino]-1-benzyl-2-hydroxypropyl]carbamoyl)-2-methylpropyl]pyridine-2-carboxamide
-
-
N-[(1S)-1-[[(1S,2S)-1-([[4-(1,3-benzodioxol-5-yl)benzyl]oxy]methyl)-4-[[(1S)-2-[[(1S)-1-carbamoyl-3-methylbutyl]amino]-1-methyl-2-oxoethyl]amino]-2-hydroxy-4-oxobutyl]carbamoyl]-2-methylpropyl]pyridine-2-carboxamide
-
-
N-[(1S)-1-[[(1S,2S)-1-benzyl-4-[[(1S)-2-[[(1S)-1-carbamoyl-3-methylbutyl]amino]-1-methyl-2-oxoethyl]amino]-2-hydroxy-4-oxobutyl]carbamoyl]-2-methylpropyl]pyridine-2-carboxamide
-
-
N-[(1S)-1-[[(1S,2S)-1-[[(4-bromobenzyl)oxy]methyl]-4-[[(1S)-2-[[(1S)-1-carbamoyl-3-methylbutyl]amino]-1-methyl-2-oxoethyl]amino]-2-hydroxy-4-oxobutyl]carbamoyl]-2-methylpropyl]pyridine-2-carboxamide
-
-
N-[(1S)-1-[[(1S,2S)-3-([(1S)-2-amino-1-[(4'-methylbiphenyl-4-yl)methyl]-2-oxoethyl]amino)-1-benzyl-2-hydroxypropyl]carbamoyl]-2-methylpropyl]pyridine-2-carboxamide
-
-
N-[(1S)-1-[[(1S,2S)-3-[[(1S)-2-amino-1-(biphenyl-3-ylmethyl)-2-oxoethyl]amino]-1-benzyl-2-hydroxypropyl]carbamoyl]-2-methylpropyl]pyridine-2-carboxamide
-
-
N-[(1S)-1-[[(1S,2S)-3-[[(1S)-2-amino-1-(biphenyl-4-ylmethyl)-2-oxoethyl](benzyl)amino]-1-benzyl-2-hydroxypropyl]carbamoyl]-2-methylpropyl]pyridine-2-carboxamide
-
-
N-[(1S)-1-[[(1S,2S)-3-[[(1S)-2-amino-1-(biphenyl-4-ylmethyl)-2-oxoethyl]amino]-1-benzyl-2-hydroxypropyl]carbamoyl]-2-methylpropyl]pyridine-2-carboxamide
-
-
N-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-cyclohexylcarbamoyl-2-hydroxypropyl]-2,4,6-trifluorobenzamide
-
-
N-[(1S,2S)-1-(biphenyl-4-ylmethoxymethyl)-3-cyclo-hexylcarbamoyl-2-hydroxypropyl]-2,4,6-trifluorobenzamide
-
-
N-[(1S,2S)-1-[[(4-bromobenzyl)oxy]methyl]-4-[[(1S)-2-[[(1S)-1-carbamoyl-3-methylbutyl]amino]-1-methyl-2-oxoethyl]amino]-2-hydroxy-4-oxobutyl]-2,4,6-trifluorobenzamide
-
-
N-[(1S,2S)-3-cyclohexylcarbamoyl-2-hydroxy-1-(4-thiophen-3-yl-benzyloxymethyl)-propyl]-2,4,6-trifluorobenzamide
-
-
N-[(1S,2S)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butyl-carbamoyl)-ethylcarbamoyl]-2-hydroxy-1-(4-thiophen-3-yl-benzyloxymethyl)-propyl]-2,4,6-trifluorobenzamide
-
-
N-[(1S,2S)-3-[[2-(1,3-benzodioxol-5-yl)ethyl][3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propanoyl]amino]-1-benzyl-2-hydroxypropyl]-4-(benzyloxy)-3,5-dimethoxybenzamide
-
-
N-[(1SR,3RS)-4,4-difluoro-3-hydroxycyclohexyl]-2-(2-naphthyl)-N-(4-pentylphenyl)acetamide
-
-
N-[(1SR,3SR)-4,4-difluoro-3-hydroxycyclohexyl]-2-(2-naphthyl)-N-(4-pentylphenyl)acetamide
-
-
N-[(2'-chlorobiphenyl-4-yl)methyl]-N-[2-(dibutylamino)ethyl]benzamide
-
IC50: 191 nM
N-[(2S,3S)-2-hydroxy-3-[(phenoxyacetyl)amino]-4-phenylbutyl]-N-[2-(4-methoxyphenyl)ethyl]piperidine-4-carboxamide
-
inhibitor candidate, designed according to inhibitor modeling. Selectivity index Ki value Cathepsin D to Ki value PlmII is 15
N-[(2S,3S)-3-[[(3-chlorophenoxy)acetyl]amino]-2-hydroxy-4-phenylbutyl]-N-[2-(4-methoxyphenyl)ethyl]piperidine-4-carboxamide
-
-
N-[(2S,3S)-5-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-[(4-bromobenzyl)oxy]-3-hydroxy-5-oxopentan-2-yl]-2,4,6-trifluorobenzamide
-
inhibitor candidate, designed according to inhibitor modeling. Selectivity index Ki value Cathepsin D to Ki value PlmII is above 400
N-[(3-ethyl-1,2-oxazol-5-yl)methyl]-N-[1-(3-methylbutyl)piperidin-4-yl]-4-pentylbenzamide
-
N-[(3S)-3-[(2S,5S,14S)-14-[(3,3-dimethylbutanoyl)amino]-2-(1-methylethyl)-3,11,15-trioxo-1,4,10-triazacyclopentadecan-5-yl]-3-hydroxypropanoyl]-L-valyl-L-leucylglycinamide
-
-
N-[(3S,4S)-3-hydroxy-6-phenyl-4-[[N-(pyridin-2-ylcarbonyl)-L-valyl]amino]hexanoyl]-L-alanyl-L-leucinamide
-
-
N-[(4'-butylbiphenyl-4-yl)methyl]-N-[2-(dibutylamino)ethyl]benzamide
-
IC50: 591 nM
N-[(4'-chlorobiphenyl-4-yl)methyl]-N-[2-(dibutylamino)ethyl]benzamide
-
IC50: 446 nM
N-[(4'-chlorobiphenyl-4-yl)methyl]-N-[3-(dibutylamino)propyl]-4-pentylbenzamide
-
IC50: 407 nM
N-[(4'-cyanobiphenyl-4-yl)methyl]-N-[2-(dibutylamino)ethyl]benzamide
-
IC50: 160 nM
N-[(cyclopentylamino)carbonothioyl]-4-ethoxy-3-nitrobenzamide
-
-
N-[(E)-[(2,4-dimethylphenyl)amino][(4-oxo-1,4,5,6,7,8-hexahydroquinolin-2-yl)amino]methylidene]benzamide
-
N-[1-(3-methylbutyl)piperidin-4-yl]-4-pentyl-N-[4-[(pyridin-3-ylmethyl)carbamoyl]benzyl]benzamide
-
-
N-[1-(3-methylbutyl)piperidin-4-yl]-5-pentyl-N-[[4'-(piperidin-1-ylcarbonyl)biphenyl-4-yl]methyl]pyridine-2-carboxamide
N-[1-(3-methylbutyl)piperidin-4-yl]-N-(2-[4-[methyl(2-methylquinolin-4-yl)amino]phenyl]ethyl)-4-pentylbenzamide
-
N-[1-(3-methylbutyl)piperidin-4-yl]-N-[4-[(2-methylquinolin-4-yl)amino]benzyl]-4-pentylbenzamide
-
-
N-[1-(3-methylbutyl)piperidin-4-yl]-N-[4-[methyl(pyridin-4-yl)amino]benzyl]-4-pentylbenzamide
-
-
N-[1-(3-methylbutyl)piperidin-4-yl]-N-[[methyl(pyridin-3-yl)amino]methyl]-4-pentylbenzamide
-
N-[1-Benzyl-3-(2-biphenyl-4-yl-1-carbamoyl-ethylamino)-2-hydroxy-propyl]-2-(3-1H-indol-3-yl-propionylamino)-3-methyl-butyramide
-
-
N-[2-(dibutylamino)ethyl]-4-pentyl-N-(3-phenoxybenzyl)benzamide
-
IC50: 469 nM
N-[2-(dibutylamino)ethyl]-4-pentyl-N-(4-piperidin-1-ylbenzyl)benzamide
-
IC50: 369 nM
N-[2-(dibutylamino)ethyl]-4-pentyl-N-(4-pyridin-2-ylbenzyl)benzamide
-
IC50: 380 nM
N-[2-(dibutylamino)ethyl]-4-pentyl-N-(4-pyridin-3-ylbenzyl)benzamide
-
IC50: 374 nM
N-[2-(dibutylamino)ethyl]-4-pentyl-N-(4-pyridin-4-ylbenzyl)benzamide
-
IC50: 212 nM
N-[2-(dibutylamino)ethyl]-4-pentyl-N-(4-pyrimidin-5-ylbenzyl)benzamide
-
IC50: 531 nM
N-[2-(dibutylamino)ethyl]-4-pentyl-N-(4-thiomorpholin-4-ylbenzyl)benzamide
-
IC50: 188 nM
N-[2-(dibutylamino)ethyl]-4-pentyl-N-([4'-(thiomorpholin-4-ylcarbonyl)biphenyl-4-yl]methyl)benzamide
-
IC50: 56 nM
N-[2-(dibutylamino)ethyl]-4-pentyl-N-[4-(1H-pyrrol-1-yl)benzyl]benzamide
-
IC50: 240 nM
N-[2-(dibutylamino)ethyl]-4-pentyl-N-[4-(4-phenylpiperazin-1-yl)benzyl]benzamide
-
IC50: 200 nM
N-[2-(dibutylamino)ethyl]-4-pentyl-N-[4-(5-phenylpyridin-2-yl)benzyl]benzamide
-
IC50: 2345 nM
N-[2-(dibutylamino)ethyl]-4-pentyl-N-[4-(5-pyrimidin-5-ylpyridin-2-yl)benzyl]benzamide
-
IC50: 8530 nM
N-[2-(dibutylamino)ethyl]-4-pentyl-N-[4-(6-phenylpyridin-3-yl)benzyl]benzamide
-
IC50: 589 nM
N-[2-(dibutylamino)ethyl]-4-pentyl-N-[4-(6-pyrimidin-5-ylpyridin-3-yl)benzyl]benzamide
-
IC50: 2229 nM
N-[2-(dibutylamino)ethyl]-4-pentyl-N-[4-(phenylamino)benzyl]benzamide
-
IC50: 224 nM
N-[2-(dibutylamino)ethyl]-4-pentyl-N-[4-(pyridin-4-ylamino)benzyl]benzamide
-
IC50: 1816 nM
N-[2-(dibutylamino)ethyl]-4-pentyl-N-[4-(trifluoromethyl)benzyl]benzamide
-
IC50: 596 nM
N-[2-(dibutylamino)ethyl]-4-propyl-N-[4-(trifluoromethyl)benzyl]benzamide
-
IC50: 0.0396 mM
N-[2-(dibutylamino)ethyl]-N-(3-phenoxybenzyl)-4-propylbenzamide
-
IC50: 0.0159 mM
N-[2-(dibutylamino)ethyl]-N-(4-pyridin-4-ylbenzyl)benzamide
-
IC50: 295 nM
N-[2-(dibutylamino)ethyl]-N-(4-pyrimidin-5-ylbenzyl)benzamide
N-[2-(dibutylamino)ethyl]-N-(4-[methyl(phenyl)amino]benzyl)-4-pentylbenzamide
-
IC50: 574 nM
N-[2-(dibutylamino)ethyl]-N-(4-[methyl(pyridin-4-yl)amino]benzyl)-4-pentylbenzamide
-
IC50: 3015 nM
N-[2-(dibutylamino)ethyl]-N-([3'-(trifluoromethyl)biphenyl-4-yl]methyl)benzamide
-
IC50: 390 nM
N-[2-(dibutylamino)ethyl]-N-([4'-(2-hydroxyethoxy)biphenyl-4-yl]methyl)-4-pentylbenzamide
-
IC50: 511 nM
N-[2-(dibutylamino)ethyl]-N-([4'-(2-hydroxyethoxy)biphenyl-4-yl]methyl)benzamide
-
IC50: 104 nM
N-[2-(dibutylamino)ethyl]-N-([4'-(2-hydroxyethyl)biphenyl-4-yl]methyl)benzamide
-
IC50: 151 nM
N-[2-(dibutylamino)ethyl]-N-([4'-(2-morpholin-4-yl-2-oxoethyl)biphenyl-4-yl]methyl)-4-pentylbenzamide
N-[2-(dibutylamino)ethyl]-N-[(3',4'-dimethoxybiphenyl-4-yl)methyl]benzamide
-
IC50: 428 nM
N-[2-(dibutylamino)ethyl]-N-[(3'-methylbiphenyl-4-yl)methyl]benzamide
-
IC50: 293 nM
N-[2-(dibutylamino)ethyl]-N-[4-(1H-indol-1-yl)benzyl]-4-pentylbenzamide
-
IC50: 670 nM
N-[2-(dibutylamino)ethyl]-N-[4-(4-methylpiperazin-1-yl)benzyl]-4-pentylbenzamide
-
IC50: 2547 nM
N-[2-(dibutylamino)ethyl]-N-[4-(diethylamino)benzyl]-4-pentylbenzamide
-
IC50: 1491 nM
N-[2-hydroxy-2-(1,2,3,4-tetrahydrophenanthren-9-yl)ethyl]-4-methyl-N-(4-methylpentyl)pentan-1-aminium
-
-
N-[2-hydroxy-2-(1,2,3,4-tetrahydrophenanthren-9-yl)ethyl]-N-pentylpentan-1-aminium
-
-
N-[3-(2,7-dichloro-9H-fluoren-4-yl)-3-hydroxypropyl]-N-pentylpentan-1-aminium
-
-
N-[3-(9H-fluoren-2-yl)-3-hydroxypropyl]-N-pentylpentan-1-aminium
-
-
N-[3-(dibutylamino)propyl]-4-pentyl-N-([4'-(2-pyrrolidin-1-ylethoxy)biphenyl-4-yl]methyl)benzamide
-
IC50: 221 nM
N-[3-(dibutylamino)propyl]-N-[(2'-methoxybiphenyl-4-yl)methyl]-4-pentylbenzamide
N-[3-(dibutylamino)propyl]-N-[(2'-methylbiphenyl-4-yl)methyl]-4-pentylbenzamide
-
IC50: 597 nM
N-[3-(dibutylamino)propyl]-N-[(3',4'-dimethoxybiphenyl-4-yl)methyl]-4-pentylbenzamide
-
IC50: 468 nM
N-[3-(dibutylamino)propyl]-N-[(3'-methoxybiphenyl-4-yl)methyl]-4-pentylbenzamide
-
IC50: 580 nM
N-[3-(dibutylamino)propyl]-N-[(4'-methoxybiphenyl-4-yl)methyl]-4-pentylbenzamide
-
IC50: 246 nM
N-[3-[(2-benzo[1,3]dioxol-5-yl-ethyl)-[3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propionyl]-amino]-1-benzyl-2-hydroxy-propyl]-4-benzyloxy-3,5-dimethoxy-benzamide
-
-
N-[3-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]-3-hydroxypropyl]-N-pentylpentan-1-aminium
-
-
N-[4,4-difluoro-3-oxocyclohexyl]-2-(2-naphthyl)-N-(4-pentylphenyl)-acetamide
-
-
N-[4-(([2-(dibutylamino)ethyl][(4-pentylphenyl)carbonyl]amino)methyl)phenyl]-2-methoxypyridine-4-carboxamide
-
IC50: 154 nM
N-[4-(([2-(dibutylamino)ethyl][(4-pentylphenyl)carbonyl]amino)methyl)phenyl]piperidine-3-carboxamide
-
IC50: 202 nM
N-[4-(([2-(dibutylamino)ethyl][(4-pentylphenyl)carbonyl]amino)methyl)phenyl]piperidine-4-carboxamide
-
IC50: 464 nM
N-[4-(([2-(dibutylamino)ethyl][(4-pentylphenyl)carbonyl]amino)methyl)phenyl]pyrazine-2-carboxamide
-
IC50: 243 nM
N-[4-(1,3-benzodioxol-5-yl)benzyl]-4-pentyl-N-(2-piperidin-1-ylethyl)benzamide
-
IC50: 334 nM
N-[4-(1,3-benzodioxol-5-yl)benzyl]-4-pentyl-N-(2-[4-(3-phenylpropyl)piperidin-1-yl]ethyl)benzamide
-
IC50: 165 nM
N-[4-(1,3-benzodioxol-5-yl)benzyl]-N',N'-dibutyl-N-(4-pentylbenzyl)ethane-1,2-diamine
-
IC50: 831 nM
N-[4-(1,3-benzodioxol-5-yl)benzyl]-N-(2-([2-(diethylamino)ethyl](ethyl)amino)ethyl)-4-pentylbenzamide
-
IC50: 439 nM
N-[4-(1,3-benzodioxol-5-yl)benzyl]-N-(2-morpholin-4-ylethyl)-4-pentylbenzamide
-
IC50: 2897 nM
N-[4-(1,3-benzodioxol-5-yl)benzyl]-N-(2-[benzyl(2-hydroxyethyl)amino]ethyl)-4-pentylbenzamide
-
IC50: 334 nM
N-[4-(1,3-benzodioxol-5-yl)benzyl]-N-(2-[bis(1-methylethyl)amino]ethyl)-4-pentylbenzamide
-
IC50: 1501 nM
N-[4-(1,3-benzodioxol-5-yl)benzyl]-N-(3-butylheptyl)-4-pentylbenzamide
-
-
N-[4-(1,3-benzodioxol-5-yl)benzyl]-N-[2-(4-benzylpiperidin-1-yl)ethyl]-4-pentylbenzamide
-
IC50: 190 nM
N-[4-(1,3-benzodioxol-5-yl)benzyl]-N-[2-(dibutylamino)ethyl]-4-pentylbenzamide
-
IC50: 101 nM
N-[4-(1,3-benzodioxol-5-yl)benzyl]-N-[2-(dibutylamino)ethyl]benzamide
-
IC50: 56 nM
N-[4-(1,3-benzodioxol-5-yl)benzyl]-N-[2-(diethylamino)ethyl]-4-pentylbenzamide
-
IC50: 1519 nM
N-[4-(1,3-benzodioxol-5-yl)benzyl]-N-[2-(dipropylamino)ethyl]-4-pentylbenzamide
-
IC50: 531 nM
N-[4-(1,3-benzodioxol-5-yl)benzyl]-N-[3-(dibutylamino)propyl]-4-pentylbenzamide
-
IC50:195 nM
N-[4-(2,2'-bipyridin-5-yl)benzyl]-N-[2-(dibutylamino)ethyl]-4-pentylbenzamide
N-[4-(2,4'-bipyridin-5-yl)benzyl]-N-[2-(dibutylamino)ethyl]-4-pentylbenzamide
-
IC50: 642 nM
N-[4-(3,3'-bipyridin-6-yl)benzyl]-N-[2-(dibutylamino)ethyl]-4-pentylbenzamide
-
IC50: 5266 nM
N-[4-(3,4'-bipyridin-6-yl)benzyl]-N-[2-(dibutylamino)ethyl]-4-pentylbenzamide
-
IC50: 4553 nM
N-[4-(3,4-diethylisoxazol-5-yl)benzyl]-N-[1-(3-methylbutyl)piperidin-4-yl]-4-pentylbenzamide
-
-
N-[4-(4-benzylpiperazin-1-yl)benzyl]-N-[2-(dibutylamino)ethyl]-4-pentylbenzamide
-
IC50: 646 nM
N-[4-(benzylamino)benzyl]-N-[2-(dibutylamino)ethyl]-4-pentylbenzamide
-
IC50: 429 nM
N-[4-(benzyloxy)benzyl]-4-butoxy-N-[2-(dibutylamino)ethyl]benzamide
-
IC50: 0.0034 mM
N-[4-(benzyloxy)benzyl]-4-butyl-N-[2-(dibutylamino)ethyl]benzamide
-
IC50: 0.0013 mM
N-[4-(benzyloxy)benzyl]-N',N'-dibutyl-N-(4-pentylbenzyl)ethane-1,2-diamine
-
IC50: 845 nM
N-[4-(benzyloxy)benzyl]-N-[2-(dibutylamino)ethyl]-4-pentylbenzamide
-
IC50: 112 nM
N-[4-(benzyloxy)benzyl]-N-[2-(dibutylamino)ethyl]-4-propylbenzamide
-
IC50: 0.0089 mM
N-[4-([[1-(3-methylbutyl)piperidin-4-yl][(4-pentylphenyl)carbonyl]amino]methyl)phenyl]-1-benzothiophene-2-carboxamide
-
-
N-[4-[5-(3,4-dimethoxybenzyl)-1,2,4-oxadiazol-3-yl]benzyl]-N-[1-(3-methylbutyl)piperidin-4-yl]-4-pentylbenzamide
-
-
N-[[(1S)-3,3-difluoro-4,4-dihydroxycyclohexyl]methyl]-N-(4-pentylphenyl)naphthalene-2-carboxamide
-
N-[[5-(2,5-dichlorophenyl)furan-2-yl]methyl]-N-[1-(3-methylbutyl)piperidin-4-yl]-4-pentylbenzamide
N-[[5-(3,4-dichlorophenyl)furan-2-yl]methyl]-N-[1-(3-methylbutyl)piperidin-4-yl]-4-pentylbenzamide
N-[[5-(3,4-dimethoxybenzyl)-1,2,4-oxadiazol-3-yl]methyl]-N-[1-(3-methylbutyl)piperidin-4-yl]-4-pentylbenzamide
-
N-[[5-(4-chlorophenyl)-1,2-oxazol-3-yl]methyl]-N-[1-(3-methylbutyl)piperidin-4-yl]-4-pentylbenzamide
-
N-[[5-(4-chlorophenyl)isoxazol-3-yl]methyl]-N-[1-(3-methylbutyl)piperidin-4-yl]-4-pentylbenzamide
-
-
N2-(3-bromophenyl)-N-[4-[(phenylsulfanyl)methyl]phenyl]-N2-(phenylsulfonyl)glycinamide
-
N2-[(2S,3S)-2-hydroxy-4-phenyl-3-[[N-(pyridin-2-ylcarbonyl)-L-valyl]amino]butyl]-L-leucinamide
-
-
Nalpha-[(2S,3S)-2-hydroxy-4-phenyl-3-[[N-(pyridin-2-ylcarbonyl)-L-valyl]amino]butyl]-L-phenylalaninamide
-
-
pepstatin
pepstatin A
Piperidine-4-carboxylic acid [3-(4-benzyloxy-3,5-dimethoxy-benzoylamino)-2-hydroxy-4-phenyl-butyl]-[2-(4-methoxy-phenyl)-ethyl]-amide
-
-
piperidine-4-carboxylic acid [3-[2-(3-chloro-phenoxy)-acetylamino]-2-hydroxy-4-phenyl-butyl]-[2-(4-methoxy-phenyl)-ethyl]-amide
-
-
Piperidine-4-carboxylic acid {3-[2-(3-chloro-phenoxy)-acetylamino]-2-hydroxy-4-phenyl-butyl}-[2-(4-methoxy-phenyl)-ethyl]-amide
-
-
pyridine-2-carboxylic acid ((R)-1-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methylpropyl)amide
-
-
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-(3-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)-ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methyl-propyl)-amide
-
-
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-(4-benzo-[1,3]dioxol-5-yl-benzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methylpropyl)-amide
-
-
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(2-(3-methoxyphenyl)ethylcarbamoyl)propylcarbamoyl)-2-methylpropyl)amide
-
-
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methylpropyl)amide
-
-
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-(biphenyl-3-ylmethoxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-hydroxy-propylcar-bamoyl)-2-methyl-propyl)-amide
-
-
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-(biphenyl-4-ylmethoxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-hydroxy-propylcarbamoyl)-2-methyl-propyl)-amide
-
-
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-benzyloxymethyl-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methylpropyl)amide
-
-
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxy-1-phenethylpropylcarbamoyl)-2-methylpropyl)amide
-
-
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-benzo-[1,3]dioxol-5-yl-benzyloxymethyl)-3-butylcarbamoyl-2-hydroxy-propylcarbamoyl]-2-methyl-propyl)-amide
-
-
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(2-phenylaminoethyl-carbamoyl)propylcarbamoyl]-2-methylpropyl)amide
-
-
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(3-methoxypropylcarbamoyl)propylcarbamoyl]-2-methylpropyl)amide
-
-
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(3-phenylpropylcarbamoyl)propylcarbamoyl]-2-methylpropyl)amide
-
-
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-(4-cyanobenzylcarbamoyl)-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide
-
-
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-(cyclohexylmethylcarbamoyl)-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide
-
-
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-butylcarbamoyl-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide
-
-
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-cyclohexylcarbamoyl-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide
-
-
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(biphenyl-4-ylmethoxymethyl)-3-butylcarbamoyl-2-hydroxy-propylcarbamoyl]-2-methylpropyl)-amide
-
-
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-3-butylcarbamoyl-2-hydroxy-1-(4-thiophen-3-yl-benzyloxymethyl)-propylcarbamoyl]-2-methyl-propyl)-amide
-
-
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-hydroxy-1-(3-thiophen-3-yl-benzyloxymethyl)-propyl-carbamoyl]-2-methyl-propyl)-amide
-
-
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-hydroxy-1-(4-thiophen-3-yl-benzyloxymethyl)-propyl-carbamoyl]-2-methyl-propyl)-amide
-
-
pyridine-2-carboxylic acid((S)-1-[(1S,2S)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-hydroxy-1-(4-thiophen-3-yl-benzyloxymethyl)-propyl-carbamoyl]-2-methyl-propyl)-amide
-
-
SC-50083
-
IC50: 0.0003467 mM
tert-butyl (5S)-5-((S)-2-(4-(4-((2S,3S)-1-((3S,4S)-1-(butylamino)-3-hydroxy-6-methyl-1-oxoheptan-4-ylamino)-3-methyl-1-oxopentan-2-ylcarbamoyl)phenoxy)benzamido)-4-methylpentanamido)-6-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-6-oxohexylcarbamate
-
-
[4'-(([2-(dibutylamino)ethyl](phenylcarbonyl)amino)methyl)biphenyl-4-yl]acetic acid
-
IC50: 197 nM
[4'-(([2-(dibutylamino)ethyl][(4-pentylphenyl)carbonyl]amino)methyl)biphenyl-4-yl]acetic acid
-
IC50: 463 nM
[5-([[(4-bromophenyl)carbonyl]oxy]methyl)-2,3,4,7-tetrahydro-1H-azepin-3-yl]methyl 4-aminobenzoate
Ki value for human cathepsin D 0.165 mM
[5-[(benzoyloxy)methyl]-2,3,4,7-tetrahydro-1H-azepin-3-yl]methyl 4-aminobenzoate
-
[6-([[(4-aminophenyl)carbonyl]oxy]methyl)-2,5,6,7-tetrahydro-1H-azepin-4-yl]methyl 7aH-indole-3-carboxylate
Ki value for human cathepsin D above 0.1 mM
[6-([[(4-aminophenyl)carbonyl]oxy]methyl)-2,5,6,7-tetrahydro-1H-azepin-4-yl]methyl naphthalene-1-carboxylate
Ki value for human cathepsin D 0.262 mM
[6-([[(4-nitrophenyl)carbonyl]oxy]methyl)-2,5,6,7-tetrahydro-1H-azepin-4-yl]methyl naphthalene-1-carboxylate
Ki value for human cathepsin D 0.051 mM
additional information
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.001 - 0.00233
4-(4-dimethylaminophenylazo)benzoyl-CH2-CH2-CO-CO-ALERMFLSFP-diaminopimelate-5-[(2-aminoethyl)amino]naphthalene-1-sulfonic acid
0.00294 - 0.00611
4-(4-dimethylaminophenylazo)benzoyl-CH2-CH2-CO-ERMFLSFP-diaminopimelate-5-[(2-aminoethyl)amino]naphthalene-1-sulfonic acid
0.000489
4-[[4'-(dimethylamino)phenyl]azo]-benzoyl-Glu-Arg-Met-Phe-Leu-Ser-Phe-Pro-(gamma-aminobutyryl)-5-[(2'-aminoethyl)-amino]naphthalenesulfonic acid
-
pH 5.0, 37°C
0.063
Abz-Thr-Ile-Nle-(4-nitro)Phe-Gln-Arg-NH2
pH 4.5, temperature not specified in the publication
0.0139 - 0.0334
Ala-Leu-Glu-Arg-Nle-Phe-Phe(NO2)-Ser-Phe-Pro
0.06 - 0.11
Ala-Leu-Glu-Arg-Thr-Phe-Phe(NO2)-Ser-Phe-Pro-Thr
0.00017 - 0.0012
EDANS-CO-CH2-CH2-CO-Ala-Leu-Glu-Arg-Met-Phe-Leu-Ser-Phe-Pro-Dap-(DABCYL)-OH
0.006 - 0.025
Leu-Glu-Arg-Ile-Phe-Phe(NO2)-Ser-Phe
0.02
Leu-Glu-Arg-Val-Phe-Phe(NO2)-Ser-Phe
-
pH 4.4, 37°C
0.0274
Leu-Ser-Phe(NO2)-Nle-Ala-Leu-Ome
-
pH 4.4, 37°C
0.03 - 0.069
Lys-Ala-Ile-Glu-Phe-Phe(NO2)-Arg-Leu
0.055 - 0.109
Lys-Asp-Ile-Glu-Phe-Phe(NO2)-Arg-Leu
0.006 - 0.008
Lys-Glu-Leu-Val-Phe-Phe(NO2)-Ala-Leu-Lys
0.025
Lys-Glu-Phe-Ile-Phe-Phe(NO2)-Ala-Leu-Lys
-
pH 4.4, 37°C
0.046
Lys-Glu-Phe-Val-Lys-Phe(NO2)-Ala-Leu-Lys
-
pH 4.4, 37°C, mutant enzyme S77D
0.007 - 0.02
Lys-Glu-Phe-Val-Phe-Phe(NO2)-Ala-Leu-Lys
0.01
Lys-Glu-Phe-Val-Phe-Phe(NO2)-Arg-Leu-Lys
-
pH 4.4, 37°C, recombinant enzyme
0.051 - 0.117
Lys-Lys-Ile-Glu-Phe-Phe(NO2)-Arg-Leu
0.021 - 0.085
Lys-Phe-Ile-Glu-Phe-Phe(NO2)-Arg-Leu
0.037 - 0.053
Lys-Pro-Ala-Glu-Phe-Phe(NO2)-Arg-Leu
0.087 - 0.221
Lys-Pro-Asp-Glu-Phe-Phe(NO2)-Arg-Leu
0.006 - 0.041
Lys-Pro-Ile-Ala-Phe-Phe(NO2)-Arg-Leu
0.024 - 0.076
Lys-Pro-Ile-Asp-Phe-Phe(NO2)-Arg-Leu
0.013
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Ala-Leu
-
pH 4.4, 37°C
0.171
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Arg-Arg
-
pH 4.4, 37°C
0.101
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Arg-Asp
-
pH 4.4, 37°C
0.013
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Arg-Ile
-
pH 4.4, 37°C
0.023 - 0.07
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Arg-Leu
0.067
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Arg-Ser
-
pH 4.4, 37°C
0.017
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Arg-Val
-
pH 4.4, 37°C
0.081
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Glu-Leu
-
pH 4.4, 37°C
0.056
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Lys-Leu
-
pH 4.4, 37°C
0.052
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Ser-Leu
-
pH 4.4, 37°C
0.016
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Val-Leu
-
pH 4.4, 37°C
0.008
Lys-Pro-Ile-Leu-Phe-Phe(NO2)-Arg-Leu
-
pH 4.4, 37°C
0.004 - 0.05
Lys-Pro-Ile-Lys-Phe-Phe(NO2)-Arg-Leu
0.022
Lys-Pro-Ile-Nle-Phe-Phe(NO2)-Arg-Leu
-
pH 4.4, 37°C
0.017 - 0.039
Lys-Pro-Ile-Ser-Phe-Phe(NO2)-Arg-Leu
0.006 - 0.01
Lys-Pro-Ile-Val-Phe-Phe(NO2)-Arg-Leu
0.035 - 0.25
Lys-Pro-Lys-Glu-Phe-Phe(NO2)-Arg-Leu
0.024 - 0.07
Lys-Pro-Phe-Glu-Phe-Phe(NO2)-Arg-Leu
0.056 - 0.092
Lys-Pro-Ser-Glu-Phe-Phe(NO2)-Arg-Leu
0.049 - 0.11
Lys-Ser-Ile-Glu-Phe-Phe(NO2)-Arg-Leu
additional information
additional information
-
-
-
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.952 - 2.52
4-(4-dimethylaminophenylazo)benzoyl-CH2-CH2-CO-CO-ALERMFLSFP-diaminopimelate-5-[(2-aminoethyl)amino]naphthalene-1-sulfonic acid
0.431 - 6.08
4-(4-dimethylaminophenylazo)benzoyl-CH2-CH2-CO-ERMFLSFP-diaminopimelate-5-[(2-aminoethyl)amino]naphthalene-1-sulfonic acid
2.31
4-[[4'-(dimethylamino)phenyl]azo]-benzoyl-Glu-Arg-Met-Phe-Leu-Ser-Phe-Pro-(gamma-aminobutyryl)-5-[(2'-aminoethyl)-amino]naphthalenesulfonic acid
-
pH 5.0, 37°C
2.1 - 7.4
Ala-Leu-Glu-Arg-Nle-Phe-Phe(NO2)-Ser-Phe-Pro
3.8 - 6
Ala-Leu-Glu-Arg-Thr-Phe-Phe(NO2)-Ser-Phe-Pro-Thr
0.103 - 2.1
EDANS-CO-CH2-CH2-CO-Ala-Leu-Glu-Arg-Met-Phe-Leu-Ser-Phe-Pro-Dap-(DABCYL)-OH
10 - 15
Leu-Glu-Arg-Ile-Phe-Phe(NO2)-Ser-Phe
9
Leu-Glu-Arg-Val-Phe-Phe(NO2)-Ser-Phe
-
pH 4.4, 37°C
10.4
Leu-Ser-Phe(NO2)-Nle-Ala-Leu-Ome
-
pH 4.4, 37°C
0.8 - 2
Lys-Ala-Ile-Glu-Phe-Phe(NO2)-Arg-Leu
0.6 - 1.1
Lys-Asp-Ile-Glu-Phe-Phe(NO2)-Arg-Leu
1.5 - 6
Lys-Glu-Leu-Val-Phe-Phe(NO2)-Ala-Leu-Lys
7
Lys-Glu-Phe-Asn-Phe-Phe(NO2)-Ala-Leu-Lys
-
pH 4.4, 37°C, recombinant enzyme
15.2
Lys-Glu-Phe-Ile-Phe-Phe(NO2)-Ala-Leu-Lys
-
pH 4.4, 37°C
0.84
Lys-Glu-Phe-Val-Lys-Phe(NO2)-Ala-Leu-Lys
-
pH 4.4, 37°C, mutant enzyme S77D
9.05 - 19
Lys-Glu-Phe-Val-Phe-Phe(NO2)-Ala-Leu-Lys
11
Lys-Glu-Phe-Val-Phe-Phe(NO2)-Arg-Leu-Lys
-
pH 4.4, 37°C, recombinant enzyme
0.17 - 0.4
Lys-Lys-Ile-Glu-Phe-Phe(NO2)-Arg-Leu
1 - 2.6
Lys-Phe-Ile-Glu-Phe-Phe(NO2)-Arg-Leu
0.5 - 0.53
Lys-Pro-Ala-Glu-Phe-Phe(NO2)-Arg-Leu
0.3 - 0.4
Lys-Pro-Asp-Glu-Phe-Phe(NO2)-Arg-Leu
0.73 - 1.8
Lys-Pro-Ile-Ala-Phe-Phe(NO2)-Arg-Leu
0.25 - 0.86
Lys-Pro-Ile-Asp-Phe-Phe(NO2)-Arg-Leu
5.7
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Ala-Leu
-
pH 4.4, 37°C
0.53
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Arg-Arg
-
pH 4.4, 37°C
1.2
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Arg-Asp
-
pH 4.4, 37°C
0.9
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Arg-Ile
-
pH 4.4, 37°C
1.7 - 3.5
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Arg-Leu
0.44
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Arg-Ser
-
pH 4.4, 37°C
0.7
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Arg-Val
-
pH 4.4, 37°C
6.3
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Glu-Leu
-
pH 4.4, 37°C
1.6
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Lys-Leu
-
pH 4.4, 37°C
1.7
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Ser-Leu
-
pH 4.4, 37°C
2.6
Lys-Pro-Ile-Glu-Phe-Phe(NO2)-Val-Leu
-
pH 4.4, 37°C
1.7
Lys-Pro-Ile-Leu-Phe-Phe(NO2)-Arg-Leu
-
pH 4.4, 37°C
0.03 - 0.08
Lys-Pro-Ile-Lys-Phe-Phe(NO2)-Arg-Leu
3.1
Lys-Pro-Ile-Nle-Phe-Phe(NO2)-Arg-Leu
-
pH 4.4, 37°C
0.73 - 1.1
Lys-Pro-Ile-Ser-Phe-Phe(NO2)-Arg-Leu
1.6 - 3.6
Lys-Pro-Ile-Val-Phe-Phe(NO2)-Arg-Leu
0.05 - 0.1
Lys-Pro-Lys-Glu-Phe-Phe(NO2)-Arg-Leu
2.4 - 3.1
Lys-Pro-Phe-Glu-Phe-Phe(NO2)-Arg-Leu
0.2 - 0.32
Lys-Pro-Ser-Glu-Phe-Phe(NO2)-Arg-Leu
1 - 1.3
Lys-Ser-Ile-Glu-Phe-Phe(NO2)-Arg-Leu
additional information
additional information
-
-
-
kcat/KM VALUE [1/mMs-1]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
620 - 1660
EDANS-CO-CH2-CH2-CO-Ala-Leu-Glu-Arg-Met-Phe-Leu-Ser-Phe-Pro-Dap-(DABCYL)-OH
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0014
(2R,3R)-4-(N-benzyl-N'-benzyloxycarbonyl-hydrazino)-2-(4-bromobenzyloxy)-3-hydroxy-N-(2-piperidin-1-ylethyl)-butyramide
-
-
0.00012
(2R,3R,4R)-2-(benzyloxy)-3,4-dihydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-4-[(2R)-3-oxo-1-oxa-4-azacyclotridecan-2-yl]butanamide
-
-
0.00038
(2R,3R,4R)-2-(benzyloxy)-3,4-dihydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-4-[(2R,11E)-3-oxo-1-oxa-4-azacyclotridec-11-en-2-yl]butanamide
-
-
0.000085
(2R,3R,4R,5R)-2,5-bis(benzyloxy)-3,4-dihydroxy-N,N'-bis[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]hexanediamide
-
-
0.000011
(2R,3R,4R,5R)-2,5-bis[[(2E)-3-(1,3-benzodioxol-5-yl)prop-2-en-1-yl]oxy]-3,4-dihydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-6-oxo-6-[2-(3-phenylpropanoyl)hydrazino]hexanamide
-
-
0.000006
(2R,3R,4R,5R)-2,5-bis[[(2E)-3-(4-acetylphenyl)prop-2-en-1-yl]oxy]-3,4-dihydroxy-N,N'-bis[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]hexanediamide
-
-
0.000145
(2R,3R,4R,5R)-2,5-bis[[(2E)-3-(4-acetylphenyl)prop-2-en-1-yl]oxy]-3,4-dihydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-6-oxo-6-[2-(3-phenylpropanoyl)hydrazino]hexanamide
-
-
0.000007
(2R,3R,4R,5R)-2,5-bis[[(2E)-3-bromoprop-2-en-1-yl]oxy]-3,4-dihydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-6-oxo-6-[2-(3-phenylpropanoyl)hydrazino]hexanamide
-
-
0.000142
(2R,3R,4R,5R)-2,5-bis[[(2E)-3-bromoprop-2-en-1-yl]oxy]-6-[2-[(4-tert-butylphenyl)carbonyl]hydrazino]-3,4-dihydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-6-oxohexanamide
-
-
0.0015
(2R,3R,4R,5R)-2,5-bis[[(2E)-3-bromoprop-2-en-1-yl]oxy]-N'1,N'6-bis[(4-tert-butylphenyl)carbonyl]-3,4-dihydroxyhexanedihydrazide
-
-
0.0041
(2R,3R,4R,5R)-3,4-dihydroxy-N,N'-bis[(1S)-2-methyl-1-(methylcarbamoyl)propyl]-2,5-bis(prop-2-en-1-yloxy)hexanediamide
-
-
0.000096
(2R,3R,4R,5R)-3,4-dihydroxy-N,N'-bis[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-2,5-bis(prop-2-en-1-yloxy)hexanediamide
-
-
0.000013
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E)-3-(2,4-dimethoxy-3,5-pyrimidin)-2-propenyl-oxy]-3,4-dihydroxyhexane-1,6-diamide
-
-
0.000181
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E)-3-(2,5-dimethyl-3,4-oxazol)-2-propenyloxy]-3,4-dihydroxyhexane-1,6-diamide
-
-
0.000014
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E)-3-(3,4-methylenedioxyphenyl)-2-propenyloxy]-3,4-dihydroxyhexane-1,6-diamide
-
-
0.000015
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E)-3-(3-thienyl)-2-propenyloxy]-3,4-dihydroxyhexane-1,6-diamide
-
-
0.000006
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E)-3-(4-acetylphenyl)-2-propenyloxy]-3,4-dihydroxyhexane-1,6-diamide
-
the best dual inhibitor for EC 3.4.23.38 and EC 3.4.23.39
0.000059
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E)-3-(4-fluorophenyl)-2-propenyloxy]-3,4-dihydroxyhexane-1,6-diamide
-
-
0.000129
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E)-3-(4-tolyl)-2-propenyloxy]-3,4-dihydroxyhexane-1,6-diamide
-
-
0.000047
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E)-3-bromo-2-propenyloxy]-3,4-dihydroxyhexane-1,6-diamide
-
-
0.000029
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E)-3-phenyl-2-propenyloxy]-3,4-dihydroxyhexane-1,6-diamide
-
-
0.000041
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E)-5-phenyl-pent-2-en-4-ynyl]-3,4-dihydroxyhexane-1,6-diamide
-
-
0.00013
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E)-5-trimethylsilyl-pent-2-en-4-ynyl]-3,4-dihydroxyhexane-1,6-diamide
-
-
0.000032
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E)-pent-2-en-4-ynyl]-3,4-dihydroxyhexane-1,6-diamide
-
-
0.0000089
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E,4E)-5-(methoxycarbonyl)-pent-2,4-dienyloxy]-3,4-dihydroxyhexane-1,6-diamide
-
-
0.000015
(2R,3R,4R,5R)-N1,N6-bis[(1S,2R)-2-hydroxy-1-indanyl]-2,5-bis[(2E,4E)-5-phenyl-pentadienyloxy]-3,4-dihydroxyhexane-1,6-diamide
-
-
0.0011
(2R,3R,4R,5R,14E)-5-(benzyloxy)-3,4-dihydroxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-6-oxo-1-oxa-7-azacyclohexadec-14-ene-2-carboxamide
-
-
0.003
(2S,3R)-4-(N-benzyl-N'-benzyloxycarbonyl-hydrazino)-2-(4-bromobenzyloxy)-3-hydroxy-N-(2-piperidin-1-yl-ethyl)-butyramide
-
-
0.0015
(2S,5S,14S,17S,18S)-N-(2-amino-2-oxoethyl)-17-benzyl-18-hydroxy-14-[[N-(3-methylbutanoyl)-L-valyl]amino]-2-(1-methylethyl)-3,8,15,20-tetraoxo-1,4,9,16-tetraazacycloicosane-5-carboxamide
-
-
0.00054
(2S,5S,6R)-3-aza-2-(p-bromobenzyl)-5-hydroxy-7-phenyl-6-[(picolyl-L-valinyl)amino]heptanoyl amide
-
-
0.000129
(2S,5S,6R)-3-aza-2-[m-(m-aminophenyl)benzyl]-5-hydroxy-7-phenyl-6-[(picolyl-L-valinyl)amino]heptanoyl amide
-
-
0.00093
(2S,5S,6R)-3-aza-2-[m-(p-methylphenyl)benzyl]-5-hydroxy-7-phenyl-6-[(picolyl-L-valinyl)amino]heptanoyl amide
-
-
0.00015
(2S,5S,6R)-3-aza-2-[p-(m-aminophenyl)benzyl]-5-hydroxy-7-phenyl-6-[(picolyl-L-valinyl)amino]heptanoyl amide
-
-
0.000121
(2S,5S,6R)-3-aza-2-[p-(p-methylphenyl)benzyl]-5-hydroxy-7-phenyl-6-[(picolyl-L-valinyl)amino]heptanoyl amide
-
-
0.00143
(2S,5S,6R)-3-aza-5-hydroxy-2-[m-(o-methoxyphenyl)-benzyl]-7-phenyl-6-[(picolyl-L-valinyl)amino]heptanoyl amide
-
-
0.000379
(2S,5S,6R)-3-aza-5-hydroxy-2-[p-(o-methoxyphenyl)-benzyl]-7-phenyl-6-[(picolyl-L-valinyl)amino]heptanoyl amide
-
-
0.000579
(2S,5S,6R)-3-aza-5-hydroxy-7-phenyl-2-(m-phenylbenzyl)-6-[(picolyl-L-valinyl)amino]heptanoyl amide
-
-
0.000117
(2S,5S,6R)-3-aza-5-hydroxy-7-phenyl-2-(p-phenylbenzyl)-6-[(picolyl-L-valinyl)amino]heptanoyl amide
-
-
0.00049
(3S,4S)-4-[([4-[4-amino-3-(4-chlorophenyl)butanoyl]-1-(biphenyl-4-ylmethyl)piperazin-2-yl]acetyl)amino]-N-butyl-3-hydroxy-5-phenylpentanamide
-
-
0.000007
(3S,4S)-4-[[(2S)-2-(benzylamino)-3-methylbutanoyl]amino]-N-[(1S)-1-(cyclohexylmethyl)-2-[[3-(1H-imidazol-1-yl)propyl]amino]-2-oxoethyl]-3-hydroxy-5-phenylpentanamide
-
-
0.348
(3S,4S)-5-(4-bromobenzyloxy)-3-hydroxy-4-(2-thiophen-2-ylacetylamino)pentanoic acid [(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethyl]amide
-
-
0.284
(3S,4S)-5-(4-bromobenzyloxy)-4-(3,3-diphenylpropionylamino)-3-hydroxypentanoic acid [(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethyl]amide
-
-
0.139
(3S,4S)-5-(4-bromobenzyloxy)-4-diphenylacetylamino-3-hydroxypentanoic acid [(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethyl]amide
-
-
0.00005
(3S,4S)-N-butyl-3-hydroxy-6-methyl-4-((2S,3R)-3-methyl-2-(2-(naphthalen-2-yl)acetamido)pentanamido)heptanamide
-
-
0.0000589
(3S,4S)-N-butyl-3-hydroxy-6-methyl-4-((2S,3S)-3-methyl-2-(2-(naphthalen-2-yloxy)acetamido)pentanamido)heptanamide
-
-
0.0472
(3S,4S)-pyrrolidine-3,4-diyl bis(3,3-dimethylbutanoate)
pH 4.5, temperature not specified in the publication
0.0512
(3S,4S)-pyrrolidine-3,4-diyl bis(3-methylbutanoate)
pH 4.5, temperature not specified in the publication
0.0001
(3S,4S)-pyrrolidine-3,4-diyl bis(naphthalen-1-ylacetate)
pH 4.5, temperature not specified in the publication
0.001
(3S,4S)-pyrrolidine-3,4-diyl bis(naphthalen-2-ylacetate)
pH 4.5, temperature not specified in the publication
0.0114
(3S,4S)-pyrrolidine-3,4-diyl bis(phenylacetate)
pH 4.5, temperature not specified in the publication
0.019
(3S,4S)-pyrrolidine-3,4-diyl dibenzoate
pH 4.5, temperature not specified in the publication
0.163
(3S,4S)-pyrrolidine-3,4-diyl dicyclohexanecarboxylate
pH 4.5, temperature not specified in the publication
0.000014
(3S,6S,9S,12S,15S,18S)-15-(3-amino-3-oxopropyl)-18-sec-butyl-3,9-dibutyl-1-((S)-1-((S)-2,6-diaminohexanoyl)pyrrolidin-2-yl)-6-(hydroxymethyl)-12-isobutyl-1,4,7,13,16-pentaoxo-2,5,8,11,14,17-hexaazanonadecan-19-oic acid
-
-
0.0000005
(4R)-3-[(2S,3S)-3-[[(2,6-dimethylphenoxy)acetyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
-
0.00007
(4R)-N-tert-butyl-3-[(2S,3S)-2-hydroxy-3-([N-[(isoquinolin-5-yloxy)acetyl]-S-methyl-L-cysteinyl]amino)-4-phenylbutanoyl]-1,3-thiazolidine-4-carboxamide
-
-
0.0000928
(5S)-1-[(2S,3R)-2-hydroxy-4-phenyl-3-[(picolyl-L-valinyl)amino]butyl]-5-(p-phenylbenzyl)imidazolidine-2,4-dione
-
-
0.00000004
(5S,8S,12S,13S,16S,19S)-13-benzyl-12-hydroxy-8,23,23-trimethyl-16,19-bis(1-methylethyl)-5-(2-methylpropyl)-4,7,10,15,18,21-hexaoxo-3,6,9,14,17,20-hexaazatetracosan-1-amide
-
-
0.0000013
(6S,9S,12R,13S,17S,20R,21S)-13,21-dihydroxy-2,17-dimethyl-6,9-bis(1-methylethyl)-4,7,10,15,18-pentaoxo-12,20-bis(trifluoromethyl)-5,8,11,16,19-pentaazatricosan-23-oic acid
-
-
0.00001
(R)-N-[(1S,2R)-2-hydroxyindan-1-yl]-3-[(2S,3S)-3-(2,6-dimethyl-4-(pyridine-2-ylmethyl)amino-phenoxyacetyl)amino-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
pH 4.0, 25°C
0.000006
(R)-N-[(1S,2R)-2-hydroxyindan-1-yl]-3-[(2S,3S)-3-(2,6-dimethyl-4-(pyridine-4-ylmethyl)amino-phenoxyacetyl)amino-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
pH 4.0, 25°C
0.000007
(R)-N-[(1S,2R)-2-hydroxyindan-1-yl]-3-[(2S,3S)-3-(2,6-dimethyl-4-ethylamino-phenoxyacetyl)amino-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
pH 4.0, 25°C
0.000025
(R)-N-[(1S,2R)-2-hydroxyindan-1-yl]-3-[(2S,3S)-3-(2,6-dimethyl-4-methylamino-phenoxyacetyl)amino-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
pH 4.0, 25°C
0.00001
(R)-N-[(1S,2R)-2-hydroxyindan-1-yl]-3-[(2S,3S)-3-(4-hydroxymethylphenoxyacetyl)amino-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
pH 4.0, 25°C
0.144
(S)-2,3-dihydro-1H-indole-2-carboxylic acid ((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl)amide
-
-
0.000011
(S)-propyl 6-(tert-butoxycarbonylamino)-2-((S)-2-(4-(4-((2S,3S)-1-((3S,4S)-1-(butylamino)-3-hydroxy-6-methyl-1-oxoheptan-4-ylamino)-3-methyl-1-oxopentan-2-ylcarbamoyl)phenoxy)benzamido)-4-methylpentanamido)hexanoate
-
not cytotoxic against human fibroblasts at 0.100 mM and are highly selective for plasmepsins vs human cathepsin D
0.0000099
(S)-propyl 6-amino-2-((S)-2-(4-(4-((2S,3S)-1-((3S,4S)-1-(butylamino)-3-hydroxy-6-methyl-1-oxoheptan-4-ylamino)-3-methyl-1-oxopentan-2-ylcarbamoyl)phenoxy)benzamido)-4-methylpentanamido)hexanoate
-
-
0.000013
1-(3-methylbutyl)-N-(4-pentylbenzyl)-N-(4-pyridin-3-ylbenzyl)piperidin-4-amine
-
-
0.0000048
1-acetyl-piperidine-4-carboxylic acid (2-benzo[1,3]dioxol-5-yl-ethyl)-[3-(4-benzyloxy-3,5-dimethoxy-benzoylamino)-2-hydroxy-4-phenyl-butyl]-amide
-
-
0.000004
1-acetyl-piperidine-4-carboxylic acid (2-benzo[1,3]dioxol-5-yl-ethyl)-[3-[2-(3-chloro-phenoxy)-acetylamino]-2-hydroxy-4-phenyl-butyl]-amide
-
-
0.000003
1-acetyl-piperidine-4-carboxylic acid (2-benzo[1,3]dioxol-5-yl-ethyl)-[3-[2-(3-chloro-phenylamino)-acetylamino]-2-hydroxy-4-phenyl-butyl]-amide
-
-
0.000002
1-methyl-piperidine-4-carboxylic acid (2-benzo[1,3]dioxol-5-yl-ethyl)-(3-[2-(3-chloro-phenoxy)-acetylamino]-2-hydroxy-4-phenyl-butyl)-amide
-
-
0.0000041
1-Methyl-piperidine-4-carboxylic acid [3-(4-benzyloxy-3,5-dimethoxy-benzoylamino)-2-hydroxy-4-phenyl-butyl]-[2-(4-methoxy-phenyl)-ethyl]-amide
-
-
0.000002
1-methyl-piperidine-4-carboxylic acid [3-[2-(3-chloro-phenoxy)-acetylamino]-2-hydroxy-4-phenyl-butyl]-[2-(4-methoxy-phenyl)-ethyl]-amide
-
-
0.0015
17-Benzyl-14-[2-(3,3-dimethyl-butyrylamino)-3-methyl-butyrylamino]-18-hydroxy-2-isopropyl-3,8,15,20-tetraoxo-1,4,9,16tetraaza-cycloicosane-5-carboxylic acid carbamoylmethyl-amide
-
-
0.0008
2,3,4,7-tetrahydro-1H-azepine-3,5-diyldimethanediyl bis(4-aminobenzoate)
-
0.000096
2,5-Bis-allyloxy-3,4-dihydroxy-hexanedioic acid bis-[(2-hydroxy-indan-1-yl)-amide]
-
-
0.000085
2,5-Bis-benzyloxy-3,4-dihydroxy-hexanedioic acid bis-[(2-hydroxy-indan-1-yl)-amide]
-
-
4
2-([2-[4-([[3-(naphthalen-2-ylmethoxy)-7-azabicyclo[2.2.1]hept-2-yl]oxy]methyl)phenoxy]ethyl]sulfanyl)-1,3-benzothiazole
-
-
0.000018
3-amino-N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-1-(2-methylpropyl)-5-phenylpentyl]benzamide
-
-
0.000065
4-(1,3-benzodioxol-5-yl)-Nalpha-[(2S,3S)-2-hydroxy-3-([N-[3-(1H-indol-3-yl)propanoyl]-L-valyl]amino)-4-phenylbutyl]-L-phenylalaninamide
-
-
0.00003
4-(1-benzofuran-2-yl)-Nalpha-[(2S,3S)-2-hydroxy-4-phenyl-3-[[N-(pyridin-2-ylcarbonyl)-L-valyl]amino]butyl]-L-phenylalaninamide
-
-
0.02
4-(benzyloxy)-N-[(1S,2S)-3-[(1-benzylpiperidin-4-yl)amino]-1-(cyclohexylmethyl)-2-hydroxypropyl]-3,5-dimethoxybenzamide
-
-
0.0061
4-([[(4-phenoxyphenyl)amino]carbonyl]amino)benzenecarboximidamide
-
-
0.00003
4-amino-N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-1-(2-methylpropyl)-5-phenylpentyl]benzamide
-
-
0.00006
4-chloro-5-(4-chlorophenoxy)-2-[([[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl)amino]benzenesulfonate
-
-
0.002
6-[3-(1,3-benzothiazol-2-ylsulfanyl)propyl]-7-(2-naphthalen-1-ylethoxy)-1,2,3,4-tetrahydro-1,4-epiminonaphthalene
-
-
0.131
benzo[1,3]dioxole-5-carboxylic acid ((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl)-amide
-
-
0.0004
benzyl 2-benzyl-2-[(2S,3R)-3-[(4-bromobenzyl)oxy]-2-hydroxy-4-oxo-4-[(2-piperidin-1-ylethyl)amino]butyl]hydrazinecarboxylate
-
-
0.0007
benzyl 3-benzyl-4-([2-[(1-formyl-3-methylbutyl)amino]-2-oxo-1-phenylethyl]amino)-4-oxobutanoate
-
-
0.00000025
benzyl [(1S,4S,5R,6R,7S,10S)-4,7-bis[(4-cyanophenoxy)methyl]-5,6-dihydroxy-1,10-bis(1-methylethyl)-2,9,12-trioxo-14-phenyl-13-oxa-3,8,11-triazatetradec-1-yl]carbamate
-
-
0.0000019
extract from Plexaura homomalla
-
pH 4.4, 37°C
-
0.0000464
extract from Xestospongia muta
-
pH 4.4, 37°C
-
0.0000013
KNI-10333
-
at pH 5.0 and 25°C
0.000003
KNI-10343
-
at pH 5.0 and 25°C
0.000004
KNI-10395
-
at pH 5.0 and 25°C
0.0000056
KNI-10742
-
at pH 5.0 and 25°C
0.0000033
KNI-10743
-
at pH 5.0 and 25°C
0.000044
L-lysyl-L-prolyl-L-phenylalanyl-N-[(1S)-1-benzyl-2-[[(1S)-1-benzyl-2-[[(1S)-2-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-1-(hydroxymethyl)-2-oxoethyl]amino]-2-oxoethyl]amino]ethyl]-L-norleucinamide
-
-
0.01
LCu(CH3COO)2
-
pH 4.7, 37°C
0.013
LCuCl2
-
pH 4.7, 37°C
0.000034
methyl 4'-([[1-(1H-imidazol-2-ylmethyl)piperidin-4-yl][(4-pentylphenyl)carbonyl]amino]methyl)biphenyl-4-carboxylate
-
-
0.004
N'1-[(E)-(2,3-dihydroxyphenyl)methylidene]-N'3-[(Z)-(2,3-dihydroxyphenyl)methylidene]benzene-1,3-dicarbohydrazide
-
pH 4.4, 37°C
0.00043
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis(N-benzyl-2-phenylacetamide)
pH 4.5, temperature not specified in the publication
0.000019
N-((1S,2S)-1-(4-benzo[1,3]dioxol-5-yl-benzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-hydroxy-propyl)-2,4,6-trifluorobenzamide
-
-
0.39
N-((1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-[2-(3-methoxyphenyl)ethylcarbamoyl]propyl)-2,4,6-trifluorobenzamide
-
-
0.01
N-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl)-2,4,6-trifluorobenzamide
-
-
0.091
N-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropyl)-3,4-dichlorobenzamide
-
-
0.000308
N-((1S,2S)-1-(biphenyl-4-ylmethoxymethyl)-2-hydroxy-3-[2-(3-methoxy-phenyl)-ethylcarbamoyl]-propyl)-2,4,6-trifluorobenzamide
-
-
0.000048
N-((1S,2S)-1-(biphenyl-4-ylmethoxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-hydroxy-propyl)-2,4,6-trifluorobenzamide
-
-
0.000693
N-((1S,2S)-2-hydroxy-3-[2-(3-methoxy-phenyl)-ethyl-carbamoyl]-1-(4-thiophen-3-yl-benzyloxymethyl)-propyl)-2,4,6-trifluorobenzamide
-
-
0.00001
N-((2S)-1-((2S)-6-amino-1-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-1-oxohexan-2-ylamino)-1-oxopropan-2-yl)-4-(4-((2S,3S)-1-((3S,4S)-1-(butylamino)-3-hydroxy-6-methyl-1-oxoheptan-4-ylamino)-3-methyl-1-oxopentan-2-ylcarbamoyl)phenoxy)benzamide
-
-
0.00000059
N-((2S)-1-((2S)-6-amino-1-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-1-oxohexan-2-ylamino)-4-methyl-1-oxopentan-2-yl)-4-(4-((2S,3R)-1-((3S,4S)-1-(butylamino)-3-hydroxy-6-methyl-1-oxoheptan-4-ylamino)-3-methyl-1-oxopentan-2-ylcarbamoyl)phenoxy)benzamide
-
-
0.0000039
N-((2S,3S)-1-((3S,4S)-1-(butylamino)-3-hydroxy-6-methyl-1-oxoheptan-4-ylamino)-3-methyl-1-oxopentan-2-yl)-4-(4-((2S)-1-((2S)-1-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-1-oxopropan-2-ylamino)-1-oxopropan-2-ylcarbamoyl)phenoxy)benzamide
-
-
0.0000263
N-((2S,3S)-1-((3S,4S)-1-(butylamino)-3-hydroxy-6-methyl-1-oxoheptan-4-ylamino)-3-methyl-1-oxopentan-2-yl)-4-(4-((2S)-1-((2S)-1-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-1-oxopropan-2-ylamino)-4-methyl-1-oxopentan-2-ylcarbamoyl)phenoxy)benzamide
-
not cytotoxic against human fibroblasts at 0.100 mM and are highly selective for plasmepsins vs human cathepsin D
0.000103
N-((2S,3S)-1-((3S,4S)-1-(butylamino)-3-hydroxy-6-methyl-1-oxoheptan-4-ylamino)-3-methyl-1-oxopentan-2-yl)-4-(4-((2S)-1-((2S)-1-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-4-methyl-1-oxopentan-2-ylamino)-4-methyl-1-oxopentan-2-ylcarbamoyl)phenoxy)benzamid
-
-
0.0000121
N-((2S,3S)-1-((3S,4S)-1-(butylamino)-3-hydroxy-6-methyl-1-oxoheptan-4-ylamino)-3-methyl-1-oxopentan-2-yl)-4-(4-((2S)-1-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-4-methyl-1-oxopentan-2-ylcarbamoyl)phenoxy)benzamide
-
not cytotoxic against human fibroblasts at 0.100 mM and are highly selective for plasmepsins vs human cathepsin D
0.000112
N-((2S,3S)-1-((3S,4S)-1-(butylamino)-3-hydroxy-6-methyl-1-oxoheptan-4-ylamino)-3-methyl-1-oxopentan-2-yl)-4-(4-(4-(6-methoxyquinolin-8-ylamino)pentylcarbamoyl)phenoxy)benzamide
-
-
0.000035
N-((S)-1-(((2S,3S)-5-(((R)-1-(((S)-1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-chloro-1-oxopropan-2-yl)amino)-3-hydroxy-5-oxo-1-phenylpentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)-picolinamide
-
pH 5.0, 37°C
0.000333
N-((S)-1-(((2S,3S)-5-(((S)-1-(((S)-1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-cyano-1-oxopropan-2-yl)amino)-3-hydroxy-5-oxo-1-phenylpentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)picolinamide
-
pH 5.0, 37°C
0.0003
N-(2-benzo[1,3]dioxol-5-yl-ethyl)-N-[3-[2-(2,5-dimethyl-phenoxy)-acetylamino]-2-hydroxy-4-phenyl-butyl]-3-(dioxo-1,3-dihydro-isoindol-2-yl)-propionamide
-
-
0.00022
N-(2-benzo[1,3]dioxol-5-yl-ethyl)-N-[3-[2-(3-chloro-phenoxy)-acetylamino]-2-hydroxy-4-phenyl-butyl]-3-(dioxo-1,3-dihydro-isoindol-2-yl)-propionamide
-
-
0.00063
N-benzyl-2-bromo-N-[(4-[[2-(2,4-dichlorophenyl)ethyl](4-phenylbutanoyl)amino]pyrrolidin-3-yl)methyl]-4,5-dimethoxybenzamide
pH 4.5, temperature not specified in the publication
0.0005
N-benzyl-2-bromo-N-[(4-[[2-(2,4-dichlorophenyl)ethyl][3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propanoyl]amino]pyrrolidin-3-yl)methyl]-4,5-dimethoxybenzamide
pH 4.5, temperature not specified in the publication
0.000046
N-[(1S)-1-([(1S,2S)-3-[(2-amino-2-oxoethyl)(benzyl)amino]-1-benzyl-2-hydroxypropyl]carbamoyl)-2-methylpropyl]pyridine-2-carboxamide
-
-
0.0000011
N-[(1S)-1-[[(1S,2S)-1-([[4-(1,3-benzodioxol-5-yl)benzyl]oxy]methyl)-4-[[(1S)-2-[[(1S)-1-carbamoyl-3-methylbutyl]amino]-1-methyl-2-oxoethyl]amino]-2-hydroxy-4-oxobutyl]carbamoyl]-2-methylpropyl]pyridine-2-carboxamide
-
-
0.00000056
N-[(1S)-1-[[(1S,2S)-1-benzyl-4-[[(1S)-2-[[(1S)-1-carbamoyl-3-methylbutyl]amino]-1-methyl-2-oxoethyl]amino]-2-hydroxy-4-oxobutyl]carbamoyl]-2-methylpropyl]pyridine-2-carboxamide
-
-
0.0000022
N-[(1S)-1-[[(1S,2S)-1-[[(4-bromobenzyl)oxy]methyl]-4-[[(1S)-2-[[(1S)-1-carbamoyl-3-methylbutyl]amino]-1-methyl-2-oxoethyl]amino]-2-hydroxy-4-oxobutyl]carbamoyl]-2-methylpropyl]pyridine-2-carboxamide
-
-
0.000121
N-[(1S)-1-[[(1S,2S)-3-([(1S)-2-amino-1-[(4'-methylbiphenyl-4-yl)methyl]-2-oxoethyl]amino)-1-benzyl-2-hydroxypropyl]carbamoyl]-2-methylpropyl]pyridine-2-carboxamide
-
-
0.000579
N-[(1S)-1-[[(1S,2S)-3-[[(1S)-2-amino-1-(biphenyl-3-ylmethyl)-2-oxoethyl]amino]-1-benzyl-2-hydroxypropyl]carbamoyl]-2-methylpropyl]pyridine-2-carboxamide
-
-
0.00065
N-[(1S)-1-[[(1S,2S)-3-[[(1S)-2-amino-1-(biphenyl-4-ylmethyl)-2-oxoethyl](benzyl)amino]-1-benzyl-2-hydroxypropyl]carbamoyl]-2-methylpropyl]pyridine-2-carboxamide
-
-
0.000117
N-[(1S)-1-[[(1S,2S)-3-[[(1S)-2-amino-1-(biphenyl-4-ylmethyl)-2-oxoethyl]amino]-1-benzyl-2-hydroxypropyl]carbamoyl]-2-methylpropyl]pyridine-2-carboxamide
-
-
0.23
N-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-cyclohexylcarbamoyl-2-hydroxypropyl]-2,4,6-trifluorobenzamide
-
-
0.000214
N-[(1S,2S)-1-(biphenyl-4-ylmethoxymethyl)-3-cyclo-hexylcarbamoyl-2-hydroxypropyl]-2,4,6-trifluorobenzamide
-
-
0.00001
N-[(1S,2S)-1-[[(4-bromobenzyl)oxy]methyl]-4-[[(1S)-2-[[(1S)-1-carbamoyl-3-methylbutyl]amino]-1-methyl-2-oxoethyl]amino]-2-hydroxy-4-oxobutyl]-2,4,6-trifluorobenzamide
-
-
0.00026
N-[(1S,2S)-3-cyclohexylcarbamoyl-2-hydroxy-1-(4-thiophen-3-yl-benzyloxymethyl)-propyl]-2,4,6-trifluorobenzamide
-
-
0.000055
N-[(1S,2S)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butyl-carbamoyl)-ethylcarbamoyl]-2-hydroxy-1-(4-thiophen-3-yl-benzyloxymethyl)-propyl]-2,4,6-trifluorobenzamide
-
-
0.0001
N-[(1S,2S)-3-[[2-(1,3-benzodioxol-5-yl)ethyl][3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propanoyl]amino]-1-benzyl-2-hydroxypropyl]-4-(benzyloxy)-3,5-dimethoxybenzamide
-
-
0.0000043
N-[(2S,3S)-3-[[(3-chlorophenoxy)acetyl]amino]-2-hydroxy-4-phenylbutyl]-N-[2-(4-methoxyphenyl)ethyl]piperidine-4-carboxamide
-
-
0.0000002
N-[(3S)-3-[(2S,5S,14S)-14-[(3,3-dimethylbutanoyl)amino]-2-(1-methylethyl)-3,11,15-trioxo-1,4,10-triazacyclopentadecan-5-yl]-3-hydroxypropanoyl]-L-valyl-L-leucylglycinamide
-
-
0.000046
N-[(3S,4S)-3-hydroxy-6-phenyl-4-[[N-(pyridin-2-ylcarbonyl)-L-valyl]amino]hexanoyl]-L-alanyl-L-leucinamide
-
-
0.000011
N-[1-Benzyl-3-(2-biphenyl-4-yl-1-carbamoyl-ethylamino)-2-hydroxy-propyl]-2-(3-1H-indol-3-yl-propionylamino)-3-methyl-butyramide
-
-
0.0001
N-[3-[(2-benzo[1,3]dioxol-5-yl-ethyl)-[3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propionyl]-amino]-1-benzyl-2-hydroxy-propyl]-4-benzyloxy-3,5-dimethoxy-benzamide
-
-
0.000056
N-[4-(1,3-benzodioxol-5-yl)benzyl]-N-(3-butylheptyl)-4-pentylbenzamide
-
-
0.0033
N2-[(2S,3S)-2-hydroxy-4-phenyl-3-[[N-(pyridin-2-ylcarbonyl)-L-valyl]amino]butyl]-L-leucinamide
-
-
0.0032
Nalpha-[(2S,3S)-2-hydroxy-4-phenyl-3-[[N-(pyridin-2-ylcarbonyl)-L-valyl]amino]butyl]-L-phenylalaninamide
-
-
0.000000037
pepstatin
-
pH 5.0, 37°C
0.000000024 - 0.00000007
pepstatin A
0.000009
Piperidine-4-carboxylic acid [3-(4-benzyloxy-3,5-dimethoxy-benzoylamino)-2-hydroxy-4-phenyl-butyl]-[2-(4-methoxy-phenyl)-ethyl]-amide
-
-
0.000004 - 0.0000043
piperidine-4-carboxylic acid [3-[2-(3-chloro-phenoxy)-acetylamino]-2-hydroxy-4-phenyl-butyl]-[2-(4-methoxy-phenyl)-ethyl]-amide
0.00005
PS-273800
-
-
0.015
pyridine-2-carboxylic acid ((R)-1-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methylpropyl)amide
-
-
0.0000057
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-(3-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)-ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methyl-propyl)-amide
-
-
0.0000011
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-(4-benzo-[1,3]dioxol-5-yl-benzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methylpropyl)-amide
-
-
0.029
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(2-(3-methoxyphenyl)ethylcarbamoyl)propylcarbamoyl)-2-methylpropyl)amide
-
-
0.0022
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-(4-bromobenzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methylpropyl)amide
-
-
0.0000044
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-(biphenyl-3-ylmethoxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-hydroxy-propylcar-bamoyl)-2-methyl-propyl)-amide
-
-
0.0000009
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-(biphenyl-4-ylmethoxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-hydroxy-propylcarbamoyl)-2-methyl-propyl)-amide
-
-
0.011
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-1-benzyloxymethyl-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxypropylcarbamoyl)-2-methylpropyl)amide
-
-
0.046
pyridine-2-carboxylic acid ((S)-1-((1S,2S)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)ethylcarbamoyl]-2-hydroxy-1-phenethylpropylcarbamoyl)-2-methylpropyl)amide
-
-
0.000045
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-benzo-[1,3]dioxol-5-yl-benzyloxymethyl)-3-butylcarbamoyl-2-hydroxy-propylcarbamoyl]-2-methyl-propyl)-amide
-
-
0.074
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(2-phenylaminoethyl-carbamoyl)propylcarbamoyl]-2-methylpropyl)amide
-
-
0.248
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(3-methoxypropylcarbamoyl)propylcarbamoyl]-2-methylpropyl)amide
-
-
0.03
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-2-hydroxy-3-(3-phenylpropylcarbamoyl)propylcarbamoyl]-2-methylpropyl)amide
-
-
0.256
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-(4-cyanobenzylcarbamoyl)-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide
-
-
0.041
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-(cyclohexylmethylcarbamoyl)-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide
-
-
0.068
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-butylcarbamoyl-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide
-
-
0.025
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(4-bromobenzyloxymethyl)-3-cyclohexylcarbamoyl-2-hydroxypropylcarbamoyl]-2-methylpropyl)amide
-
-
0.000016
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-1-(biphenyl-4-ylmethoxymethyl)-3-butylcarbamoyl-2-hydroxy-propylcarbamoyl]-2-methylpropyl)-amide
-
-
0.000013
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-3-butylcarbamoyl-2-hydroxy-1-(4-thiophen-3-yl-benzyloxymethyl)-propylcarbamoyl]-2-methyl-propyl)-amide
-
-
0.0000019
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-hydroxy-1-(3-thiophen-3-yl-benzyloxymethyl)-propyl-carbamoyl]-2-methyl-propyl)-amide
-
-
0.0000011
pyridine-2-carboxylic acid ((S)-1-[(1S,2S)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-hydroxy-1-(4-thiophen-3-yl-benzyloxymethyl)-propyl-carbamoyl]-2-methyl-propyl)-amide
-
-
0.0005 - 0.0007
Ro40-4388
0.00025
Ro40-5576
0.000403
tert-butyl (5S)-5-((S)-2-(4-(4-((2S,3S)-1-((3S,4S)-1-(butylamino)-3-hydroxy-6-methyl-1-oxoheptan-4-ylamino)-3-methyl-1-oxopentan-2-ylcarbamoyl)phenoxy)benzamido)-4-methylpentanamido)-6-(4-(6-methoxyquinolin-8-ylamino)pentylamino)-6-oxohexylcarbamate
-
-
0.0004
[5-([[(4-bromophenyl)carbonyl]oxy]methyl)-2,3,4,7-tetrahydro-1H-azepin-3-yl]methyl 4-aminobenzoate
-
0.0024
[6-([[(4-aminophenyl)carbonyl]oxy]methyl)-2,5,6,7-tetrahydro-1H-azepin-4-yl]methyl 7aH-indole-3-carboxylate
-
0.001
[6-([[(4-aminophenyl)carbonyl]oxy]methyl)-2,5,6,7-tetrahydro-1H-azepin-4-yl]methyl naphthalene-1-carboxylate
-
0.0013
[6-([[(4-nitrophenyl)carbonyl]oxy]methyl)-2,5,6,7-tetrahydro-1H-azepin-4-yl]methyl naphthalene-1-carboxylate
-
additional information
additional information
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00419
(1R,2R,3R,4S)-3-[(4-butylphenyl)sulfonyl]-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine
Plasmodium falciparum
pH and temperature not specified in the publication
0.00005
(1R,2R,3R,4S)-3-[(4-heptylphenyl)sulfonyl]-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine
Plasmodium falciparum
pH and temperature not specified in the publication
0.00013
(1R,2R,3R,4S)-3-[(4-hexylphenyl)sulfonyl]-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine
Plasmodium falciparum
pH and temperature not specified in the publication
0.00017
(1R,2R,3R,4S)-3-[[4-(2-cyclobutylethyl)phenyl]sulfonyl]-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine
Plasmodium falciparum
pH and temperature not specified in the publication
0.00003
(1R,2R,3R,4S)-3-[[4-(2-cyclopentylethyl)phenyl]sulfonyl]-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine
Plasmodium falciparum
pH and temperature not specified in the publication
0.00038
(1R,2R,3R,4S)-3-[[4-(3-cyclohexylpropyl)phenyl]sulfonyl]-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine
Plasmodium falciparum
pH and temperature not specified in the publication
0.00019
(1R,2R,3R,4S)-3-[[4-(3-cyclopentylpropyl)phenyl]sulfonyl]-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine
Plasmodium falciparum
pH and temperature not specified in the publication
0.00005
(1R,2R,3R,4S)-3-[[4-(4,4-dimethylpentyl)phenyl]sulfonyl]-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine
Plasmodium falciparum
pH and temperature not specified in the publication
0.00221
(1R,2R,3R,4S)-3-[[4-(4-fluorobutyl)phenyl]sulfonyl]-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine
Plasmodium falciparum
pH and temperature not specified in the publication
0.00035
(1R,2R,3R,4S)-3-[[4-(6-fluorohexyl)phenyl]sulfonyl]-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine
Plasmodium falciparum
pH and temperature not specified in the publication
0.00068
(1R,2R,3R,4S)-N-(naphthalen-2-ylmethyl)-3-[(4-pentylphenyl)sulfonyl]-7-azabicyclo[2.2.1]heptan-2-amine
Plasmodium falciparum
pH and temperature not specified in the publication
0.0009
(1R,2R,3R,4S)-N-(naphthalen-2-ylmethyl)-3-[[4-(2-propoxyethyl)phenyl]sulfonyl]-7-azabicyclo[2.2.1]heptan-2-amine
Plasmodium falciparum
pH and temperature not specified in the publication
0.00015
(1R,2R,3R,4S)-N-(naphthalen-2-ylmethyl)-3-[[4-(pentyloxy)phenyl]sulfonyl]-7-azabicyclo[2.2.1]heptan-2-amine
Plasmodium falciparum
pH and temperature not specified in the publication
0.000089
(1R,2R,3R,4S,5R)-5-[(cyclobutylamino)methyl]-N-(naphthalen-2-ylmethyl)-3-[(4-pentylphenyl)sulfonyl]-7-azabicyclo[2.2.1]heptan-2-amine
Plasmodium falciparum
pH and temperature not specified in the publication
0.0001
(1R,2R,3R,4S,5R)-5-[(cyclopentylamino)methyl]-N-(naphthalen-2-ylmethyl)-3-[(4-pentylphenyl)sulfonyl]-7-azabicyclo[2.2.1]heptan-2-amine
Plasmodium falciparum
pH and temperature not specified in the publication
0.000284
(1R,2R,3R,4S,6R)-6-[(cyclobutylamino)methyl]-N-(naphthalen-2-ylmethyl)-3-[(4-pentylphenyl)sulfonyl]-7-azabicyclo[2.2.1]heptan-2-amine
Plasmodium falciparum
pH and temperature not specified in the publication
0.000289
(1R,2R,3R,4S,6R)-6-[(cyclopentylamino)methyl]-N-(naphthalen-2-ylmethyl)-3-[(4-pentylphenyl)sulfonyl]-7-azabicyclo[2.2.1]heptan-2-amine
Plasmodium falciparum
pH and temperature not specified in the publication
0.7
(1R,2R,3S,4S)-2,3-bis(naphthalen-2-ylmethoxy)-7-azabicyclo[2.2.1]heptane
Plasmodium falciparum
pH and temperature not specified in the publication
0.014
(1R,4S)-6-[2-(1,3-benzothiazol-2-ylsulfanyl)ethoxy]-7-(naphthalen-1-ylmethoxy)-1,2,3,4-tetrahydro-1,4-epiminonaphthalene
Plasmodium falciparum
pH and temperature not specified in the publication
0.01
(1R,4S)-6-[2-(1,3-benzothiazol-2-ylsulfanyl)ethoxy]-7-(naphthalen-2-ylmethoxy)-1,2,3,4-tetrahydro-1,4-epiminonaphthalene
Plasmodium falciparum
pH and temperature not specified in the publication
0.013
(1R,4S)-6-[2-(1,3-benzothiazol-2-ylsulfanyl)ethoxy]-7-[2-(naphthalen-1-yl)ethoxy]-1,2,3,4-tetrahydro-1,4-epiminonaphthalene
Plasmodium falciparum
pH and temperature not specified in the publication
0.005
(1R,4S)-6-[2-[(6-chloro-1,3-benzothiazol-2-yl)sulfanyl]ethoxy]-7-(naphthalen-1-ylmethoxy)-1,2,3,4-tetrahydro-1,4-epiminonaphthalene
Plasmodium falciparum
pH and temperature not specified in the publication
0.004
(1R,4S)-6-[2-[(6-chloro-1,3-benzothiazol-2-yl)sulfanyl]ethoxy]-7-(naphthalen-2-ylmethoxy)-1,2,3,4-tetrahydro-1,4-epiminonaphthalene
Plasmodium falciparum
pH and temperature not specified in the publication
0.003
(1R,4S)-6-[2-[(6-chloro-1,3-benzothiazol-2-yl)sulfanyl]ethoxy]-7-[2-(naphthalen-1-yl)ethoxy]-1,2,3,4-tetrahydro-1,4-epiminonaphthalene
Plasmodium falciparum
pH and temperature not specified in the publication
0.004
(1R,4S)-6-[3-(1,3-benzothiazol-2-ylsulfanyl)propyl]-7-(naphthalen-1-ylmethoxy)-1,2,3,4-tetrahydro-1,4-epiminonaphthalene
Plasmodium falciparum
pH and temperature not specified in the publication
0.002
(1R,4S)-6-[3-[(6-chloro-1,3-benzothiazol-2-yl)sulfanyl]propyl]-7-(naphthalen-1-ylmethoxy)-1,2,3,4-tetrahydro-1,4-epiminonaphthalene
Plasmodium falciparum
pH and temperature not specified in the publication
0.01
(1RS) 3,3-difluoro-N-[2-(2-naphthyl)ethyl]-4-oxo-N-(4-pentylphenyl)cyclohexanecarboxamide
Plasmodium falciparum
-
pH 5.0, 37°C
0.043
(1RS,4RS)-3,3-difluoro-4-hydroxy-N-[2-(2-naphthyl)ethyl]-N(4-pentylphenyl)cyclohexanecarboxamide
Plasmodium falciparum
-
pH 5.0, 37°C
0.01
(1S)-3,3-difluoro-4,4-dihydroxy-N-(naphthalen-2-ylmethyl)-N-(4-pentylphenyl)cyclohexanecarboxamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.07
(1S,2S,3R,4R)-2-([4-[3-(1,3-benzodioxol-5-yl)propyl]benzyl]oxy)-3-(naphthalen-2-ylmethoxy)-7-azabicyclo[2.2.1]heptane
Plasmodium falciparum
pH and temperature not specified in the publication
1
(1S,2S,3R,4R)-2-[(4-bromobenzyl)oxy]-3-(naphthalen-2-ylmethoxy)-7-azabicyclo[2.2.1]heptane
Plasmodium falciparum
pH and temperature not specified in the publication
0.0148
(1S,2S,3S,4R)-3-(4-bromophenylsulfonyl)-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine
Plasmodium falciparum
-
-
0.00039
(1S,2S,3S,4R)-3-(4-hexylphenylsulfonyl)-N-((2'-methoxybiphenyl-3-yl)methyl)-7-azabicyclo[2.2.1]heptan-2-amine
Plasmodium falciparum
-
-
0.00013
(1S,2S,3S,4R)-3-(4-hexylphenylsulfonyl)-N-(naphthalen-2-ylmethyl)-7-azabicyclo[2.2.1]heptan-2-amine
Plasmodium falciparum
-
-
0.00021
(1S,2S,3S,4R)-N-(3-bromobenzyl)-3-(4-hexylphenylsulfonyl)-7-azabicyclo[2.2.1]heptan-2-amine
Plasmodium falciparum
-
-
0.038
(1SR,4RS)-3,3-difluoro-4-hydroxy-N-[2-(2-naphthyl)ethyl]-N(4-pentylphenyl)cyclohexanecarboxamide
Plasmodium falciparum
-
pH 5.0, 37°C
0.0000043
(1Z)-(3,4-dimethoxyphenyl)-N'-[[(3,4,5-trichlorophenoxy)acetyl]oxy]ethanimidamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.0000043
(1Z)-N'-{[(4-chloro-3,5-dimethylphenoxy)acetyl]oxy}-2-(3,4-dimethoxyphenyl)ethanimidamide
Plasmodium falciparum
-
pH 4.5, 37°C
0.15
(2E)-2-[(2H-1,3-benzodioxol-5-yl)methylidene]hydrazine-1-carboximidamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.02158
(2R,3R,4R,5R)-2,5-bis(benzyloxy)-3,4-dihydroxy-N,N'-bis[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]hexanediamide
Plasmodium falciparum
-
-
0.000006
(2R,3R,4S,6R)-6-[[(E)-2-(4-acetylphenyl)ethenyl]oxy]-2-[[(2E)-3-(4-acetylphenyl)prop-2-en-1-yl]oxy]-3,4-dihydroxy-N,N'-bis[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]heptanediamide
Plasmodium falciparum
-
predicted inhibition constant, temperature not specified in the publication, pH not specified in the publication
0.0013
(3S,4S)-pyrrolidine-3,4-diyl bis(naphthalen-1-ylacetate)
Plasmodium falciparum
pH and temperature not specified in the publication
0.0244
(3S,4S)-pyrrolidine-3,4-diyl dibenzoate
Plasmodium falciparum
pH and temperature not specified in the publication
0.0005
(5-[[(4-bromobenzoyl)oxy]methyl]-2,3,4,7-tetrahydro-1H-azepin-3-yl)methyl 4-aminobenzoate
Plasmodium falciparum
pH and temperature not specified in the publication
0.00105
1,2-diphenylhydrazine
Plasmodium falciparum
pH and temperature not specified in the publication
0.0212
1-(4-chlorophenyl)-2-[2-(pyridin-2-yl)-1H-benzimidazol-1-yl]ethanone
Plasmodium falciparum
-
pH 5.0, temperature not specified in the publication
0.0305
1-(4-nitrophenyl)-2-[2-(pyridin-2-yl)-1H-benzimidazol-1-yl]ethanone
Plasmodium falciparum
-
pH 5.0, temperature not specified in the publication
0.00947
1-(benzylamino)-3-(3,6-dichloro-9H-carbazol-9-yl)propan-2-ol
Plasmodium falciparum
pH and temperature not specified in the publication
0.0147
1-(biphenyl-4-yl)-2-[2-(pyridin-2-yl)-1H-benzimidazol-1-yl]ethanone
Plasmodium falciparum
-
pH 5.0, temperature not specified in the publication
0.196
1-(diphenylmethyl)azetidin-3-ol
Plasmodium falciparum
pH and temperature not specified in the publication
0.125
1-amino-3-(4-nitroanilino)propan-2-ol
Plasmodium falciparum
pH and temperature not specified in the publication
0.2
1-phenyl-N-(propan-2-yl)methanesulfonamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.02
1-[2-hydroxy-3-(1,2,3,4,5,6,7,8-octahydrophenanthren-9-yloxy)propyl]-4-(3-methoxyphenyl)piperazin-1-ium
Plasmodium falciparum
-
pH 5.0, temperature not specified in the publication
0.002
1-[3-chloro-6-(trifluoromethyl)phenanthren-9-yl]-3-(dibutylamino)propan-1-ol
Plasmodium falciparum
pH and temperature not specified in the publication
0.005
1-[6-chloro-3-(3,4-dichlorophenyl)naphthalen-1-yl]-2-(dibutylamino)ethanol
Plasmodium falciparum
pH and temperature not specified in the publication
0.0016
2,2-diphenylacetohydrazide
Plasmodium falciparum
pH and temperature not specified in the publication
0.000039
2,3,4-trifluoro-N-([[1-(3-methylbutyl)piperidin-4-yl](4-pentylbenzoyl)amino]methyl)benzamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.000039
2,3-difluoro-4-methyl-N-[4-([[1-(3-methylbutyl)piperidin-4-yl][(4-pentylphenyl)carbonyl]amino]methyl)phenyl]benzamide
Plasmodium falciparum
-
-
0.0000961
2-(1,3-benzothiazol-2-ylamino)-N-(2-chlorophenyl)-6-oxo-1,4,5,6­tetrahydro-4-pyrimidinecarboxamide
Plasmodium falciparum
-
pH 4.5, 37°C
0.0001452
2-(1-naphthyl)-N'-[(4-nitrobenzoyl)oxy]ethanimidamide
Plasmodium falciparum
-
pH 4.5, 37°C
0.019
2-(2-naphthyl)-N-(4-pentylphenyl)-N-piperidin-4-ylacetamide hydrochloride
Plasmodium falciparum
-
pH 5.0, 37°C
0.005
2-(dihexylamino)-1-(1,2,3,4-tetrahydrophenanthren-9-yl)ethanol
Plasmodium falciparum
pH and temperature not specified in the publication
0.009
2-([2-[4-([[(1S,2S,3R,4R)-3-(naphthalen-2-ylmethoxy)-7-azabicyclo[2.2.1]hept-2-yl]oxy]methyl)phenoxy]ethyl]sulfanyl)-1,3-benzothiazole
Plasmodium falciparum
pH and temperature not specified in the publication
0.000441
2-([4'-(([2-(dibutylamino)ethyl](4-pentylbenzyl)amino)methyl)biphenyl-4-yl]oxy)ethanol
Plasmodium falciparum
-
IC50: 441 nM
0.0243
2-amino-3-[(oxolan-2-yl)methyl]quinazolin-4(3H)-one
Plasmodium falciparum
pH and temperature not specified in the publication
0.000189
2-anilino-3-chloro-N-phenyl-4-(phenylimino)-2-butenamide
Plasmodium falciparum
-
pH 4.5, 37°C
0.0001871
2-anilino-4-(3-furyl)-6-oxo-N-phenyl-1-cyclohexene-1-carboxamide
Plasmodium falciparum
-
pH 4.5, 37°C
0.00165
2-methoxybenzohydrazide
Plasmodium falciparum
pH and temperature not specified in the publication
0.001
2-nitrobenzohydrazide
Plasmodium falciparum
pH and temperature not specified in the publication
0.00645
2-[(Z)-1-(4-chlorophenyl)-2-[3-(pyridin-2-yl)isoquinolin-1-yl]ethenyl]hydrazine-1-carboximidothioic acid
Plasmodium falciparum
pH and temperature not specified in the publication
0.00147
2-[4'-(([2-(dibutylamino)ethyl](4-pentylbenzyl)amino)methyl)biphenyl-4-yl]ethanol
Plasmodium falciparum
-
IC50: 0.00147 mM
0.005
2-[bis(4-methylpentyl)amino]-1-(1,2,3,4-tetrahydrophenanthren-9-yl)ethanol
Plasmodium falciparum
pH and temperature not specified in the publication
0.0004
3'-(((1S,2S,3S,4R)-3-(4-hexylphenylsulfonyl)-7-azabicyclo[2.2.1]heptan-2-ylamino)methyl)biphenyl-2-ol
Plasmodium falciparum
-
-
0.018
3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,5a,6,11,11a-octahydrotetracen-1-yl 3,4-di-O-acetyl-2,6-dideoxyhexopyranoside
Plasmodium falciparum
-
pH 5.0, temperature not specified in the publication
0.0002011
3-chloro-N-([2-(2-methoxybenzoyl)hydrazino]carbonothioyl)-1-benzothiophene-2-carboxamide
Plasmodium falciparum
-
pH 4.5, 37°C
0.062
3-[3-(4-chlorophenyl)-3-hydroxy-3-phenylpropyl]-3-azoniabicyclo[4.2.1]nonane
Plasmodium falciparum
-
pH 5.0, temperature not specified in the publication
0.000713 - 0.000918
4'-(([2-(dibutylamino)ethyl](4-pentylbenzyl)amino)methyl)biphenyl-4-carbonitrile
0.000208
4'-(([2-(dibutylamino)ethyl](phenylcarbonyl)amino)methyl)biphenyl-3-carboxylic acid
Plasmodium falciparum
-
IC50: 208 nM
0.000495
4'-(([2-(dibutylamino)ethyl](phenylcarbonyl)amino)methyl)biphenyl-4-carboxylic acid
Plasmodium falciparum
-
IC50: 495 nM
0.000077
4'-(([2-(dibutylamino)ethyl][(4-pentylphenyl)carbonyl]amino)methyl)-N,N-dimethylbiphenyl-4-carboxamide
Plasmodium falciparum
-
IC50: 77 nM
0.00145
4,4'-(hydrazine-1,2-diyl)dipyridine
Plasmodium falciparum
pH and temperature not specified in the publication
0.184
4-(1,2-benzothiazol-3-yl)-N-methylpiperazine-1-carboxamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.15
4-(imidazo[2,1-b][1,3]thiazol-6-yl)aniline
Plasmodium falciparum
pH and temperature not specified in the publication
0.0000064
4-amino-N'-(benzyloxy)-N-(2-methylphenyl)-1,2,5-oxadiazole-3-carboximidamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.0000064
4-amino-N'-(benzyloxy)-N-(2-methylphenyl)-1,2,5-oxadiazole-3­carboximidamide
Plasmodium falciparum
-
pH 4.5, 37°C
0.000305
4-amino-N'-(benzyloxy)-N-(4-methylphenyl)-1,2,5-oxadiazole-3­carboximidamide
Plasmodium falciparum
-
pH 4.5, 37°C
0.0000055
4-amino-N'-[(2,4-dichlorobenzyl)oxy]-N-(2-methylphenyl)-1,2,5­oxadiazole-3-carboximidamide
Plasmodium falciparum
-
pH 4.5, 37°C
0.0000055
4-amino-N'-[(2,4-dichlorophenyl)methoxy]-N-(2-methylphenyl)-1,2,5-oxadiazole-3-carboximidamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.0000426
4-amino-N'-[(2-methyl-1-naphthyl)methoxy]-1,2,5-oxadiazole-3­carboximidamide
Plasmodium falciparum
-
pH 4.5, 37°C
0.0059
4-butoxy-N-[2-(dibutylamino)ethyl]-N-(3-phenoxybenzyl)benzamide
Plasmodium falciparum
-
IC50: 0.0059 mM
0.0103
4-butoxy-N-[2-(dibutylamino)ethyl]-N-[4-(trifluoromethyl)benzyl]benzamide
Plasmodium falciparum
-
IC50: 0.0103 mM
0.0023
4-butyl-N-[2-(dibutylamino)ethyl]-N-(3-phenoxybenzyl)benzamide
Plasmodium falciparum
-
IC50: 0.0023 mM
0.0039
4-butyl-N-[2-(dibutylamino)ethyl]-N-[4-(trifluoromethyl)benzyl]benzamide
Plasmodium falciparum
-
IC50: 0.0039 mM
0.007
4-methyl-N-[2-[2-(naphthalen-2-yl)hydrazinyl]phenyl]benzene-1-sulfonamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.152
5-methyl-N3-phenyl-1H-pyrazole-3,4-diamine
Plasmodium falciparum
pH and temperature not specified in the publication
0.00461
5-[4-([(1S,2R,3R,4R)-3-[(naphthalen-2-ylmethyl)amino]-7-azabicyclo[2.2.1]hept-2-yl]sulfonyl)phenyl]pentan-1-ol
Plasmodium falciparum
pH and temperature not specified in the publication
0.056
5-[bis[(benzyloxy)carbonyl]amino]-6-[[1-hydrazinyl-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-6-oxohexan-1-aminium
Plasmodium falciparum
-
pH 5.0, temperature not specified in the publication
0.0000573
6-((2-[(5-chloro-2-methoxyphenyl)amino]-2-oxoethyl)thio)-5-cyano-N-(2-methoxyphenyl)-2-methyl-4-phenyl-1,4-dihydro-3-pyridinecarboxamide
Plasmodium falciparum
-
pH 4.5, 37°C
0.001831
6-bromo-2,3,4,9-tetrahydro-1H-carbazol-1-one N­phenylthiosemicarbazone
Plasmodium falciparum
-
pH 4.5, 37°C
0.00079
6-[4-([(1S,2R,3R,4R)-3-[(naphthalen-2-ylmethyl)amino]-7-azabicyclo[2.2.1]hept-2-yl]sulfonyl)phenyl]hexan-1-ol
Plasmodium falciparum
pH and temperature not specified in the publication
0.0000006
Ac-Val-Val-Sta-Ala-Sta
Plasmodium falciparum
-
IC50: 0.6 nM
0.00125
butanehydrazide
Plasmodium falciparum
pH and temperature not specified in the publication
0.00015
butyloxycarbonyl-His-Pro-Phe-His-Leu-PSI[CH(OH)-CH2]-Val-Ile-His
Plasmodium falciparum
-
IC50: 150 nM
0.001
butyloxycarbonyl-His-Pro-Phe-His-Sta-Leu-Phe-NH2
Plasmodium falciparum
-
IC50: 1000 nM
0.0000001
Iva-Val-Val-Sta-Ala-Sta
Plasmodium falciparum
-
IC50: 0.1 nM
100
Lac-Val-Sta-Ala-Sta
Plasmodium falciparum
-
IC50: 100 mM
0.014
LCu(CH3COO)2
Plasmodium falciparum
-
pH 4.7, 37°C
0.017
LCuCl2
Plasmodium falciparum
-
pH 4.7, 37°C
0.000124
methyl [4'-(([2-(dibutylamino)ethyl](phenylcarbonyl)amino)methyl)biphenyl-4-yl]acetate
Plasmodium falciparum
-
IC50: 124 nM
0.000183
methyl [4'-(([2-(dibutylamino)ethyl][(4-pentylphenyl)carbonyl]amino)methyl)biphenyl-4-yl]acetate
Plasmodium falciparum
-
IC50: 183 nM
0.000034
methyl [4'-([[1-(1H-imidazol-2-ylmethyl)piperidin-4-yl](4-pentylbenzoyl)amino]methyl)biphenyl-4-yl]acetate
Plasmodium falciparum
pH and temperature not specified in the publication
0.000034
methyl [4'-([[1-(1H-imidazol-2-ylmethyl)piperidin-4-yl][(4-pentylphenyl)carbonyl]amino]methyl)biphenyl-4-yl]acetate
Plasmodium falciparum
-
-
0.000014
methyl [4'-([[1-(3-methylbutyl)piperidin-4-yl][(4-pentylcyclohexyl)carbonyl]amino]methyl)biphenyl-4-yl]acetate
Plasmodium falciparum
-
-
0.000011
methyl [4'-([[1-(3-methylbutyl)piperidin-4-yl][(4-pentylphenyl)carbonyl]amino]methyl)biphenyl-4-yl]acetate
Plasmodium falciparum
-
-
0.0000076
N',N'''-1,2-phenylenebis[N-(3-chlorophenyl)urea]
Plasmodium falciparum
-
pH 4.5, 37°C
0.00462
N',N''-[1,10-phenanthroline-2,9-diyldi(E)methylylidene]bis[N-(2-methylphenyl)pyridine-2-carbohydrazonamide]
Plasmodium falciparum
pH and temperature not specified in the publication
0.000004
N'-(3,4-dimethylacridin-9-yl)-2-hydroxybenzohydrazide
Plasmodium falciparum
pH and temperature not specified in the publication
0.0000005
N'-(3,4-dimethylacridin-9-yl)-3-methylbenzohydrazide
Plasmodium falciparum
pH and temperature not specified in the publication
0.0000076
N'-(4-chlorophenyl)-N'-(2-[[(3-chlorophenyl)carbamoyl]amino]phenyl)urea
Plasmodium falciparum
pH and temperature not specified in the publication
0.0002364
N'-[(4-methoxy-3-nitrobenzoyl)oxy]-2-(1-naphthyl)ethanimidamide
Plasmodium falciparum
-
pH 4.5, 37°C
0.00055
N,N'-(3S,4S)-pyrrolidine-3,4-diylbis(N-benzyl-2-phenylacetamide)
Plasmodium falciparum
pH and temperature not specified in the publication
0.0002374
N,N'-([(4,6-dimethyl-2-quinazolinyl)amino]methylylidene)dipropanamide
Plasmodium falciparum
-
pH 4.5, 37°C
0.095
N,N-dibutyl-3-(1,4-dihydronaphthalen-1-yl)-3-hydroxybutan-1-aminium
Plasmodium falciparum
-
pH 5.0, temperature not specified in the publication
0.0013
N,N-dibutyl-N'-(4-pentylbenzyl)-N'-(4-pyridin-2-ylbenzyl)ethane-1,2-diamine
Plasmodium falciparum
-
IC50: 0.0013 mM
0.001603
N,N-dibutyl-N'-(4-pentylbenzyl)-N'-(4-pyridin-4-ylbenzyl)ethane-1,2-diamine
Plasmodium falciparum
-
IC50: 0.001603 mM
0.000000001631
N,N-dibutyl-N'-(4-pentylbenzyl)-N'-(4-pyrimidin-5-ylbenzyl)ethane-1,2-diamine
Plasmodium falciparum
-
IC50: 0.001631 nM
0.002
N,N-dibutyl-N'-(4-pentylbenzyl)-N'-([4'-(2-pyrrolidin-1-ylethoxy)biphenyl-4-yl]methyl)ethane-1,2-diamine
Plasmodium falciparum
-
IC50: 0.002 mM
0.001022
N,N-dibutyl-N'-[(2'-fluorobiphenyl-4-yl)methyl]-N'-(4-pentylbenzyl)ethane-1,2-diamine
Plasmodium falciparum
-
IC50: 0.001022 mM
0.0000621
N-((2,3-dihydro-1,4-benzodioxin-6-ylamino)[(6-methyl-4-oxo-1,4-dihydro-2-pyrimidinyl)amino]methylene)benzamide
Plasmodium falciparum
-
pH 4.5, 37°C
0.0001181
N-((2,3-dihydro-1,4-benzodioxin-6-ylamino)[(6-oxo-4-propyl-1,6-dihydro-2-pyrimidinyl)amino]methylene)-4-methoxybenzamide
Plasmodium falciparum
-
pH 4.5, 37°C
0.000046
N-((4'-[2-(benzylamino)-2-oxoethyl]biphenyl-4-yl)methyl)-N-[2-(dibutylamino)ethyl]-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 46 nM
0.000022
N-((S)-1-(((2S,3S)-3-hydroxy-5-oxo-5-(((S)-1-oxo-3-phenyl-1-(prop-2-yn-1-ylamino)propan-2-yl)amino)-1-phenylpentan-2-yl)-amino)-3-methyl-1-oxobutan-2-yl)picolinamide
Plasmodium falciparum
-
pH 5.0, 37°C
0.000028
N-((S)-1-(((2S,3S)-5-(((R)-1-(((S)-1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-chloro-1-oxopropan-2-yl)amino)-3-hydroxy-5-oxo-1-phenylpentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)-picolinamide
Plasmodium falciparum
-
pH 5.0, 37°C
0.000141
N-((S)-1-(((2S,3S)-5-(((S)-1-(((S)-1-amino-4-methyl-1-oxopentan-2-yl)amino)-1-oxopent-4-yn-2-yl)amino)-3-hydroxy-5-oxo-1-phenylpentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)-picolinamide
Plasmodium falciparum
-
pH 5.0, 37°C
0.000333
N-((S)-1-(((2S,3S)-5-(((S)-1-(((S)-1-amino-4-methyl-1-oxopentan-2-yl)amino)-3-cyano-1-oxopropan-2-yl)amino)-3-hydroxy-5-oxo-1-phenylpentan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)picolinamide
Plasmodium falciparum
-
pH 5.0, 37°C
0.0001464
N-(([2-(4-ethylphenyl)-6-methyl-2H-1,2,3-benzotriazol-5-yl]amino)carbonothioyl)-2-nitrobenzamide
Plasmodium falciparum
-
pH 4.5, 37°C
0.0001229
N-(([6-methyl-2-(4-methylphenyl)-2H-1,2,3-benzotriazol-5-yl]amino)carbonothioyl)-2-nitrobenzamide
Plasmodium falciparum
-
pH 4.5, 37°C
0.094
N-(2,5-dimethyl-1H-pyrrol-1-yl)-4-hydroxybenzamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.0000389
N-(2-([3-(1,3-benzodioxol-5-yl)-3-oxo-1-propen-1-yl]amino)phenyl)-4-nitrobenzenesulfonamide
Plasmodium falciparum
-
pH 4.5, 37°C
0.000000003329
N-(2-aminoethyl)-N-(biphenyl-4-ylmethyl)-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 0.003329 nM
0.0000875
N-(2-methoxyphenyl)-2-(5H-[1,2,4]triazino[5,6-b]indol-3­ylthio)butanamide
Plasmodium falciparum
-
pH 4.5, 37°C
0.0000095
N-(3,4-dichlorophenyl)-2-[(4,6-dimethyl-2-pyrimidinyl)amino]­3a,4,5,6,7,7a-hexahydro-1H-benzimidazole-1-carboxamide
Plasmodium falciparum
-
pH 4.5, 37°C
0.0000095
N-(3,4-dichlorophenyl)-2-[(4,6-dimethylpyrimidin-2-yl)amino]-3a,4,5,6,7,7a-hexahydro-1H-benzimidazole-1-carboxamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.001088
N-(3,4-dimethylphenyl)-N'-(imino[(4,6,7-trimethyl-2-quinazolinyl)amino]methyl)thiourea
Plasmodium falciparum
-
pH 4.5, 37°C
0.1
N-(3-carbamoylthiophen-2-yl)thiophene-2-carboxamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.013
N-(4-hexylphenyl)-2-(2-naphthyl)-N-piperidin-4-ylacetamide hydrochloride
Plasmodium falciparum
-
pH 5.0, 37°C
0.001912
N-(4-[5-(1,3-benzodioxol-5-yl)pyridin-2-yl]benzyl)-N-[2-(dibutylamino)ethyl]-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 1912 nM
0.000437
N-(4-[6-(1,3-benzodioxol-5-yl)pyridin-3-yl]benzyl)-N-[2-(dibutylamino)ethyl]-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 437 nM
0.000289
N-(4-[benzyl(methyl)amino]benzyl)-N-[2-(dibutylamino)ethyl]-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 289 nM
0.0047
N-(biphenyl-4-ylmethyl)-4-butoxy-N-[2-(dibutylamino)ethyl]benzamide
Plasmodium falciparum
-
IC50: 0.0047 mM
0.0015
N-(biphenyl-4-ylmethyl)-4-butyl-N-[2-(dibutylamino)ethyl]benzamide
Plasmodium falciparum
-
IC50: 0.0015 mM
0.002067
N-(biphenyl-4-ylmethyl)-N',N'-dibutyl-N-(4-pentylbenzyl)ethane-1,2-diamine
Plasmodium falciparum
-
IC50: 0.002067 mM
0.003943
N-(biphenyl-4-ylmethyl)-N-(2-[bis(1-methylethyl)amino]ethyl)-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 0.003943 mM
0.001161
N-(biphenyl-4-ylmethyl)-N-[2-(butylamino)ethyl]-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 0.001161 mM
0.000143 - 0.000252
N-(biphenyl-4-ylmethyl)-N-[2-(dibutylamino)ethyl]-4-pentylbenzamide
0.0129
N-(biphenyl-4-ylmethyl)-N-[2-(dibutylamino)ethyl]-4-propylbenzamide
Plasmodium falciparum
-
IC50: 0.0129 mM
0.002317
N-(biphenyl-4-ylmethyl)-N-[2-(diethylamino)ethyl]-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 0.002317 mM
0.0000044
N-(cyclopentylcarbamothioyl)-4-ethoxy-3-nitrobenzamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.007
N-([(1RS)-3,3-difluoro-4-oxocyclohexyl]methyl)-2-(2-naphthyl)-N-(4-pentylphenyl)acetamide
Plasmodium falciparum
-
pH 5.0, 37°C
0.1
N-([(1RS)-3,3-difluoro-4-oxocyclopentyl]methyl)-2-(2-naphthyl)-N-(4-pentylphenyl)acetamide
Plasmodium falciparum
-
value above, pH 5.0, 37°C
0.019
N-([(1RS,4RS)-3,3-difluoro-4-hydroxycyclohexyl]methyl)-2-(2-naphthyl)-N-(4-pentylphenyl)acetamide
Plasmodium falciparum
-
pH 5.0, 37°C
0.016
N-([(1RS,4SR)-3,3-difluoro-4-hydroxycyclohexyl]methyl)-2-(2-naphthyl)-N-(4-pentylphenyl)acetamide
Plasmodium falciparum
-
pH 5.0, 37°C
0.1
N-([(1SR,4RS)-3,3-difluoro-4-hydroxycyclopentyl]methyl)-2-(2-naphthyl)-N-(4-pentylphenyl)acetamide
Plasmodium falciparum
-
value above, pH 5.0, 37°C
0.1
N-([(1SR,4SR)-3,3-difluoro-4-hydroxycyclopentyl]methyl)-2-(2-naphthyl)-N-(4-pentylphenyl)acetamide
Plasmodium falciparum
-
value above, pH 5.0, 37°C
0.0000088
N-([(2,4-dimethylphenyl)amino][(4-oxo-1,4,5,6,7,8-hexahydro-2-quinazolinyl)amino]methylene)benzamide
Plasmodium falciparum
-
pH 4.5, 37°C
0.0017
N-([3',5'-bis(trifluoromethyl)biphenyl-4-yl]methyl)-N-[2-(dibutylamino)ethyl]benzamide
Plasmodium falciparum
-
IC50: 0.0017 mM
0.00119
N-([3',5'-bis(trifluoromethyl)biphenyl-4-yl]methyl)-N-[3-(dibutylamino)propyl]-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 0.00119 mM
0.000019
N-([5-[3,5-bis(trifluoromethyl)phenyl]furan-2-yl]methyl)-N-[1-(3-methylbutyl)piperidin-4-yl]-4-pentylbenzamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.000019
N-([5-[3,5-bis(trifluoromethyl)phenyl]furan-2-yl]methyl)-N-[1-(3-methylbutyl)piperidin-4-yl]-5-pentylpyridine-2-carboxamide
Plasmodium falciparum
-
-
0.000031
N-([[1-(3-methylbutyl)piperidin-4-yl](4-pentylbenzoyl)amino]methyl)-1-benzothiophene-2-carboxamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.000146
N-([[1-(3-methylbutyl)piperidin-4-yl](4-pentylbenzoyl)amino]methyl)pyridine-3-carboxamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.00003
N-benzyl-2-([3-(3-nitrophenyl)acryloyl]amino)benzamide
Plasmodium falciparum
-
pH 4.5, 37°C
0.00081
N-benzyl-2-bromo-N-[[4-([[3-(2,4-dichlorophenyl)propyl](3-phenylpropyl)amino]methyl)pyrrolidin-3-yl]methyl]-4,5-dimethoxybenzamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.00064
N-benzyl-2-bromo-N-[[4-([[3-(2,4-dichlorophenyl)propyl][2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl]amino]methyl)pyrrolidin-3-yl]methyl]-4,5-dimethoxybenzamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.000072
N-benzyl-4'-(([2-(dibutylamino)ethyl][(4-pentylphenyl)carbonyl]amino)methyl)biphenyl-4-carboxamide
Plasmodium falciparum
-
IC50: 72 nM
0.002
N-butyl-N-[2-[6-chloro-3-(3,4-dichlorophenyl)naphthalen-1-yl]-2-hydroxyethyl]butan-1-aminium
Plasmodium falciparum
-
pH 5.0, temperature not specified in the publication
0.005
N-hexyl-N-[2-hydroxy-2-(1,2,3,4-tetrahydrophenanthren-9-yl)ethyl]hexan-1-aminium
Plasmodium falciparum
-
pH 5.0, temperature not specified in the publication
0.017
N-hexyl-N-[2-hydroxy-2-(phenanthren-9-yl)ethyl]hexan-1-aminium
Plasmodium falciparum
-
pH 5.0, temperature not specified in the publication
0.024
N-[(1SR,3RS)-4,4-difluoro-3-hydroxycyclohexyl]-2-(2-naphthyl)-N-(4-pentylphenyl)acetamide
Plasmodium falciparum
-
pH 5.0, 37°C
0.02
N-[(1SR,3SR)-4,4-difluoro-3-hydroxycyclohexyl]-2-(2-naphthyl)-N-(4-pentylphenyl)acetamide
Plasmodium falciparum
-
pH 5.0, 37°C
0.000191
N-[(2'-chlorobiphenyl-4-yl)methyl]-N-[2-(dibutylamino)ethyl]benzamide
Plasmodium falciparum
-
IC50: 191 nM
0.0000043
N-[(2S,3S)-2-hydroxy-3-[(phenoxyacetyl)amino]-4-phenylbutyl]-N-[2-(4-methoxyphenyl)ethyl]piperidine-4-carboxamide
Plasmodium falciparum
-
predicted inhibition constant, temperature not specified in the publication, pH not specified in the publication
0.00001
N-[(2S,3S)-5-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-[(4-bromobenzyl)oxy]-3-hydroxy-5-oxopentan-2-yl]-2,4,6-trifluorobenzamide
Plasmodium falciparum
-
predicted inhibition constant, temperature not specified in the publication, pH not specified in the publication
0.000018
N-[(3-ethyl-1,2-oxazol-5-yl)methyl]-N-[1-(3-methylbutyl)piperidin-4-yl]-4-pentylbenzamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.000591
N-[(4'-butylbiphenyl-4-yl)methyl]-N-[2-(dibutylamino)ethyl]benzamide
Plasmodium falciparum
-
IC50: 591 nM
0.000446
N-[(4'-chlorobiphenyl-4-yl)methyl]-N-[2-(dibutylamino)ethyl]benzamide
Plasmodium falciparum
-
IC50: 446 nM
0.000407
N-[(4'-chlorobiphenyl-4-yl)methyl]-N-[3-(dibutylamino)propyl]-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 407 nM
0.00016
N-[(4'-cyanobiphenyl-4-yl)methyl]-N-[2-(dibutylamino)ethyl]benzamide
Plasmodium falciparum
-
IC50: 160 nM
0.0000045
N-[(cyclopentylamino)carbonothioyl]-4-ethoxy-3-nitrobenzamide
Plasmodium falciparum
-
pH 4.5, 37°C
0.0000088
N-[(E)-[(2,4-dimethylphenyl)amino][(4-oxo-1,4,5,6,7,8-hexahydroquinolin-2-yl)amino]methylidene]benzamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.000146
N-[1-(3-methylbutyl)piperidin-4-yl]-4-pentyl-N-[4-[(pyridin-3-ylmethyl)carbamoyl]benzyl]benzamide
Plasmodium falciparum
-
-
0.000054
N-[1-(3-methylbutyl)piperidin-4-yl]-5-pentyl-N-[[4'-(piperidin-1-ylcarbonyl)biphenyl-4-yl]methyl]pyridine-2-carboxamide
0.000145
N-[1-(3-methylbutyl)piperidin-4-yl]-N-(2-[4-[methyl(2-methylquinolin-4-yl)amino]phenyl]ethyl)-4-pentylbenzamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.000145
N-[1-(3-methylbutyl)piperidin-4-yl]-N-[4-[(2-methylquinolin-4-yl)amino]benzyl]-4-pentylbenzamide
Plasmodium falciparum
-
-
0.000113
N-[1-(3-methylbutyl)piperidin-4-yl]-N-[4-[methyl(pyridin-4-yl)amino]benzyl]-4-pentylbenzamide
Plasmodium falciparum
-
-
0.000113
N-[1-(3-methylbutyl)piperidin-4-yl]-N-[[methyl(pyridin-3-yl)amino]methyl]-4-pentylbenzamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.000469
N-[2-(dibutylamino)ethyl]-4-pentyl-N-(3-phenoxybenzyl)benzamide
Plasmodium falciparum
-
IC50: 469 nM
0.000369
N-[2-(dibutylamino)ethyl]-4-pentyl-N-(4-piperidin-1-ylbenzyl)benzamide
Plasmodium falciparum
-
IC50: 369 nM
0.00038
N-[2-(dibutylamino)ethyl]-4-pentyl-N-(4-pyridin-2-ylbenzyl)benzamide
Plasmodium falciparum
-
IC50: 380 nM
0.000374
N-[2-(dibutylamino)ethyl]-4-pentyl-N-(4-pyridin-3-ylbenzyl)benzamide
Plasmodium falciparum
-
IC50: 374 nM
0.000212
N-[2-(dibutylamino)ethyl]-4-pentyl-N-(4-pyridin-4-ylbenzyl)benzamide
Plasmodium falciparum
-
IC50: 212 nM
0.000531
N-[2-(dibutylamino)ethyl]-4-pentyl-N-(4-pyrimidin-5-ylbenzyl)benzamide
Plasmodium falciparum
-
IC50: 531 nM
0.000188
N-[2-(dibutylamino)ethyl]-4-pentyl-N-(4-thiomorpholin-4-ylbenzyl)benzamide
Plasmodium falciparum
-
IC50: 188 nM
0.000056
N-[2-(dibutylamino)ethyl]-4-pentyl-N-([4'-(thiomorpholin-4-ylcarbonyl)biphenyl-4-yl]methyl)benzamide
Plasmodium falciparum
-
IC50: 56 nM
0.00024
N-[2-(dibutylamino)ethyl]-4-pentyl-N-[4-(1H-pyrrol-1-yl)benzyl]benzamide
Plasmodium falciparum
-
IC50: 240 nM
0.0002
N-[2-(dibutylamino)ethyl]-4-pentyl-N-[4-(4-phenylpiperazin-1-yl)benzyl]benzamide
Plasmodium falciparum
-
IC50: 200 nM
0.002345
N-[2-(dibutylamino)ethyl]-4-pentyl-N-[4-(5-phenylpyridin-2-yl)benzyl]benzamide
Plasmodium falciparum
-
IC50: 2345 nM
0.00853
N-[2-(dibutylamino)ethyl]-4-pentyl-N-[4-(5-pyrimidin-5-ylpyridin-2-yl)benzyl]benzamide
Plasmodium falciparum
-
IC50: 8530 nM
0.000589
N-[2-(dibutylamino)ethyl]-4-pentyl-N-[4-(6-phenylpyridin-3-yl)benzyl]benzamide
Plasmodium falciparum
-
IC50: 589 nM
0.002229
N-[2-(dibutylamino)ethyl]-4-pentyl-N-[4-(6-pyrimidin-5-ylpyridin-3-yl)benzyl]benzamide
Plasmodium falciparum
-
IC50: 2229 nM
0.000224
N-[2-(dibutylamino)ethyl]-4-pentyl-N-[4-(phenylamino)benzyl]benzamide
Plasmodium falciparum
-
IC50: 224 nM
0.001816
N-[2-(dibutylamino)ethyl]-4-pentyl-N-[4-(pyridin-4-ylamino)benzyl]benzamide
Plasmodium falciparum
-
IC50: 1816 nM
0.000596
N-[2-(dibutylamino)ethyl]-4-pentyl-N-[4-(trifluoromethyl)benzyl]benzamide
Plasmodium falciparum
-
IC50: 596 nM
0.0396
N-[2-(dibutylamino)ethyl]-4-propyl-N-[4-(trifluoromethyl)benzyl]benzamide
Plasmodium falciparum
-
IC50: 0.0396 mM
0.0159
N-[2-(dibutylamino)ethyl]-N-(3-phenoxybenzyl)-4-propylbenzamide
Plasmodium falciparum
-
IC50: 0.0159 mM
0.000295
N-[2-(dibutylamino)ethyl]-N-(4-pyridin-4-ylbenzyl)benzamide
Plasmodium falciparum
-
IC50: 295 nM
0.000204 - 0.000351
N-[2-(dibutylamino)ethyl]-N-(4-pyrimidin-5-ylbenzyl)benzamide
0.000574
N-[2-(dibutylamino)ethyl]-N-(4-[methyl(phenyl)amino]benzyl)-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 574 nM
0.003015
N-[2-(dibutylamino)ethyl]-N-(4-[methyl(pyridin-4-yl)amino]benzyl)-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 3015 nM
0.00039
N-[2-(dibutylamino)ethyl]-N-([3'-(trifluoromethyl)biphenyl-4-yl]methyl)benzamide
Plasmodium falciparum
-
IC50: 390 nM
0.000511
N-[2-(dibutylamino)ethyl]-N-([4'-(2-hydroxyethoxy)biphenyl-4-yl]methyl)-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 511 nM
0.000104
N-[2-(dibutylamino)ethyl]-N-([4'-(2-hydroxyethoxy)biphenyl-4-yl]methyl)benzamide
Plasmodium falciparum
-
IC50: 104 nM
0.000151
N-[2-(dibutylamino)ethyl]-N-([4'-(2-hydroxyethyl)biphenyl-4-yl]methyl)benzamide
Plasmodium falciparum
-
IC50: 151 nM
0.000074 - 0.000091
N-[2-(dibutylamino)ethyl]-N-([4'-(2-morpholin-4-yl-2-oxoethyl)biphenyl-4-yl]methyl)-4-pentylbenzamide
0.000428
N-[2-(dibutylamino)ethyl]-N-[(3',4'-dimethoxybiphenyl-4-yl)methyl]benzamide
Plasmodium falciparum
-
IC50: 428 nM
0.000293
N-[2-(dibutylamino)ethyl]-N-[(3'-methylbiphenyl-4-yl)methyl]benzamide
Plasmodium falciparum
-
IC50: 293 nM
0.00067
N-[2-(dibutylamino)ethyl]-N-[4-(1H-indol-1-yl)benzyl]-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 670 nM
0.002547
N-[2-(dibutylamino)ethyl]-N-[4-(4-methylpiperazin-1-yl)benzyl]-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 2547 nM
0.001491
N-[2-(dibutylamino)ethyl]-N-[4-(diethylamino)benzyl]-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 1491 nM
0.005
N-[2-hydroxy-2-(1,2,3,4-tetrahydrophenanthren-9-yl)ethyl]-4-methyl-N-(4-methylpentyl)pentan-1-aminium
Plasmodium falciparum
-
pH 5.0, temperature not specified in the publication
0.019
N-[2-hydroxy-2-(1,2,3,4-tetrahydrophenanthren-9-yl)ethyl]-N-pentylpentan-1-aminium
Plasmodium falciparum
-
pH 5.0, temperature not specified in the publication
0.024
N-[3-(2,7-dichloro-9H-fluoren-4-yl)-3-hydroxypropyl]-N-pentylpentan-1-aminium
Plasmodium falciparum
-
pH 5.0, temperature not specified in the publication
0.032
N-[3-(9H-fluoren-2-yl)-3-hydroxypropyl]-N-pentylpentan-1-aminium
Plasmodium falciparum
-
pH 5.0, temperature not specified in the publication
0.000221
N-[3-(dibutylamino)propyl]-4-pentyl-N-([4'-(2-pyrrolidin-1-ylethoxy)biphenyl-4-yl]methyl)benzamide
Plasmodium falciparum
-
IC50: 221 nM
0.000322 - 0.0011
N-[3-(dibutylamino)propyl]-N-[(2'-methoxybiphenyl-4-yl)methyl]-4-pentylbenzamide
0.000597
N-[3-(dibutylamino)propyl]-N-[(2'-methylbiphenyl-4-yl)methyl]-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 597 nM
0.000468
N-[3-(dibutylamino)propyl]-N-[(3',4'-dimethoxybiphenyl-4-yl)methyl]-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 468 nM
0.00058
N-[3-(dibutylamino)propyl]-N-[(3'-methoxybiphenyl-4-yl)methyl]-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 580 nM
0.000246
N-[3-(dibutylamino)propyl]-N-[(4'-methoxybiphenyl-4-yl)methyl]-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 246 nM
0.002
N-[3-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]-3-hydroxypropyl]-N-pentylpentan-1-aminium
Plasmodium falciparum
-
pH 5.0, temperature not specified in the publication
0.024
N-[4,4-difluoro-3-oxocyclohexyl]-2-(2-naphthyl)-N-(4-pentylphenyl)-acetamide
Plasmodium falciparum
-
pH 5.0, 37°C
0.000154
N-[4-(([2-(dibutylamino)ethyl][(4-pentylphenyl)carbonyl]amino)methyl)phenyl]-2-methoxypyridine-4-carboxamide
Plasmodium falciparum
-
IC50: 154 nM
0.000202
N-[4-(([2-(dibutylamino)ethyl][(4-pentylphenyl)carbonyl]amino)methyl)phenyl]piperidine-3-carboxamide
Plasmodium falciparum
-
IC50: 202 nM
0.000464
N-[4-(([2-(dibutylamino)ethyl][(4-pentylphenyl)carbonyl]amino)methyl)phenyl]piperidine-4-carboxamide
Plasmodium falciparum
-
IC50: 464 nM
0.000243
N-[4-(([2-(dibutylamino)ethyl][(4-pentylphenyl)carbonyl]amino)methyl)phenyl]pyrazine-2-carboxamide
Plasmodium falciparum
-
IC50: 243 nM
0.000334
N-[4-(1,3-benzodioxol-5-yl)benzyl]-4-pentyl-N-(2-piperidin-1-ylethyl)benzamide
Plasmodium falciparum
-
IC50: 334 nM
0.000165
N-[4-(1,3-benzodioxol-5-yl)benzyl]-4-pentyl-N-(2-[4-(3-phenylpropyl)piperidin-1-yl]ethyl)benzamide
Plasmodium falciparum
-
IC50: 165 nM
0.000831
N-[4-(1,3-benzodioxol-5-yl)benzyl]-N',N'-dibutyl-N-(4-pentylbenzyl)ethane-1,2-diamine
Plasmodium falciparum
-
IC50: 831 nM
0.000439
N-[4-(1,3-benzodioxol-5-yl)benzyl]-N-(2-([2-(diethylamino)ethyl](ethyl)amino)ethyl)-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 439 nM
0.002897
N-[4-(1,3-benzodioxol-5-yl)benzyl]-N-(2-morpholin-4-ylethyl)-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 2897 nM
0.000334
N-[4-(1,3-benzodioxol-5-yl)benzyl]-N-(2-[benzyl(2-hydroxyethyl)amino]ethyl)-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 334 nM
0.001501
N-[4-(1,3-benzodioxol-5-yl)benzyl]-N-(2-[bis(1-methylethyl)amino]ethyl)-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 1501 nM
0.00019
N-[4-(1,3-benzodioxol-5-yl)benzyl]-N-[2-(4-benzylpiperidin-1-yl)ethyl]-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 190 nM
0.000101
N-[4-(1,3-benzodioxol-5-yl)benzyl]-N-[2-(dibutylamino)ethyl]-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 101 nM
0.000056
N-[4-(1,3-benzodioxol-5-yl)benzyl]-N-[2-(dibutylamino)ethyl]benzamide
Plasmodium falciparum
-
IC50: 56 nM
0.001519
N-[4-(1,3-benzodioxol-5-yl)benzyl]-N-[2-(diethylamino)ethyl]-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 1519 nM
0.000531
N-[4-(1,3-benzodioxol-5-yl)benzyl]-N-[2-(dipropylamino)ethyl]-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 531 nM
0.000195
N-[4-(1,3-benzodioxol-5-yl)benzyl]-N-[3-(dibutylamino)propyl]-4-pentylbenzamide
Plasmodium falciparum
-
IC50:195 nM
0.000587 - 0.000736
N-[4-(2,2'-bipyridin-5-yl)benzyl]-N-[2-(dibutylamino)ethyl]-4-pentylbenzamide
0.000642
N-[4-(2,4'-bipyridin-5-yl)benzyl]-N-[2-(dibutylamino)ethyl]-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 642 nM
0.005266
N-[4-(3,3'-bipyridin-6-yl)benzyl]-N-[2-(dibutylamino)ethyl]-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 5266 nM
0.004553
N-[4-(3,4'-bipyridin-6-yl)benzyl]-N-[2-(dibutylamino)ethyl]-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 4553 nM
0.000018
N-[4-(3,4-diethylisoxazol-5-yl)benzyl]-N-[1-(3-methylbutyl)piperidin-4-yl]-4-pentylbenzamide
Plasmodium falciparum
-
-
0.000646
N-[4-(4-benzylpiperazin-1-yl)benzyl]-N-[2-(dibutylamino)ethyl]-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 646 nM
0.000429
N-[4-(benzylamino)benzyl]-N-[2-(dibutylamino)ethyl]-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 429 nM
0.0034
N-[4-(benzyloxy)benzyl]-4-butoxy-N-[2-(dibutylamino)ethyl]benzamide
Plasmodium falciparum
-
IC50: 0.0034 mM
0.0013
N-[4-(benzyloxy)benzyl]-4-butyl-N-[2-(dibutylamino)ethyl]benzamide
Plasmodium falciparum
-
IC50: 0.0013 mM
0.000845
N-[4-(benzyloxy)benzyl]-N',N'-dibutyl-N-(4-pentylbenzyl)ethane-1,2-diamine
Plasmodium falciparum
-
IC50: 845 nM
0.000112
N-[4-(benzyloxy)benzyl]-N-[2-(dibutylamino)ethyl]-4-pentylbenzamide
Plasmodium falciparum
-
IC50: 112 nM
0.0089
N-[4-(benzyloxy)benzyl]-N-[2-(dibutylamino)ethyl]-4-propylbenzamide
Plasmodium falciparum
-
IC50: 0.0089 mM
0.000031
N-[4-([[1-(3-methylbutyl)piperidin-4-yl][(4-pentylphenyl)carbonyl]amino]methyl)phenyl]-1-benzothiophene-2-carboxamide
Plasmodium falciparum
-
-
0.000032
N-[4-[5-(3,4-dimethoxybenzyl)-1,2,4-oxadiazol-3-yl]benzyl]-N-[1-(3-methylbutyl)piperidin-4-yl]-4-pentylbenzamide
Plasmodium falciparum
-
-
0.007
N-[[(1S)-3,3-difluoro-4,4-dihydroxycyclohexyl]methyl]-N-(4-pentylphenyl)naphthalene-2-carboxamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.000067
N-[[5-(2,5-dichlorophenyl)furan-2-yl]methyl]-N-[1-(3-methylbutyl)piperidin-4-yl]-4-pentylbenzamide
0.000047
N-[[5-(3,4-dichlorophenyl)furan-2-yl]methyl]-N-[1-(3-methylbutyl)piperidin-4-yl]-4-pentylbenzamide
0.000032
N-[[5-(3,4-dimethoxybenzyl)-1,2,4-oxadiazol-3-yl]methyl]-N-[1-(3-methylbutyl)piperidin-4-yl]-4-pentylbenzamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.000236
N-[[5-(4-chlorophenyl)-1,2-oxazol-3-yl]methyl]-N-[1-(3-methylbutyl)piperidin-4-yl]-4-pentylbenzamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.000236
N-[[5-(4-chlorophenyl)isoxazol-3-yl]methyl]-N-[1-(3-methylbutyl)piperidin-4-yl]-4-pentylbenzamide
Plasmodium falciparum
-
-
0.00899
N2-(3-bromophenyl)-N-[4-[(phenylsulfanyl)methyl]phenyl]-N2-(phenylsulfonyl)glycinamide
Plasmodium falciparum
pH and temperature not specified in the publication
0.0000002
pepstatin
Plasmodium falciparum
-
pH 5.0, temperature not specified in the publication
0.0000875
pepstatin A
Plasmodium falciparum
-
pH 4.5, 37°C
0.0003467
SC-50083
Plasmodium falciparum
-
IC50: 0.0003467 mM
0.000197
[4'-(([2-(dibutylamino)ethyl](phenylcarbonyl)amino)methyl)biphenyl-4-yl]acetic acid
Plasmodium falciparum
-
IC50: 197 nM
0.000463
[4'-(([2-(dibutylamino)ethyl][(4-pentylphenyl)carbonyl]amino)methyl)biphenyl-4-yl]acetic acid
Plasmodium falciparum
-
IC50: 463 nM
0.006
[5-[(benzoyloxy)methyl]-2,3,4,7-tetrahydro-1H-azepin-3-yl]methyl 4-aminobenzoate
Plasmodium falciparum
pH and temperature not specified in the publication
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
2.2
-
assay at, PSM2 produces more cleavage sites at pH 4.5 than at pH 2.2. At pH 2.2 PSM2 activity is observed only without maturation
4.7
-
assay at
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
3 - 5
-
the zpepproPMII chimeric protein (porcine pepsinogen prosegment fused to the mature region of PMII) activates at pH 3-5. Activation at these pH values is consistent with the pH-dependent autoactivation observed for wildtype zymogen PMII
3.5 - 6
-
pH 3.5: about 65% of maximal activity, pH 6.0: about 30% of maximal activity, hydrolysis of Leu-Glu-Arg-Ile-Phe-Phe(NO2)-Ser-Phe
3.5 - 6.5
-
active over the range
4 - 5.5
-
pH 4.0: about 40% of maximal activity, pH 5.5: about 10% of maximal activity
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0
-
assay at, at pH 4.5 the number of cleavage sites is lower at 0°C than at room temperature
additional information
-
assay at room temperature. At pH 4.5 the number of cleavage sites is lower at 0°C than at room temperature
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
isolate 3D7
UniProt
Manually annotated by BRENDA team
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
-
the proplasmepsin II gene is not transcribed until the later trophozoite stage of parasite growth
Manually annotated by BRENDA team
additional information
-
Plasmodium falciparum-infected cultured human erythrocytes
Manually annotated by BRENDA team
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
-
proplasmepsin II is a type II integral membrane protein that is transported though the secretory pathway before cleavage to the soluble form
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
physiological function
enzyme overexpression fails to change the susceptibility of Plasmodium falciparum to artemisinin, chloroquine and piperaquine
malfunction
-
multiple plasmepsin knockout mutants lacking plasmepsins I-III and I-IV, respectively show a significant increased parasite susceptibility to cyteine protease inhibitors. A ninefold increase in the potency of the calpain inhibitor N-acetyl-leucinyl-leucinyl-norleucinal (ALLN) against parasites lacking all four plasmepsins (I-IV) is observed. It is hypothesized that plasmepsins and some cysteine proteases play redundant or complementary roles in the digestive vacuole and that the absence of all plasmepsins (I-IV) renders these parasites highly susceptible to N-acetyl-leucinyl-leucinyl-norleucinal-mediated inhibition of falcipains
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
36924
-
x * 36924, calculation from nucleotide sequence
38000
-
activated form
43000
-
precursor form
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
proteolytic modification
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
crystal structure of Met205Ser mutant enzyme in complex with the two inhibitors rs367 and rs370, crystals are grown at 293 K by vapor diffusion in hanging drops
crystal structure of uncomplexed plasmepsin II as well as the complex with the potent inhibitor EH58, crystals are grown at 20°C by vapor diffusion in hanging drops
-
crystal structures of Plm II, uncomplexed and in complex with different inhibitors, reveal considerable conformational flexibility
-
crystallization of proplasmepsin II by sitting drops
-
generation of 3D-QSAR pharmacophore models for binding of PlmII inhibitors. A series of 26 inhibitors were modeled in the binding clefts of the PlmII and human cathepsin D to establish QSAR models of the proteases inhibition. The contributions of the P2 and P3' residues to the inhibitor’s binding affinity are responsible for the target selectivity
-
hanging drop method, X-ray structure of plasmepsin II complexed with the potent non-peptidomimetic achiral inhibitor at 1.6 A
-
in complex with inhibitors, sitting drop vapor diffusion method, using either 0.1 M HEPES pH 7.5 and 1.4 M sodium citrate tribasic dihydrate or 0.2 M lithium sulfate, 1.26 M ammonium sulfate, 0.1 M Tris pH 8.5
-
ligand docking studies with plasmepsin II predict binding of benzimidazole compounds at the center of the extended substrate-binding cleft. According to the plausible mode of binding,the pyridine ring of benzimidazole compounds interact with S1' subsite residues whereas the acetophenone moiety is in contact with S1-S3 subsites of plasmepsin II active center
-
molecular dynamics simulation using inhibitor (R)-N-[(1S,2R)-2-Hydroxyindan-1-yl]-3-[(2S,3S)-3-(2,6-dimethyl-4-(pyridine-4-ylmethyl)amino-phenoxyacetyl)amino-2-hydroxy-4-phenylbutanoyl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide
-
plasmepsin II in complex with inhibitor N-[(1S)-1-([(1S,2S)-1-([(4-bromobenzyl)oxy]methyl)-4-([(1S)-2-([(1S)-1-carbamoylbutyl]amino)-2-hydroxy-1-methylethyl]amino)-2-hydroxy-4-oxobutyl]carbamoyl)-2-methylpropyl]-4,5-dihydropyridine-2-carboxamide
-
plasmepsin II in complex with isovaleryl pepstatin
-
plasmepsin II in complex with pepstatin A
-
sequence and structural analysis combined with molecular dynamics simulations to predict the functional residues. Residues Y17, V105, T108, L191, L242, Q275, and T298 are important for plasmepsin function. Residues V105 and T108 are localized in a flap of an interior pocket. There is a rapid conformational change in the L3 region of plasmepsins that closes the active site
the aspartic acid residues in structure PDB 1lfA is noncoplanar. The catalytic water molecule is present, but the plane of the carboxylate group of Asp214 is rotated by 66° from its original position
-
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
D158A
-
active-site mutant of both plasmepsin II and IV shows neither autocatalytic processing nor proteolytic activities
D338A
-
active-site mutant of both plasmepsin II and IV shows neither autocatalytic processing nor proteolytic activities
I287E
-
changes in substrate specificity compared to wild-type enzyme, the turnover-number for Ala-Leu-Glu-Arg-Nle-Phe-Phe(NO2)-Ser-Phe-Pro is 42% of that of the wild-type enzyme, the Km-value is 51% of that of the wild-type enzyme
M13E
-
the turnover-number for Ala-Leu-Glu-Arg-Nle-Phe-Phe(NO2)-Ser-Phe-Pro is 1.16fold higher than the turnover-number of the wild-type enzyme, the Km-value is 54% of that of the wild-type enzyme
M13E/I287E
-
changes in substrate specificity compared to wild-type enzyme, the turnover-number for Ala-Leu-Glu-Arg-Nle-Phe-Phe(NO2)-Ser-Phe-Pro is 1.48fold higher than the turnover-number of the wild-type enzyme, the Km-value is 1.23fold higher than that of the wild-type enzyme
M205S
mutant enzyme with reduced chances of autolysis during purification
proteolytic modification
-
prodomain processing of plasmepsin II and plasmepsin IV occurs via an intra- and inter-molecular autocatalytic event as well as via a transcatalytic event between them
S77D
-
changes in substrate specificity compared to wild-type enzyme, cleavage of Lys-Glu-Phe-Val-Lys-Phe(NO2)-Ala-Leu-Lys that is not cleaved by the wild-type enzyme, the turnover-number for Ala-Leu-Glu-Arg-Nle-Phe-Phe(NO2)-Ser-Phe-is 54% of the turnover-number of the wild-type enzyme, the Km-value is 71% of that of the wild-type enzyme
additional information
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
Ni-NTA column chromatography and Superdex 75 gel filtration
-
proplasmepsin
-
protein is autoactivated at pH 4.7
-
using a Q-Sepharose fast flow column
-
using nickel affinity chromatography and gel filtration
-
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
DNA encoding the last 48 residues of the pro-part and the whole mature sequence of Plasmodium falciparum plasmepsin II is cloned into the T7-dependent vector pET3a for expression in Escherichia coli BL21
-
DNA encoding the last 48 residues of the propart and the whole mature sequence of plasmepsin II is inserted into the T7 dependent vector pET 3a for high level expression in Escherichia coli
-
engineering a plasmepsin II with the active site surface of plasmepsin I and expression in Escherichia coli
-
expressed in Escherichia coli
-
expressed in Escherichia coli as a recombinant protein
-
expressed in Escherichia coli Rosetta-gami B (DE3) pLysS cells
-
expression as a glutathione-S-transferase-proteinase fusion construct in Escherichia coli
-
expression in Escherichia coli
-
PSM2 (residues 78-453) are recombinantly expressed
-
recombinantly expressed in Escherichia coli
-
recombinantly expressed in Escherichia coli BL21
-
wild-type and mutant enzymes
-
RENATURED/Commentary
ORGANISM
UNIPROT
LITERATURE
differential scanning calorimetry reveals that the native state of PMII is irreversibly unfolded, and in the pH range of 6.5-8.0, PMII refolds to a denatured state with higher thermal stability than native state. The denatured state can also be formed upon partially unfolding PMII at pH 11.0 and 37°C for 2 h, followed by adjustment to a pH in the range of 6.5-8.0. While the denatured state can be folded/unfolded reversibly, the native state exists as a kinetically trapped state. The native state is kinetically trapped by an unfolding barrier of 25.5 kcal/mol, and yet once unfolded, is prevented from folding by a comparable folding barrier
-
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
analysis
-
cheap and high-throughput heterogeneous enzymatic assay for measuring plasmepsin II activity in order to use it as a tool in the discovery of new inhibitors of this enzyme
medicine
molecular biology
-
plasmepsin 2 but not plasmepsin 4 is a pential tool for hydrogen/deuterium exchange coupled to mass spectroscopy (DXMS) studies
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Gluzman, I.Y.; Francis, S.E.; Oksman, A.; Smith, C.E.; Duffin, K.L.; Goldberg, D.E.
Order and specificity of the Plasmodium falciparum hemoglobin degradation pathway
J. Clin. Invest.
93
1602-1608
1994
Plasmodium falciparum
Manually annotated by BRENDA team
Ersmark, K.; Feierberg, I.; Bjelic, S.; Hamelink, E.; Hackett, F.; Blackman, M.J.; Hulten, J.; Samuelsson, B.; Aqvist, J.; Hallberg, A.
Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity
J. Med. Chem.
47
110-122
2004
Plasmodium falciparum
Manually annotated by BRENDA team
Berry, C.
Plasmepsins as antimalarial targets
Curr. Opin. Drug Discov. Devel.
3
624-629
2000
Plasmodium falciparum
Manually annotated by BRENDA team
Dahlgren, A.; Kvarnstrom, I.; Vrang, L.; Hamelink, E.; Hallberg, A.; Rosenquist, A.; Samuelsson, B.
New inhibitors of the malaria aspartyl proteases plasmepsin I and II
Bioorg. Med. Chem.
11
3423-3437
2003
Plasmodium falciparum
Manually annotated by BRENDA team
Francis, S.E.; Banerjee, R.; Goldberg, D.E.
Biosynthesis and maturation of the malaria aspartic hemoglobinases plasmepsins I and II
J. Biol. Chem.
272
14961-14968
1997
Plasmodium falciparum
Manually annotated by BRENDA team
Moon, R.P.; Bur, D.; Loetscher, H.; D'Arcy, A.; Tyas, L.; Oefner, C.; Grueninger-Leitch, F.; Mona, D.; Rupp, K.; Dorn, A.; Matile, H.; Certa, U.; Berry, C.; Kay, J.; Ridley, R.G.
Studies on plasmepsins I and II from the malarial parasite Plasmodium falciparum and their exploitation as drug targets
Adv. Exp. Med. Biol.
436
397-406
1998
Plasmodium falciparum
Manually annotated by BRENDA team
Noteberg, D.; Hamelink, E.; Hulten, J.; Wahlgren, M.; Vrang, L.; Samuelsson, B.; Hallberg, A.
Design and synthesis of plasmepsin I and plasmepsin II inhibitors with activity in Plasmodium falciparum-infected cultured human erythrocytes
J. Med. Chem.
46
734-746
2003
Plasmodium falciparum
Manually annotated by BRENDA team
Siripurkpong, P.; Yuvaniyama, J.; Wilairat, P.; Goldberg, D.E.
Active Site Contribution to Specificity of the Aspartic Proteases Plasmepsins I and II
J. Biol. Chem.
277
41009-41013
2002
Plasmodium falciparum
Manually annotated by BRENDA team
Tyas, L.; Gluzman, I.; Moon, R.P.; Rupp, K.; Westling, J.; Ridley, R.G.; Kay, J.; Goldberg, D.E.; Berry, C.
Naturally-occurring and recombinant forms of the aspartic proteinases plasmepsins I and II from the human malaria parasite Plasmodium falciparum
FEBS Lett.
454
210-214
1999
Plasmodium falciparum
Manually annotated by BRENDA team
Tyas, L.; Moon, R.P.; Loetscher, H.; Dunn, B.M.; Kay, J.; Ridley, R.G.; Berry, C.
Plasmepsins I and II from the malarial parasite Plasmodium falciparum
Adv. Exp. Med. Biol.
436
407-411
1998
Plasmodium falciparum
Manually annotated by BRENDA team
Moon, R.P.; Tyas, L.; Certa, U.; Rupp, K.; Bur, D.; Jacquet, C.; Matile, H.; Loetscher, H.; Grueninger-Leitch, F.; et al.
Expression and characterization of plasmepsin I from Plasmodium falciparum
Eur. J. Biochem.
244
552-560
1997
Plasmodium falciparum
Manually annotated by BRENDA team
Hill, J.; Tyas, L.; Phylip, L.H.; Kay, J.; Dunn, B.M.; Berry, C.
High level expression and characterisation of plasmepsin II, an aspartic proteinase from Plasmodium falciparum
FEBS Lett.
352
155-158
1994
Plasmodium falciparum
Manually annotated by BRENDA team
Dame, J.B.; Reddy, G.R.; Yowell, C.A.; Dunn, B.M.; Kay, J.; Berry, C.
Sequence, expression and modeled structure of an aspartic proteinase from the human malaria parasite Plasmidum falciparum
Mol. Biochem. Parasitol.
64
177-190
1994
Plasmodium falciparum, Plasmodium falciparum HB3
Manually annotated by BRENDA team
Bernstein, N.K.; Cherney, M.M.; Loetscher, H.; Ridley, R.G.; James, M.N.G.
Crystal structure of the novel aspartic proteinase zymogen proplasmepsin II from Plasmodium falciparum
Nat. Struct. Biol.
6
32-37
1999
Plasmodium falciparum
Manually annotated by BRENDA team
Asojo, O.A.; Afonina, E.; Gulnik, S.V.; Yu, B.; Erickson, J.W.; Randad, R.; Medjahed, D.; Silva, A.M.
Structures of Ser205 mutant plasmepsin II from Plasmodium falciparum at 1.8 A in complex with the inhibitors rs367 and rs370
Acta Crystallogr. Sect. D
58
2001-2008
2002
Plasmodium falciparum (P46925), Plasmodium falciparum
Manually annotated by BRENDA team
Asojo, O.A.; Gulnik, S.V.; Afonina, E.; Yu, B.; Ellman, J.A.; Haque, T.S.; Silva, A.M.
Novel uncomplexed and complexed structures of plasmepsin II, an aspartic protease from Plasmodium falciparum
J. Mol. Biol.
327
173-181
2003
Plasmodium falciparum
Manually annotated by BRENDA team
Westling, J.; Cipullo, P.; Hung, S.H.; Saft, H.; Dame, J.B.; Dunn, B.M.
Active site specificity of plasmepsin II
Protein Sci.
8
2001-2009
1999
Plasmodium falciparum
Manually annotated by BRENDA team
Haque, T.S.; Skillman, A.G.; Lee, C.E.; Habashita, H.; Gluzman, I.Y.; Ewing, T.J.; Goldberg, D.E.; Kuntz, I.D.; Ellman, J.A.
Potent, low-molecular-weight non-peptide inhibitors of malarial aspartyl protease plasmepsin II
J. Med. Chem.
42
1428-1440
1999
Plasmodium falciparum
Manually annotated by BRENDA team
Le Bonniec, S.; Deregnaucourt, C.; Redeker, V.; Banerjee, R.; Grellier, P.; Goldberg, D.E.; Schrevel, J.
Plasmepsin II, an acidic hemoglobinase from the Plasmodium falciparum food vacuole, is active at neutral pH on the host erythrocyte membrane skeleton
J. Biol. Chem.
274
14218-14223
1999
Plasmodium falciparum
Manually annotated by BRENDA team
Ersmark, K.; Nervall, M.; Gutierrez-de-Teran, H.; Hamelink, E.; Janka, L.K.; Clemente, J.C.; Dunn, B.M.; Gogoll, A.; Samuelsson, B.; Qvist, J.; Hallberg, A.
Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV
Bioorg. Med. Chem.
14
2197-2208
2006
Plasmodium falciparum
Manually annotated by BRENDA team
Romeo, S.; DellAgli, M.; Parapini, S.; Rizzi, L.; Galli, G.; Mondani, M.; Sparatore, A.; Taramelli, D.; Bosisio, E.
Plasmepsin II inhibition and antiplasmodial activity of Primaquine-Statine double-drugs
Bioorg. Med. Chem. Lett.
14
2931-2934
2004
Plasmodium falciparum
Manually annotated by BRENDA team
Corminboeuf, O.; Dunet, G.; Hafsi, M.; Grimont, J.; Grisostomi, C.; Meyer, S.; Binkert, C.; Bur, D.; Jones, A.; Prade, L.; Brun, R.; Boss, C.
Inhibitors of plasmepsin II-potential antimalarial agents
Bioorg. Med. Chem. Lett.
16
6194-6199
2006
Plasmodium falciparum
Manually annotated by BRENDA team
Boss, C.; Richard-Bildstein, S.; Furnari, R.; Bourgeois, J.; Corminboeuf, O.; Grisostomi, C.; Coppex, L.; Harris, L.; Prade, L.; Meyer, S.; Binkert, C.; Fischli, W.; Brun, R.; Weller, T.
Inhibitors of plasmepsin II - potential antimalarial agents
Chimia
58
634-639
2004
Plasmodium falciparum
-
Manually annotated by BRENDA team
Kim, Y.M.; Lee, M.H.; Piao, T.G.; Lee, J.W.; Kim, J.H.; Lee, S.; Choi, K.M.; Jiang, J.H.; Kim, T.U.; Park, H.
Prodomain processing of recombinant plasmepsin II and IV, the aspartic proteases of Plasmodium falciparum, is auto- and trans-catalytic
J. Biochem.
139
189-195
2006
Plasmodium falciparum
Manually annotated by BRENDA team
Prade, L.; Jones, A.F.; Boss, C.; Richard-Bildstein, S.; Meyer, S.; Binkert, C.; Bur, D.
X-ray structure of plasmepsin II complexed with a potent achiral inhibitor
J. Biol. Chem.
280
23837-23843
2005
Plasmodium falciparum
Manually annotated by BRENDA team
Istvan, E.S.; Goldberg, D.E.
Distal substrate interactions enhance plasmepsin activity
J. Biol. Chem.
280
6890-6896
2005
Plasmodium falciparum
Manually annotated by BRENDA team
Klemba, M.; Beatty, W.; Gluzman, I.; Goldberg, D.E.
Trafficking of plasmepsin II to the food vacuole of the malaria parasite Plasmodium falciparum
J. Cell Biol.
164
47-56
2004
Plasmodium falciparum
Manually annotated by BRENDA team
Johansson, P.O.; Chen, Y.; Belfrage, A.K.; Blackman, M.J.; Kvarnstroem, I.; Jansson, K.; Vrang, L.; Hamelink, E.; Hallberg, A.; Rosenquist, A.; Samuelsson, B.
Design and synthesis of potent inhibitors of the malaria aspartyl proteases plasmepsin I and II. Use of solid-phase synthesis to explore novel statine motifs
J. Med. Chem.
47
3353-3366
2004
Plasmodium falciparum
Manually annotated by BRENDA team
Johansson, P.O.; Lindberg, J.; Blackman, M.J.; Kvarnstroem, I.; Vrang, L.; Hamelink, E.; Hallberg, A.; Rosenquist, A.; Samuelsson, B.
Design and synthesis of potent inhibitors of plasmepsin I and II: X-ray crystal structure of inhibitor in complex with plasmepsin II
J. Med. Chem.
48
4400-4409
2005
Plasmodium falciparum
Manually annotated by BRENDA team
Kiso, A.; Hidaka, K.; Kimura, T.; Hayashi, Y.; Nezami, A.; Freire, E.; Kiso, Y.
Search for substrate-based inhibitors fitting the S2 space of malarial aspartic protease plasmepsin II
J. Pept. Sci.
10
641-647
2004
Plasmodium falciparum
Manually annotated by BRENDA team
Salas, E.; Ramirez, A.; Otero-Bilbao, A.; Vazquez, R.; Reyes, O.; Mendiola, J.; Duarte, C.A.; Otero-Gonzalez, A.; Gutierrez, O.A.; Chavez, M.A.
A heterogeneous enzymatic assay for quantification of plasmepsin II activity and the evaluation of its inhibitors
J. Pharm. Biomed. Anal.
34
833-840
2004
Plasmodium falciparum
Manually annotated by BRENDA team
Ersmark, K.; Samuelsson, B.; Hallberg, A.
Plasmepsins as potential targets for new antimalarial therapy
Med. Res. Rev.
26
626-666
2006
Plasmodium falciparum
Manually annotated by BRENDA team
Hof, F.; Schutz, A.; Fah, C.; Meyer, S.; Bur, D.; Liu, J.; Goldberg, D.E.; Diederich, F.
Starving the malaria parasite: inhibitors active against the aspartic proteases plasmepsins I, II, and IV
Angew. Chem.
45
2138-2141
2006
Plasmodium falciparum
Manually annotated by BRENDA team
Bjelic, S.; Nervall, M.; Gutierrez-de-Teran, H.; Ersmark, K.; Hallberg, A.; Aqvist, J.
Computational inhibitor design against malaria plasmepsins
Cell. Mol. Life Sci.
64
2285-2305
2007
Plasmodium falciparum
Manually annotated by BRENDA team
Boss, C.; Corminboeuf, O.; Grisostomi, C.; Meyer, S.; Jones, A.F.; Prade, L.; Binkert, C.; Fischli, W.; Weller, T.; Bur, D.
Achiral, cheap, and potent inhibitors of plasmepsins I, II, and IV
ChemMedChem
1
1341-1345
2006
Plasmodium falciparum
Manually annotated by BRENDA team
DellAgli, M.; Parapini, S.; Galli, G.; Vaiana, N.; Taramelli, D.; Sparatore, A.; Liu, P.; Dunn, B.M.; Bosisio, E.; Romeo, S.
High antiplasmodial activity of novel plasmepsins I and II inhibitors
J. Med. Chem.
49
7440-7449
2006
Plasmodium falciparum
Manually annotated by BRENDA team
Bonilla, J.A.; Bonilla, T.D.; Yowell, C.A.; Fujioka, H.; Dame, J.B.
Critical roles for the digestive vacuole plasmepsins of Plasmodium falciparum in vacuolar function
Mol. Microbiol.
65
64-75
2007
Plasmodium falciparum
Manually annotated by BRENDA team
Luksch, T.; Chan, N.S.; Brass, S.; Sotriffer, C.A.; Klebe, G.; Diederich, W.E.
Computer-aided design and synthesis of nonpeptidic plasmepsin II and IV inhibitors
ChemMedChem
3
1323-1336
2008
Plasmodium falciparum (P46925), Plasmodium falciparum
Manually annotated by BRENDA team
Robbins, A.H.; Dunn, B.M.; Agbandje-McKenna, M.; McKenna, R.
Crystallographic evidence for noncoplanar catalytic aspartic acids in plasmepsin II resides in the Protein Data Bank
Acta Crystallogr. Sect. D
65
294-296
2009
Plasmodium falciparum
Manually annotated by BRENDA team
Hidaka, K.; Kimura, T.; Ruben, A.J.; Uemura, T.; Kamiya, M.; Kiso, A.; Okamoto, T.; Tsuchiya, Y.; Hayashi, Y.; Freire, E.; Kiso, Y.
Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin
Bioorg. Med. Chem.
16
10049-10060
2008
Plasmodium falciparum
Manually annotated by BRENDA team
Ramirez, A.R.; Guerra, Y.; Otero, A.; Garcia, B.; Berry, C.; Mendiola, J.; Hernandez-Zanui, A.; Chavez, M.
Generation of an affinity matrix useful in the purification of natural inhibitors of plasmepsin II, an antimalarial-drug target
Biotechnol. Appl. Biochem.
52
149-157
2009
Plasmodium falciparum
Manually annotated by BRENDA team
Valiente, P.A.; Batista, P.R.; Pupo, A.; Pons, T.; Valencia, A.; Pascutti, P.G.
Predicting functional residues in Plasmodium falciparum plasmepsins by combining sequence and structural analysis with molecular dynamics simulations
Proteins
73
440-457
2008
Plasmodium falciparum (P46925)
Manually annotated by BRENDA team
Friedman, R.; Caflisch, A.
Pepsinogen-like activation intermediate of plasmepsin II revealed by molecular dynamics analysis
Proteins
73
814-827
2008
Plasmodium falciparum
Manually annotated by BRENDA team
Moura, P.A.; Dame, J.B.; Fidock, D.A.
Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors
Antimicrob. Agents Chemother.
53
4968-4978
2009
Plasmodium falciparum
Manually annotated by BRENDA team
Degliesposti, G.; Kasam, V.; Da Costa, A.; Kang, H.K.; Kim, N.; Kim, D.W.; Breton, V.; Kim, D.; Rastelli, G.
Design and discovery of plasmepsin II inhibitors using an automated workflow on large-scale grids
ChemMedChem
4
1164-1173
2009
Plasmodium falciparum
Manually annotated by BRENDA team
Friedman, R.; Caflisch, A.
Discovery of plasmepsin inhibitors by fragment-based docking and consensus scoring
ChemMedChem
4
1317-1326
2009
Plasmodium falciparum
Manually annotated by BRENDA team
Luksch, T.; Blum, A.; Klee, N.; Diederich, W.E.; Sotriffer, C.A.; Klebe, G.
Pyrrolidine derivatives as plasmepsin inhibitors: binding mode analysis assisted by molecular dynamics simulations of a highly flexible protein
ChemMedChem
5
443-454
2010
Plasmodium falciparum (P46925), Plasmodium falciparum
Manually annotated by BRENDA team
Marcoux, J.; Thierry, E.; Vives, C.; Signor, L.; Fieschi, F.; Forest, E.
Investigating alternative acidic proteases for H/D exchange coupled to mass spectrometry: plasmepsin 2 but not plasmepsin 4 is active under quenching conditions
J. Am. Soc. Mass Spectrom.
21
76-79
2010
Plasmodium falciparum
Manually annotated by BRENDA team
Mohapatra, S.C.; Tiwari, H.K.; Singla, M.; Rathi, B.; Sharma, A.; Mahiya, K.; Kumar, M.; Sinha, S.; Chauhan, S.S.
Antimalarial evaluation of copper(II) nanohybrid solids: inhibition of plasmepsin II, a hemoglobin-degrading malarial aspartic protease from Plasmodium falciparum
J. Biol. Inorg. Chem.
15
373-385
2010
Plasmodium falciparum
Manually annotated by BRENDA team
Gupta, D.; Yedidi, R.S.; Varghese, S.; Kovari, L.C.; Woster, P.M.
Mechanism-based inhibitors of the aspartyl protease plasmepsin II as potential antimalarial agents
J. Med. Chem.
53
4234-4247
2010
Plasmodium falciparum
Manually annotated by BRENDA team
Faeh, C.; Hardegger, L.A.; Baitsch, L.; Schweizer, W.B.; Meyer, S.; Bur, D.; Diederich, F.
New organofluorine building blocks: inhibition of the malarial aspartic proteases plasmepsin II and IV by alicyclic alpha,alpha-difluoroketone hydrates
Org. Biomol. Chem.
7
3947-3957
2009
Plasmodium falciparum
Manually annotated by BRENDA team
Parr-Vasquez, C.L.; Yada, R.Y.
Functional chimera of porcine pepsin prosegment and Plasmodium falciparum plasmepsin II
Protein Eng. Des. Sel.
23
19-26
2010
Plasmodium falciparum
Manually annotated by BRENDA team
Xiao, H.; Dee, D.; Yada, R.Y.
The native conformation of plasmepsin II is kinetically trapped at neutral pH
Arch. Biochem. Biophys.
513
102-109
2011
Plasmodium falciparum
Manually annotated by BRENDA team
Saify, Z.S.; Azim, M.K.; Ahmad, W.; Nisa, M.; Goldberg, D.E.; Hussain, S.A.; Akhtar, S.; Akram, A.; Arayne, A.; Oksman, A.; Khan, I.A.
New benzimidazole derivatives as antiplasmodial agents and plasmepsin inhibitors: Synthesis and analysis of structure-activity relationships
Bioorg. Med. Chem. Lett.
22
1282-1286
2012
Plasmodium falciparum
Manually annotated by BRENDA team
Dali, B.; Keita, M.; Megnassan, E.; Frecer, V.; Miertus, S.
Insight into selectivity of peptidomimetic inhibitors with modified statine core for plasmepsin II of Plasmodium falciparum over human Cathepsin D
Chem. Biol. Drug Des.
79
411-430
2011
Plasmodium falciparum
Manually annotated by BRENDA team
Nerdy, N.
In silico docking roselle (Hibiscus sabdariffa L.) calyces flavonoids as antimalarial against plasmepsin 1 and plasmepsin 2
Asian J. Pharm. Clin. Res.
10.
183
2017
Plasmodium falciparum (P46925)
-
Manually annotated by BRENDA team
Mishra, V.; Rathore, I.; Arekar, A.; Sthanam, L.K.; Xiao, H.; Kiso, Y.; Sen, S.; Patankar, S.; Gustchina, A.; Hidaka, K.; Wlodawer, A.; Yada, R.Y.; Bhaumik, P.
Deciphering the mechanism of potent peptidomimetic inhibitors targeting plasmepsins - biochemical and structural insights
FEBS J.
285
3077-3096
2018
Plasmodium falciparum
Manually annotated by BRENDA team
Loesbanluechai, D.; Kotanan, N.; de Cozar, C.; Kochakarn, T.; Ansbro, M.R.; Chotivanich, K.; White, N.J.; Wilairat, P.; Lee, M.C.S.; Gamo, F.J.; Sanz, L.M.; Chookajorn, T.; Kuempornsin, K.
Overexpression of plasmepsin II and plasmepsin III does not directly cause reduction in Plasmodium falciparum sensitivity to artesunate, chloroquine and piperaquine
Int. J. Parasitol. Drugs Drug Resist.
9
16-22
2019
Plasmodium falciparum (Q8I6V3), Plasmodium falciparum
Manually annotated by BRENDA team
Huizing, A.P.; Mondal, M.; Hirsch, A.K.
Fighting malaria structureguided discovery of nonpeptidomimetic plasmepsin inhibitors
J. Med. Chem.
58
5151-5163
2015
Plasmodium falciparum (P46925), Plasmodium falciparum
Manually annotated by BRENDA team
Rasina, D.; Otikovs, M.; Leitans, J.; Recacha, R.; Borysov, O.V.; Kanepe-Lapsa, I.; Domraceva, I.; Pantelejevs, T.; Tars, K.; Blackman, M.J.; Jaudzems, K.; Jirgensons, A.
Fragment-based discovery of 2-aminoquinazolin-4(3H)-ones as novel class nonpeptidomimetic inhibitors of the plasmepsins I, II, and IV
J. Med. Chem.
59
374-387
2016
Plasmodium falciparum (P46925)
Manually annotated by BRENDA team
Singh, A.K.; Rathore, S.; Tang, Y.; Goldfarb, N.E.; Dunn, B.M.; Rajendran, V.; Ghosh, P.C.; Singh, N.; Latha, N.; Singh, B.K.; Rawat, M.; Rathi, B.
Hydroxyethylamine based phthalimides as new class of plasmepsin hits design, synthesis and antimalarial evaluation
PLoS ONE
10
e0139347
2015
Plasmodium falciparum
Manually annotated by BRENDA team
McGillewie, L.; Soliman, M.E.
Flap flexibility amongst plasmepsins I, II, III, IV, and V Sequence, structural, and molecular dynamics analyses
Proteins
83
1693-1705
2015
Plasmodium falciparum (P46925)
Manually annotated by BRENDA team